



MOLECULAR PHYSIOLOGY OF BILE ACID SIGNALING IN HEALTH, DISEASE, AND AGING

Alessia Perino,* Hadrien Demagny,* Laura Velazquez-Villegas, and Kristina Schoonjans

Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne (EPFL), Switzerland

Abstract

Over the past two decades, bile acids (BAs) have become established as important signaling molecules that enable fine-tuned inter-tissue communication from the liver, their site of production, over the intestine, where they are modified by the gut microbiota, to virtually any organ, where they exert their pleiotropic physiological effects. The chemical variety of BAs, to a large extent determined by the gut microbiome, also allows for a complex fine-tuning of adaptive responses in our body. This review provides an overview of the mechanisms by which BA receptors coordinate several aspects of physiology and highlights new therapeutic strategies for diseases underlying pathological BA signaling.

FXR; metabolic syndrome; microbiome; NAFLD; TGR5

1. INTRODUCTION	683
2. BAS IN A NUTSHELL	683
3. BAS AS SIGNALING FACTORS	685
4. BA SIGNALING IN HEALTH, ...	689
5. STRATEGIES TO MODULATE ...	708
6. UNDESIRE SIDE EFFECTS OF ...	710
7. FINAL REMARKS AND ...	711

1. INTRODUCTION

Bile acids (BAs) are a class of structurally diverse molecules with more than 60 species currently identified in mammals. This rich diversity not only suggests the existence of multiple mechanisms driving the synthesis and metabolism of BAs but also indicates that each of these entities may have different bioactive functions. The identification of multiple BA-responsive nuclear and membrane receptors has spurred tremendous interest into the mechanisms by which BAs coordinate signal transduction in various tissues and cell types. The nuclear receptor (NR) farnesoid X receptor (FXR) and the G-protein-coupled receptor (GPCR) Takeda G-protein-coupled receptor 5 (TGR5) are the best-studied molecular mediators of BA-dependent adaptive responses and are prospective targets for multiple disorders. Here, we provide an overview of the growing complexity of BA biology, their cross talk with the microbiome, as well as their role as signaling mediators of cellular and organismal function in

CLINICAL HIGHLIGHTS

Several diseases and conditions have been associated with an uncontrolled rise in bile acid (BA) concentrations. This is often the case when the tight feedback regulation of BA synthesis is compromised to the point that BAs become detrimental. BAs and their cognate receptors, farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5), however, exert many beneficial roles as they enable tissues to adapt to environmental, nutritional, and physiological cues. Over the last two decades, BA mimetics targeting FXR, TGR5, or both, have been proven to be efficacious in alleviating chronic metabolic and inflammatory disorders, such as obesity, Type 2 Diabetes (T2D), atherosclerosis and non-alcoholic steatohepatitis (NASH). While several aspects of BA signaling are still poorly understood, the first therapeutics targeting FXR are making their way into the clinic to treat liver diseases, such as primary biliary cholangitis (PBC) and NASH. Drugs targeting BA signaling may, hence, have a bright future and the continuing efforts on studying the impact of changing BA signaling pathways in humans will be beneficial to translate our emerging knowledge on BA physiology in model organisms into clinical benefits.

health and disease. We also cover a number of novel unanticipated functions of BAs and highlight different modes of intervention in BA signaling as therapeutic options to treat chronic metabolic and inflammatory disorders.

2. BAS IN A NUTSHELL

BAs are products of cholesterol catabolism and are composed of a steroid nucleus skeleton and an isopentanoic acid side chain (1). They are synthesized as primary BAs in the liver through well-established enzymatic pathways, which have been extensively reviewed elsewhere (2). Chenodeoxycholic acid (CDCA) and cholic acid (CA) are the main hepatic BA products in humans (FIGURE 1,

* A. Perino and H. Demagny contributed equally to this work.

A and **B**). There are four main steps that lead to primary BA synthesis: initiation, modifications of the ring structure, oxidation and shortening of the side chain, and conjugation. These sequential processes are carried out in the microsomes, cytosol, mitochondria, and peroxisomes, respectively. At least 7 mono-oxidases of the cytochrome P450 (CYP) family are involved in the incorporation of hydroxyl groups on the ring structures of

cholesterol. The bulk of primary BAs is produced by the classic pathway (**FIGURE 1A**). This branch is initiated by the rate-limiting enzyme, cholesterol 7 α -hydroxylase (CYP7A1). While humans synthesize CDCA, rodents produce muricholic acids (MCAs) via additional C6 hydroxylation. These BAs are more hydrophilic than CDCA and contribute to the species-specific differences in BA physiology (3). Sterol 12 α -hydroxylase (CYP8B1)




FIGURE 1. Bile acid (BA) synthesis and transport. **A:** scheme depicting the main biochemical transformations during BA synthesis in liver. Primary BAs (white rectangles with dashed lines) are produced from cholesterol by the classic or alternative pathway. BA 7 α -hydroxylation is catalyzed by CYP7A1 (classic pathway) or CYP7B1 (alternative pathway). Sterol ring modification is mainly catalyzed by HSD3B7 and CYP8B1, while side-chain oxidation and shortening requires CYP27A1. BAs are then conjugated (gray rectangles) in the liver, released in the gut where they are modified by the gut microbiome into secondary BAs (white rectangles) and recycled back to the liver where they are re-conjugated. **B:** summary of sites of hydroxylation on steroid nucleus of bile acid species indicated in **A**. **C:** schematic representation of the main BA transporters in the enterohepatic system. ASBT, apical sodium-dependent BA transporter; BAs, bile acids; BSEP, bile acid export pump; C6, carbon 6; C7, carbon 7; C12, carbon 12; CYP7A1, cholesterol 7 α -hydroxylase; CYP27A1, sterol 27-hydroxylase; CYP7B1, oxysterol 7 α -hydroxylase; CYP8B1, sterol 12 α -hydroxylase; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; H, hydrogen; HCA, hyocholic acid; HDCA, hyodeoxycholic acid; HSD3B7, hydroxy-delta-5-steroid dehydrogenase; I-BABP, ileal bile acid binding protein; LCA, lithocholic acid; MDCA, murideoxycholic acid; MRP3, multidrug resistance-associated protein 3; MRP4, multidrug resistance-associated protein 4; MRP2, multidrug resistance-associated protein 2; NTCP, sodium-dependent taurocholate co-transporting polypeptide; OATP1, organic anion-transporting polypeptide 1; OST β , organic solute transporter β ; TDCA, taurodeoxycholic acid; TDCAs, taurochenodeoxycholic acid; T α MCA, tauro- α -muricholic acid; T β MCA, tauro- β -muricholic acid; UDCA, ursodeoxycholic acid; α MCA, alpha-muricholic acid; α -OH, alpha hydroxyl group; β MCA, beta-muricholic acid; β -OH, beta hydroxyl group; ω MCA, omega-muricholic acid.

catalyzes the production of CA and its activity is a major enzymatic determinant of hepatic BA composition. In contrast to the classic pathway, the alternative branch depends on the chain-oxidation action of sterol 27-hydroxylase (CYP27A1), followed by 7 α -hydroxylation of its product by oxysterol 7 α -hydroxylase (CYP7B1) (2) (FIGURE 1A). Although in physiological conditions, the alternative branch is only marginal, environmental factors, such as cold exposure (4), high-fat/high-cholesterol (HF/HC) diet feeding (5), or liver disease (6), increase its contribution by enhancing the expression of CYP7B1, suggesting that the pathway mediates adaptive responses to various stresses. Finally, BA biosynthesis terminates with the conjugation of taurine in rodents and glycine or taurine in humans. Additional forms of BA conjugation include sulfation, glucuronidation, and N-acetylglucosamination (1).

BAs cycle between the liver and the intestine, and this dynamic process guarantees the distribution of adequate BA concentrations at sites of physiological actions (7). After conjugation to taurine or glycine, BAs are secreted from the liver into the bile and stored in the gallbladder along with other bile constituents. Food intake is the main trigger promoting bile secretion in the intestinal tract. This process is mediated by the gut hormone cholecystokinin (CCK), which promotes hepatic secretion of BAs and gallbladder contraction. Once released in the duodenum, the amphipathic BAs exert their detergent-like activity by forming micelles with dietary lipids and fat-soluble vitamins to facilitate intestinal lipid absorption. BAs return to the liver via the portal vein through active transport mechanisms and undergo several enterohepatic cycles a day (8). This process, termed enterohepatic circulation, is controlled by several dedicated transporters that limit fecal and urinary loss (reviewed in Refs. 9 and 10) (FIGURE 1C). BAs in the portal circulation are taken up by hepatocytes through sodium-dependent taurocholate cotransporting polypeptide (NTCP) and organic anion-transporting polypeptide 1 (OATP1). Hepatic multidrug resistance protein 3 (MRP3), MRP4 and organic solute transporter α/β (OST α/β) provide excretion routes for BAs into the systemic circulation, while bile acid export pump (BSEP) exports them across the canalicular membrane (FIGURE 1C and reviewed in (10)). At the terminal ileum, most of the conjugated BAs are reabsorbed by the enterocytes via the apical sodium-dependent BA transporter (ASBT), chaperoned from the apical to the basolateral membrane by the cytosolic ileal BA binding protein (I-BABP), and secreted into the portal circulation via basolateral BA transporters OST α/β , and MRP3. The enterohepatic circulation is efficient and recycles ~95% of the total BA pool. The remaining 5% is lost in the feces but rapidly restored through de novo synthesis in the liver, hence maintaining a constant BA pool size (2).

During their intestinal transit, BAs undergo several modifications through the action of bacteria residing in the distal part of the intestine, which deconjugate BAs or produce the secondary BAs deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), hyocholic acid (HCA), murideoxycholic acid (MDCA), ω -muricholic acid (ω MCA), and hyodeoxycholic acid (FIGURE 1, A and B). The details of BA biotransformation by the gut microbiota are described elsewhere (11) and briefly summarized in TABLE 1.

3. BAS AS SIGNALING FACTORS

The identification of dedicated BA receptors has triggered a remarkable rejuvenescence of the field and led to the novel concept that BAs, in addition to their detergent-like properties and their use as substrates for microbial metabolism (described in sect. 4.6), act as bonafide hormones (FIGURE 2). Below, we describe in detail the main findings related to FXR and TGR5, the most extensively studied BA-responsive receptors, while briefly summarizing the most pertinent studies related to other, lesser-known, BA-responsive receptors (FIGURE 3A).

3.1. FXR, a Dedicated NR for BAs

FXR (also known as NR1H4) is a NR that earned its name from the identification of farnesol as an activator (12). Later, BAs were demonstrated to be the natural ligands of FXR (13–15), with CDCA being the most potent (TABLE 2). Although initially assumed to be limited to the liver, intestine, kidney, and adrenal glands, subsequent studies showed that FXR is more broadly expressed. Upon ligand binding, FXR heterodimerizes with the retinoic acid receptor α (RXR α ; NR2B1) to activate the transcription of its target genes (FIGURE 3B). The transcriptional activity of FXR is fine-tuned by a set of coregulators, including transcriptional coactivators, such as steroid receptor coactivator 1 (SRC-1) (13, 14), peroxisome-proliferator-receptor (PPAR)- γ coactivator-1 α (PGC-1 α) (38), and methyltransferases, represented by coactivator-associated arginine (R) methyltransferase-1 (CARM-1) (39, 40), and protein arginine (R) methyltransferase-1 (PMRT-1) (41). Furthermore, FXR can be post-translationally modified. Elevated concentrations of plasma glucose favor FXR stabilization and function through O-Glc-N-acylation (42), whereas acetylation, methylation, and SUMO-ylation inhibit its transcriptional activity (43–45). Moreover, AMP-activated protein kinase (AMPK) phosphorylates and inactivates FXR in the context of cholestasis (46).

Table 1. Main BA biotransformation reactions catalyzed by intestinal bacteria

Reaction	Enzymes/Bacteria	Substrates*	Products*
Deconjugation	Bile salt hydrolase (BSH)	TCDC TCA GCDCA GCA	CDCA CA CDCA CA
Hydroxyl group oxidation	Hydroxysteroid dehydrogenase (3 α , 7 α , 12 α -HSDH)	CA CDCA	3-oxo-CA 7-oxo-DCA 3-oxo-CDCA 7-oxo-LCA
7-dehydroxylation	Bile acid oxidoreductase and bile acid dehydratase (among others)	CA CDCA α MCA/ β MCA ω MCA/HCA	DCA LCA MDCA HDCA
6 α -epimerization	Unknown	β MCA α MCA	ω MCA HCA
7 β -epimerization	7 β -hydroxysteroid dehydrogenase (7 β -HSDH)	CDCA α MCA	UDCA β MCA
3 β -epimerization	3 β -hydroxysteroid dehydrogenase (3 β -HSDH)	CA CDCA	Iso-CA Iso-CDCA

*List is nonexhaustive. CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; HCA, hyocholic acid; HDCA, hyodeoxycholic acid; Iso-CA, iso-cholic acid; Iso-CDCA, iso-chenodeoxycholic acid; LCA, lithocholic acid; MDCA, murideoxycholic acid; TCA, taurocholic acid; TCDC, taurochenodeoxycholic acid; UDCA, ursodeoxycholic acid; 3-oxo-CA, 3-oxo-cholic acid; 7-oxo-DCA, 7-oxo-deoxycholic acid; 3-oxo-CDCA, 3-oxo-chenodeoxycholic acid; 7-oxo-LCA, 7-oxo-lithocholic acid; α MCA, alpha-muricholic acid; β MCA, beta-muricholic acid; ω MCA, omega-muricholic acid.

3.2. TGR5, a Dedicated GPCR for BAs

TGR5, also known as G-protein-coupled BA receptor (GPBAR1), is a member of the rhodopsin-like subfamily of GPCRs and classified as the founder BA receptor of this subclass (47). TGR5 is encoded by a single exon gene, generating a protein comprising seven transmembrane domains, three extracellular loops, and three intracellular loops (48). Consistent with the signal-amplifying properties of GPCRs, TGR5 is minimally to moderately expressed in almost every tissue or cell type, with the exception of the gallbladder epithelium, where it is abundantly expressed (49). TGR5 is activated by both conjugated and unconjugated BAs with the following order of potency LCA > DCA > CDCA > CA (TABLE 2). The taurine-conjugated BAs are usually more potent activators than the glycine-conjugated or unconjugated BAs (31). In addition to BAs, some steroid hormone intermediates, such as pregnandiol and 5 α -pregnandione, also modulate TGR5 activity (50, 51). Semisynthetic agonists for TGR5 have been developed and are listed in TABLE 2 Upon BA stimulation, TGR5 couples to G α s proteins and activates adenylate cyclase to initiate a transient cAMP rise (31), which, in turn, induces the activity of various downstream effectors, including PKA (52–54), or the exchange protein directly

activated by cAMP (EPAC) (52, 54). TGR5 stimulation was also reported to activate MAPK signaling, mainly via ERK1/2 (55–57), proto-oncogene protein-tyrosine kinase (SRC) (58) and the mechanistic target of rapamycin (mTOR) (59, 60) (FIGURE 3B). The impact of β -arrestins on TGR5 signaling has been studied by several groups. Initial observations reported that TGR5 internalizes after activation (31) and that induction of TGR5 anti-inflammatory signaling is dependent on β -arrestin 2 (61). However, other studies demonstrated that TGR5 signaling does not require β -arrestins (53, 55). Recent evidence reported that TGR5 only indirectly interacts with β -arrestin through G-protein-coupled receptor kinase to activate the innate antiviral immune response (58).

3.3. Other Receptors Involved in BA Signaling

3.3.1. Nuclear receptors.

Other members of the NR family, including the pregnane X receptor/steroid and xenobiotic-sensing receptor (PXR/SXR; NR1I2), constitutive androstane receptor (CAR; NR1I3) and the vitamin D3 receptor (VDR; NR1I1), can respond to BAs (recently reviewed in Ref. 62). Higher concentrations of BAs are often required for their activation, suggesting that their functions become




FIGURE 2. Triple action of BAs. The chemical structure of BAs highlights the presence of a hydrophobic and a hydrophilic side (*left*) that allow BAs to act as detergents that facilitate intestinal lipid absorption. BAs also act as substrates for the gut microbiome (*middle*) and control multiple cellular processes through the activation of dedicated nuclear and membrane receptors, such as FXR and TGR5, respectively (*right*). BAs, bile acids; FXR, farnesoid X receptor; TGR5, Takeda G-protein-coupled receptor 5.

particularly relevant during pathological conditions, such as cholestasis. This is exemplified by PXR, which is a xenobiotic sensor that coordinates cytochrome P450-induced detoxification and inhibition of BA synthesis in conditions requiring protection from LCA overload (63, 64). PXR acts in synergy with CAR to control BA clearance, as well as bilirubin detoxification (65–69), but

whether BAs act as ligands for CAR is still a matter of debate. On the contrary, VDR binds LCA at lower concentrations than PXR and mediates the detoxification of its ligand by inducing the transcription of *Cyp3a* (70). Although this feature supports a protective role for VDR in gut homeostasis, recent evidence suggests that the LCA-VDR axis regulates biological pathways that go




FIGURE 3. BA receptors and signaling. *A*: table depicting the BA-responsive nuclear and membrane receptors. *B*: molecular mechanisms and signaling cascades by which TGR5 and FXR relay BA signals into adaptive cellular responses. CAR, constitutive androstane receptor; CARM-1, coactivator-associated arginine (R) methyltransferase-1; EPAC, exchange protein directly activated by cAMP; ERK1/2, extracellular signal-related kinase 1/2; FPR, formyl-peptide receptor; FXR, farnesoid X receptor; mAChR, muscarinic acetylcholine receptor; mTOR, mechanistic target of rapamycin; PGC-1 α , peroxisome-proliferator-receptor (PPAR)- γ coactivator-1 α ; PKA, protein kinase A; PMRT-1, protein arginine (R) methyltransferase-1; PTM, posttranslational modification; PXR/SXR, pregnane X receptor/steroid and xenobiotic-sensing receptor; RXR α , retinoic acid receptor α ; SRC-1, steroid receptor coactivator 1; S1PR2, sphingosine 1-phosphate receptor 2; TGR5, Takeda G-protein-coupled receptor 5; VDR, vitamin D3 receptor.

Table 2. FXR and TGR5 agonists and antagonists

Compound	Chemical Class or Synonym	Nature	Reference
<i>FXR Agonists</i>			
Chenodeoxycholic acid (CDCA)	3 α ,7 α -dihydroxy-5 β -cholanoic acid	natural bile acid	(13–15)
Obeticholic acid (OCA)	INT-747; 6 α -ethyl-chenodeoxycholic acid (6-ECDCA)	semi-synthetic bile acid (Intercept Pharmaceuticals)	(16)
GW4064	isoxazole	small molecule	(17)
Tropifexor	LJN452	small molecule	(18)
Nidufexor	LMB763	small molecule	(19)
Cilofexor	GS-9674	small molecule	(20)
EDP305		small molecule	(21)
PX20606	Px-102	small molecule	(22)
FXR-450	WAY-362450, XL335, turofexorate	small molecule	(23)
Fexaramine	benzopyran	small molecule	(24)
FexD	deuterated fexaramine analogue	small molecule	(25)
<i>FXR Antagonists</i>			
Tauro- β -muricholic acid (T β MCA)		natural bile acid	(26)
Glycoursodeoxycholic acid (GUDCA)		natural bile acid	(27)
Gly-MCA(Intestine-selective)	glycine- β -muricholic acid	modified bile acid	(28)
Guggulsterone	Z-guggulsterone4,17(20)-pregnadiene-3,16-dione	Natural sterol(guggul tree)	(29,30)
<i>TGR5 Agonists</i>			
Lithocholic acid (LCA)	3 α -hydroxy-5 β -cholanoic acid	natural bile acid	(31)
Deoxycholic acid (DCA)	3 α ,12 α -dihydroxy-5 β -cholanoic acid	natural bile acid	(31)
INT-777	6 α -ethyl-23(S)-methylcholic acid (S-EMCA)	semi-synthetic bile acid	(32,33)
BAR501	6 β -ethyl-3 α ,7 β -dihydroxy-5 β -cholan-24-ol	semi-synthetic bile acid	(34)
SB-756050	1,4-bis[[3,4-bis(methoxy)phenyl]sulfonyl]hexahydro-1H-1,4-diazepine	small molecule	(35)
Oleanolic acid		triterpene	(36)
<i>Dual FXR and TGR5 Agonists</i>			
INT-767	6 α -ethyl-3 α ,7 α ,23-trihydroxy-24-nor-5 β -cholan-23-sulfate	semi-synthetic bile acid	(37)

beyond BA detoxification and coordinate processes as diverse as adaptive and innate immunity (71–73) and gut microbiota modulation (74).

3.3.2. Cell surface receptors.

BAs can trigger acute responses through interaction with other GPCRs, including sphingosine 1-phosphate receptor 2 (S1PR2), formyl-peptide receptors (FPRs), and muscarinic acetylcholine receptors (mAChRs) (FIGURE 3A). While the main ligands for S1PR2 are sphingolipids, taurocholic acid (TCA) and other conjugated BAs can also induce its signaling (75). S1PR2 blockage reduces portal vein pressure and liver injury, suggesting a pathological role for S1PR2 in the setting of cholestasis (76, 77). FPRs are a small group of GPCRs expressed in neutrophils and monocytes (78). High concentrations of CDCA (79) and DCA (80) can interfere with the binding of N-formylmethionyl-leucyl-phenylalanine, an FPR agonist with potent chemoattractant properties in monocytes. Although these findings suggest an anti-inflammatory effect of BAs through FPRs, it is presumed that these receptors are only relevant under pathological conditions. The last group of BA-responsive GPCRs comprises the muscarinic receptors, which, upon exposure to conjugated secondary BAs, promote cancer cell growth in an epidermal growth factor receptor (EGFR)-dependent manner (81, 82). In addition, these receptors are involved in nitric oxide-induced vascular relaxation of the aorta (83), as well as in the pathology of cholestasis-induced cardiac arrhythmia (84, 85). Finally, BAs can also activate membrane receptors other than GPCRs (FIGURE 3A). Tauroursodeoxycholic acid (TUDCA), for instance, exerts antiapoptotic actions in hepatocytes through activation of the β_1 subunit of the $\alpha_5\beta_1$ -integrin pathway (86, 87). Interestingly, TUDCA promotes also other processes, such as osteoblast differentiation from mesenchymal stem cells through a similar integrin-mediated pathway (88).

4. BA SIGNALING IN HEALTH, DISEASE, AND AGING

4.1. Enterohepatic Regulation of Bile Homeostasis

Bile is a physiological fluid composed of water and a mixture of organic and inorganic solutes of diverse complexity, including BAs, cholesterol, phospholipids, and bilirubin (89). Bile is formed in hepatocytes, further processed in the biliary epithelial cells, and stored in the gallbladder, until released postprandially in the gut lumen, where the BA fraction facilitates lipid emulsification and absorption. Its main constituents are intrinsi-

cally interconnected and are subject to complex regulatory mechanisms in the liver. BA biosynthesis for instance requires hepatic cholesterol as a substrate, yet it is tightly controlled by negative feedback regulation involving both liver- and gut-driven mechanisms (FIGURE 4). In addition to its regulatory impact on BA synthesis, BA signaling coordinates the hepatic secretion of biliary cholesterol, BAs, phospholipids, and bilirubin through transporter-mediated mechanisms. As a consequence, BA-responsive receptors play a pivotal role in maintaining cholesterol solubility in bile and in coordinating bile formation and flow (extensively reviewed in Refs. 1, 10, and 90). While FXR is considered to be an essential regulator of these processes, TGR5 complements these functions by coordinating various aspects of biliary physiology. The emerging roles of liver TGR5 in other nonparenchymal cells are reviewed elsewhere (91).

4.1.1. FXR as a regulator of bile and cholesterol homeostasis.

4.1.1.1. CONTROL OF BA POOL SIZE AND COMPOSITION.

Already in 1958, it was demonstrated that the amount of bile supplied to the liver via the portal circulation influences the synthesis rate of BAs in rats (92). Several laboratories confirmed the transcriptional nature of this regulation, with *Cyp7a1* being the main target. Among the transcription factors that control BA synthesis (2, 93, 94), FXR is now recognized as being the master regulator of the BA pool size. The first studies in *Fxr*^{-/-} mice established that hepatic FXR is a cell-autonomous rheostat that regulates BA concentrations by repressing their synthesis and hepatic uptake, while concomitantly stimulating their export (95). In the liver, FXR contributes to the regulation of *Cyp7a1* via the induction of small heterodimer partner (SHP; NR0B2) (96, 97) (FIGURE 4, top right). SHP is an atypical NR with corepressor activity that potently inhibits its dimerizing NR partners, including the liver receptor homolog-1 (LRH-1; NR5A2) (96, 97), hepatocyte nuclear factor-4 α (HNF-4 α ; NR2A1) (98), and liver X receptor α (LXR α ; NR1H3) (99). This molecular network of NRs contributes to the cell-autonomous regulation of *Cyp7a1*. Studies in *Shp*^{-/-} mice have corroborated the importance of SHP in this negative regulatory cascade; however, they also suggested that other mechanisms contribute to this process (100, 101). In fact, additional studies revealed that feedback regulation of hepatic BA production is also mediated by a gut-driven mechanism, involving the induction of fibroblast growth factor 15/19 (FGF15/19) [FGF15 in mice (102); FGF19 in human (103)]. This enterokine is expressed in the enterocytes of the terminal ileum and was originally discovered as an enterohepatic signaling factor able to blunt hepatic BA synthesis (reviewed in Ref. 104).




FIGURE 4. FXR-mediated BA signaling in hepatocytes. Molecular mechanisms by which FXR controls multiple metabolic processes in hepatocytes. Hepatic FXR and intestinal FXR (through FGF15/19 release and activation of the FGFR4- β -KLOTHO signaling) synergize in the control of lipid, glucose, and amino acid homeostasis, as well as in the feedback regulation of BA synthesis. FXR target genes are highlighted in blue. ACC, acetyl-CoA carboxylase; ApoB, apolipoprotein B; ChREBP, carbohydrate-responsive element-binding protein; CREB, cAMP-response element binding protein; CYP7A1, cholesterol 7 α -hydroxylase; eIF4B, eukaryotic translation initiation factor 4B; eIF4E, eukaryotic translation initiation factor 4E; ERK, extracellular signal-regulated kinase; FAS, fatty acid synthase; FGF15/19, fibroblast growth factor 15/19; FGFR4, fibroblast growth factor receptor 4; FXR, farnesoid X receptor; G6Pase, glucose 6-phosphatase; GSK3, glycogen synthase kinase 3; HNF4 α , hepatocyte nuclear factor 4 alpha; LPK, liver pyruvate kinase; MTP, microsomal triglyceride transfer protein; PEPCK, phosphoenolpyruvate carboxykinase; SCD1, stearoyl-CoA desaturase-1; rpS6, ribosomal protein S6; SHP, small heterodimer partner; SHP2, Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2; SRC, proto-oncogene non-receptor tyrosine kinase; SREBP-1c, sterol regulatory binding protein 1c; VLDL, very low-density lipoprotein.

Tissue-specific *Fxr*^{-/-} mouse models furthermore established that eliminating FXR in the intestine profoundly disrupts BA homeostasis (105). Mechanistically, FGF15/19 reaches the liver via the portal circulation and inhibits *Cyp7a1* expression through hepatic fibroblast growth factor receptor 4 (FGFR4) and ERK/MAPK signaling (102, 106–109), as well as through SRC-dependent FXR activation (107) (FIGURE 4, top right). FGF15/19 binds to the FGFR4- β -Klotho complex (110, 111) and activates the nonreceptor SH2-containing protein tyrosine phosphatase 2 (SHP2) (107). Accordingly, *Fgfr4*^{-/-}, *Klb*^{-/-}, and hepatocyte-specific *Shp2*^{-/-} mice are unable to suppress BA synthesis upon FGF15/19 stimulation (107, 112, 113). Of note, intestinal BA-mediated secretion of FGF15/19 also signals, in part, through SHP by increasing its stability in the liver through ERK-dependent phosphorylation that inhibits its proteasomal degradation (114). A more recent study established that FXR signaling also controls BA synthesis independently of SHP and FGF15/19 by regulating *Cyp7a1* mRNA stability (115). Further studies will be

needed to establish the relative contribution of these FXR-mediated posttranscriptional responses on BA production.

Activation of FXR signaling also significantly blunts *Cyp8b1* expression, which controls the production of CA. Studies conducted in tissue-specific *Fxr*^{-/-} mouse models showed that unlike *Cyp7a1*, which is more sensitive to inhibition via the intestinal FXR-FGF15 pathway, *Cyp8b1* repression requires FXR activation in the liver, indicating differential regulation of the enzymes controlling the synthesis of the two main BA products (105). Although the molecular basis for this tissue-specific control is still poorly understood, it likely involves complex cross talk with metabolite- and hormone-sensing transcription factors.

4.1.1.2. REGULATION OF BA AND BILE HOMEOSTASIS.

Secretion of bile constituents, such as cholesterol, BAs, phospholipids, glutathione, and bilirubin, is tightly controlled by FXR signaling, which coordinates the expression of hepatic transporters involved in bile

formation and flow, as extensively reviewed by (9, 10) (FIGURE 5). Moreover, FXR activation induces the expression of transporters that provide spillover routes for BA efflux to avoid toxic BA overload (reviewed in Ref. 116). Briefly, FXR upregulates the expression of canalicular transporters, including BSEP (95, 117, 118) and multidrug resistance protein 3 (MDR3; Mdr2 in rodents) (119) to increase the biliary concentration of BAs and phospholipids and prevent cholesterol crystallization (120). FXR-dependent protection from hepatic BA overload also occurs via modulation of OST α/β , which acts as an alternative export system to BSEP at the hepatic sinusoidal membrane (121, 122). In addition to the BA transporters, BAs upregulate MRP2 (123) to excrete bilirubin and glutathione conjugates, as well as ABCG5/8 (124, 125) in charge of cholesterol efflux. FXR activation by obeticholic acid (OCA) (TABLE 2), however, is not associated with increased biliary cholesterol secretion, suggesting that the effects on hepatic ABCG5/8 induction do not necessarily result in increased transport activity (126). Of note, most of the bile constituent transporters are also upregulated in human liver slices when exposed to OCA (127), which is of relevance for cholestatic disease, as described in sect. 4.1.3. After participating in the digestion and absorption of dietary lipids in the gut, intestinal BAs are reabsorbed through different mechanisms (128). While only a fraction can diffuse passively in the duodenum (129), most of the BAs are taken up by the terminal ileum through active transport (FIGURE 5). Intestinal FXR activation downregulates the expression of ASBT (130), while it increases I-BABP and OST α/β (105, 122, 131, 132) to efficiently export BAs from the enterocytes to the portal blood.

4.1.1.3. CONTROL OF INTESTINAL CHOLESTEROL HOMEOSTASIS. In mice, activation of FXR signaling by OCA (126) and PX20606 (128) (TABLE 2) changes the BA pool composition leading to inhibition of intestinal cholesterol absorption (126) and increase of intestinal cholesterol excretion (128). Similarly, the FXR agonist GW4064 also stimulates plasma cholesterol clearance by enhancing its fecal elimination and reducing its intestinal absorption (125). Both the hepatic and intestinal pathway of FXR signaling seem to contribute to this process. As described above, hepatic FXR controls *Abcg5/8*. However, it also represses *Cyp8b1* expression, thereby reducing CA levels (105). These changes render the BA pool more hydrophylic and less efficient in emulsifying lipids. In addition to this effect, intestinal FXR stimulates transintestinal cholesterol elimination (TICE), a transport mechanism in the intestine that controls cholesterol homeostasis by increasing its intestinal elimination (133) (FIGURE 6). Studies revealed that this mechanism largely involves intestinal ABCG5/8 transporter activity and that enhanced excretion rather than decreased absorption of cholesterol accounts for FXR-mediated fecal sterol loss (128, 133). The coordinated activation of FXR in the enterohepatic organs, thus, not only controls BA production, bile formation, and flow, but also ensures the tight control of cholesterol levels in our body.

4.1.2. TGR5 and biliary physiology.

TGR5 influences BA homeostasis in a different, but complementary, manner compared with FXR, in part, because of the distinct expression profile of both receptors along the enterohepatic axis (FIGURE 6). While *Fxr* is abundant in hepatocytes and enterocytes, only marginal levels of




FIGURE 5. Transport of bile components in the enterohepatic organs. Schematic of the main bile component transporters in the enterohepatic system. FXR target genes are highlighted in blue. ABCG5, ATP-binding cassette sub-family G member 5; ABCG8, ATP-binding cassette sub-family G member 8; ASBT, apical sodium-dependent bile acid transporter; BA, bile acid; BSEP, bile acid export pump; I-BABP, ileal bile acid binding protein; MDR1, multidrug-resistant protein 1; MDR2/3, multidrug-resistant protein 2/3; MRP2, multidrug resistance-associated protein 2; MRP3, multidrug resistance-associated protein 3; MRP4, multidrug resistance-associated protein 4; NTCP, sodium-dependent taurocholate cotransporting polypeptide; OATP1, organic anion-transporting polypeptide 1; OST α , organic solute transporter α ; OST β , organic solute transporter β .




FIGURE 6. TGR5- and FXR-mediated BA signaling in the enterohepatic organs. Physiological and environmental cues, as well as disease or disease intervention (gray rectangles on top), modulate gut microbiome and BA pool size/composition to control TGR5 and FXR signaling in the various cell types of the enterohepatic system. These receptors act in a synergistic (one arrow) or complementary manner (two arrows) to regulate the physiological processes indicated in the green rectangles. Green arrows indicate an increase while red arrows indicate a reduction of the indicated cellular functions/processes. BA, bile acid; CGRP, calcitonin gene-related peptide; EEC, enteroendocrine L cell; FGF15/19, fibroblast growth factor 15/19; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; H₂O, water; TG, triglyceride; TGR5, Takeda G-protein-coupled receptor 5; TICE, transintestinal cholesterol excretion; VLDL, very low-density lipoprotein.

Tgr5 mRNA are found in these cell types. In contrast, *Tgr5* is robustly expressed in cholangiocytes and gallbladder epithelium, where TGR5 activation promotes chloride (Cl⁻) secretion through cAMP-regulated induction of the cystic fibrosis transmembrane conductance regulator (CFTR). The generated Cl⁻ gradient is subsequently used by the anion exchanger 2 (AE2) to secrete bicarbonate (HCO₃⁻) across the apical membrane (134). In cystic fibrosis, defective CFTR is responsible for impaired biliary secretion of Cl⁻ and HCO₃⁻ promoting ductal cholestasis, which can evolve into sclerosing cholangitis and cirrhosis (135). TGR5 is, furthermore, localized on cholangiocyte cilia, where its activation modulates bile flow and composition by regulating resorptive and secretory mediators (136). These findings underscore TGR5 as a pivotal regulator of biliary secretion,

which is in line with the reduced bile flow in *Tgr5*^{-/-} mice (137) (FIGURE 6). *Tgr5*^{-/-} mice are, furthermore, susceptible to BA overload-induced liver injury potentially linked to a more hydrophobic BA pool (138, 139), and a compromised biliary epithelium barrier function (140). These findings underscore TGR5 not only as a regulator of biliary secretion and flow, but also as a cytoprotective protein involved in preserving tight junction structure and function.

In addition to these functions, activation of TGR5 by LCA or the semi-synthetic BA, INT-777 (32, 33) (TABLE 2), promotes gallbladder smooth muscle cell relaxation (137, 141) (FIGURE 6). A similar phenotype is observed when BAs activate the intestinal FXR-FGF15 axis. *Fgf15*^{-/-} mice have an empty gallbladder, even in the fasted state when it is normally filled with bile (142). This

phenotype is restored after FGF15 injection, causing rapid gallbladder filling without stimulation of the bile flow. Mechanistically, FGF15 induces relaxation of the gallbladder smooth muscle via cAMP-induced signaling (142). Both ileal FXR and cholangiocyte TGR5 signaling, thus, seem to converge on the same cAMP axis, providing a unifying mechanism for coordinated regulation of gallbladder physiology.

4.1.3. BAs and hepatobiliary diseases.

Given the broad role of BA receptors in coordinating bile homeostasis and biliary physiology, it is not surprising that impaired signaling is associated with the development of hepatobiliary diseases, ranging from cholestatic liver disorders to cholesterol gallstone disease (CGD) to other gallbladder-related conditions.

4.1.3.1. CHOLESTATIC LIVER DISORDERS. Cholestasis has diverse etiologies and can result from impaired bile secretion across the canalicular membrane of the hepatocytes (intrahepatic cholestasis), or from impaired bile flow secondary to bile duct pathology, as is the case for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) (reviewed in Refs. 143–145). Consistent with the etiology of cholangitis-related disorders, genome-wide association studies (GWAS) in PBC and PSC patients have highlighted a major role for immunity-related genes (146). Of interest, a gene variant in TGR5 has been found in PSC patients, and further research should confirm the precise role of TGR5 in this disease (147). Likewise, certain FXR single-nucleotide polymorphisms can predispose to intrahepatic cholestasis of pregnancy (148) and to progressive familial intrahepatic cholestasis (149), reinforcing the importance of a preserved FXR signaling to limit pathological BA overload. Consistent with these genetic findings, ample evidence exists for a beneficial role of FXR agonism in various preclinical models of cholestasis (reviewed in Refs. 150 and 151). Stimulation of FXR signaling restores bile flow, reduces BA synthesis, and stimulates phospholipid secretion, thereby decreasing the detergent capacity of BAs (16, 119, 152). Furthermore, these effects are, in part, mediated by selective activation of intestinal FXR-FGF15/19 signaling (153) or by treatment with human FGF19 (153) or its nontumorigenic analog M70, now referred to as NGM282 (154), and they protect mice from cholestatic liver damage. Several of the FXR-related therapeutics have been tested in PBC and PSC patients, as described in sect. 5.3.

4.1.3.2. CGD AND OTHER GALLBLADDER-RELATED CONDITIONS. Quantitative trait loci analysis in inbred mouse strains and human GWAS has linked gene

variants in the cholesterol transporter ABCG5/8 with gallstones (155–158). Low-frequency variants associated with this disease were also found in genes encoding proteins controlling BA metabolism, including FXR, CYP7A1, ABCB11, apolipoprotein B (ApoB), and the CCK receptor CCKAR, as well as the phospholipid transporter ABCB4 (reviewed in Refs. 146 and 159). Moreover, *Fxr*^{-/-} mice fed a lithogenic diet exhibit several features that contribute to the development of CGD, including cholesterol supersaturation of bile, precipitation of cholesterol crystals, increased BA hydrophobicity, and gallbladder inflammation, whereas activation of FXR by GW4064 prevents its development (120). The protective effect of FXR agonists in rodents is attributed to their ability to increase the hydrophilicity of the BA pool (128, 160) and to stimulate the secretion of BAs and phospholipids by inducing the expression of their transporters BSEP and Mdr2 (120). In humans, both UDCA and CDCA are effective in reversing CGD (161–166). However, the mechanisms by which these BA species confer protection differ, as UDCA, in contrast to CDCA, is a poor agonist for FXR. Recent reports revealed that OCA might confer a higher risk for gallstone formation when administered to CGD patients (167) or to NASH patients (168). Although the higher cholesterol saturation index and the elevated FGF19 levels in gallbladder likely account for this effect (167), a residual activity of OCA toward TGR5 could be another reason. TGR5 is highly expressed in the gallbladder epithelium, where it exerts important cytoprotective actions (see sect. 4.1.2). Potential adverse effects however could arise upon chronic activation of the receptor. Gallbladder relaxation and increased size are prominent phenotypes of TGR5 agonism (137, 169). In line with these findings, mice lacking TGR5 are protected against gallstone formation (49). Although this represents a challenge for human therapeutics, tissue-specific targeting of TGR5 may overcome this undesired effect. Future clinical trials with next-generation TGR5 agonists will be needed to evaluate the exact impact of this pathway on biliary (patho)physiology.

4.2. BAs as Integrators of Nutrient Availability and Intestinal Homeostasis

Since intestinal BA levels oscillate following a rhythm that is dictated by dietary intake, these molecules serve as a proxy for nutrient availability. Thus, it is not surprising that BA-responsive receptors in enterocytes and different types of intestinal cells, including enteric neurons, smooth muscle, and enteroendocrine cells, sense and relay nutrient availability to a physiological response. FXR and TGR5, in particular, modulate a series of events, including fluid transport, hormone release,

expression of transport proteins, intestinal motility, and secretory responses that enable the uptake and availability of nutrients, fluid, and ions along the gastrointestinal tract (FIGURE 6).

4.2.1. Secretion of enteroendocrine hormones.

BAs are essential regulators of appetite- and metabolism-modulating gut hormones. The incretin glucagon-like peptide-1 (GLP-1) has received major attention because of its therapeutic potential to lower blood glucose concentrations. GLP-1 is secreted from enteroendocrine L cells following food ingestion. While glucose and free fatty acids are established nutrient-derived triggers for GLP-1 secretion (170), BAs have been identified as equally potent postprandial stimulators. TGR5 is expressed in L cells and mediates BA-induced GLP-1 release both in vitro and in vivo through a cAMP-dependent mechanism (33, 171, 172) (FIGURE 7). In addition, depending on the type of agonist, activation increases intracellular calcium levels (33, 173, 174). Receptor activation can also promote GLP-1 production by inducing its precursor proglucagon (175). TGR5 is predominantly located on the basolateral membrane of L cells, suggesting that BAs first have to cross the intestinal epithelium before stimulating GLP-1 release (173, 176, 177). A similar mechanism is proposed for peptide YY (PYY) and neurotensin, whose secretion is also blunted in *Tgr5*^{-/-} mice (177). The discovery that TGR5 agonists are GLP-1 secretagogues is currently used as a basis to identify regulatory nodes that would synergistically elevate endogenous GLP-1 levels. An interesting discovery in this respect

is the functional synergism between TGR5 and GPCRs involved in fatty acid signaling, such as free fatty acid receptor 1 (FFAR1) (178, 179), which is consistent with the exacerbated response of BAs during high-fat diet (HFD) feeding (33, 175). Another way to enhance TGR5-mediated GLP-1 secretion is to combine TGR5 agonists with somatostatin receptor 5 antagonists, which would remove the brake on GLP-1 release (180). These discoveries suggest that targeting complementary signaling pathways is more effective than TGR5 activation alone in modulating the GLP-1 response.

Contrary to TGR5, FXR is proposed to counteract GLP-1 signaling, either by blocking precursor synthesis via a mechanism involving carbohydrate-responsive element-binding protein (ChREBP) repression (181) or by reducing the expression and signaling of the short-chain free fatty acid receptor 2 (FFAR2) (182) (FIGURE 7). These studies would suggest that FXR most likely functions to regulate later phases of GLP-1 secretion. On the other hand, other studies showed that fexaramine-mediated FXR activation (183) (TABLE 2), as well as concurrent activation of both FXR and TGR5 pathways significantly induce GLP-1 secretion (184) by priming and enhancing TGR5 expression and signaling (184). These unexpected observations reinforce the notion that both BA sensors are functionally required in the coordinate regulation of GLP-1 signaling.

4.2.2. Secretion of enterokines.

As already outlined in sect. 4.1, FGF15/19 is an established ileal FXR target that signals to the liver to limit




FIGURE 7. TGR5- and FXR-mediated BA signaling in the enteroendocrine L cell. Molecular mechanisms and signaling cascades by which FXR and TGR5 control proglucagon (*Gcg*) gene transcription and GLP-1 secretion in intestinal enteroendocrine (EEC) L cells. AC, adenylyl cyclase; ATP, adenosine triphosphate; Ca²⁺, calcium; cAMP, cyclic adenosine monophosphate; ChREBP, carbohydrate-responsive element-binding protein; EEC, enteroendocrine L cell; FFAR1/2, free fatty acid receptor 1/2; Ffar2, free fatty acid receptor 2; FXR, farnesoid X receptor; Gcg, proglucagon; GLP-1, glucagon-like peptide-1; Gbpar1, G-protein-coupled bile acid receptor 1; Pc1/3, prohormone convertase 1/3; PKA, protein kinase A; SGLT1, sodium-glucose cotransporter 1; TGR5, Takeda G-protein-coupled receptor 5.

hepatic BA production (102). In addition to its regulatory role in BA homeostasis, FGF15/19 regulates several aspects of the hepatic postprandial response, including inhibition of gluconeogenesis (185) and increase in glycogen and protein synthesis (186). Furthermore, FGF15/19 coordinates a physiological feedback loop promoting gallbladder refilling after CCK-induced gallbladder emptying (142). FGF15/19 can also reach the brain where it exerts central metabolic actions, including reduction of food consumption and the regulation of glucose homeostasis (187–190). Pharmacological administration of this hormone promotes other beneficial actions, including the increase in energy expenditure and fat mass loss, improvement of insulin sensitivity, and decrease in blood triglycerides and cholesterol levels (191). However, abrogation of FGF15/19 signaling confers protection against diet-induced obesity (DIO) in *Klb*^{-/-} mice due to changes in the BA pool composition (192). More details on these dedicated effects are described in the sections below.

4.2.3. Intestinal electrolyte and fluid balance.

BAs have become established regulators of colonic fluid balance and can both stimulate or inhibit electrolyte and fluid secretion, depending on the type of BA species and its abundance (reviewed in Ref. 193). Chronic exposure to physiological concentrations of BAs inhibits the actions of Ca^{2+} and cAMP-dependent secretagogues, a process that likely involves BA receptors (194). FXR activation with GW4064 inhibits the Ca^{2+} and cAMP-dependent secretory responses (195), restoring the osmotic driving force for colonic fluid absorption. In addition, FXR stimulation attenuates diarrhea in a mouse model of ovalbumin-induced diarrhea and cholera toxin-induced intestinal fluid accumulation (195). Since food is often absorbed together with water, this effect of BAs might represent a physiological role, whereby food-triggered colonic delivery of BAs simultaneously stimulate water absorption. On the other hand, studies using colonic epithelial cell lines and primary isolated colonic crypts showed that supraphysiological concentrations of BAs increase intracellular Ca^{2+} levels, which, in turn, promote epithelial Cl^- secretion to drive intestinal fluid secretion (196, 197), causing a water secretory diarrhea. Three forms of BA diarrhea (BAD) exist, resulting from compromised ileal BA absorption associated with underlying bowel-related pathologies (type I or secondary BAD) (198), from BA overproduction due to decreased FGF15/19 levels (type II or primary, idiopathic BAD) or following cholecystectomy or other gastroenterological conditions (type III, miscellaneous BAD) (199, 200). A prospective clinical study showed

that FXR activation with OCA improves the consistency of the stool and diarrhea symptoms, both in primary and in secondary BAD patients with short ileal resection (201). These data suggest that, in addition to the well-established BA sequestrants, FXR could be a promising target for the development of novel anti-diarrheal therapeutics [reviewed in Ref. 199].

Although acute exposure to natural and synthetic TGR5 agonists has been reported to reduce Cl^- secretion in rat colon (202), the role of TGR5 in coordinating intestinal fluid balance remains poorly defined. Intriguingly, in the gallbladder, TGR5 rather stimulates Cl^- and bicarbonate excretion through activation of CFTR (134). CFTR is mutated in cystic fibrosis, a disease characterized by the production of abnormally viscous mucus in multiple organs, including the intestinal tract (203). Further studies are warranted to decipher the regulatory role of TGR5 in intestinal mucus formation.

4.2.4. Gut motility.

BAs are well-established regulators of intestinal motility (204–206) and trigger differential responses, according to the region in the gastrointestinal tract. BAs typically inhibit gastric emptying, slow down small intestinal transit to allow nutrient absorption by a process known as “ileal brake”, and finally stimulate colonic peristalsis and transit (207, 208). Consistent with these findings, jejunal BA infusion in healthy subjects delays small intestinal transit (205). Although some of these effects could be indirect by stimulating the release of regulatory peptides such as PYY or GLP-1 from L cells (207, 209) (see sect. 4.2.1), emerging evidence indicates that BAs can directly affect some of these processes through TGR5 activation (210–212). TGR5 is expressed in gastric smooth muscle, and its activation by the natural TGR5 agonist, oleanolic acid (TABLE 2), is proposed to cause gastric muscle relaxation via RhoA inhibition (54). In the colon, secondary BAs trigger the release of 5-HT and CGRP from enterochromaffin cells and intrinsic primary afferent neurons, respectively, thereby stimulating peristalsis (210). Consistently, *Tgr5*^{-/-} mice suffer from a constipated phenotype and a reduction in the frequency of defecation (210). Physiologically, these mechanisms fit with the notion that BAs act as a proxy of nutrient availability. While being released during food intake, they act as signaling molecules to prime the different regions of the intestinal tract for optimal digestion and excretion. Following food consumption, BAs favor nutrient absorption by slowing down the small intestinal transit. Once accomplished, BAs in the distal part will stimulate peristalsis to promote defecation. Consistently, pathological alterations in BA metabolism are involved in the

pathophysiology of constipation and diarrhea (reviewed in Ref. 213).

4.3. BAs in Metabolism and Energy Homeostasis

4.3.1. FXR as a regulator of lipid and nutrient metabolism.

FXR plays a pivotal role in the regulation of intermediary metabolism by influencing the expression of numerous genes involved in hepatic glucose, lipid, and amino acid metabolism (FIGURE 4). The manifold studies summarized below underscore the importance of FXR as a molecular integrator of the nutritional state, thereby coordinating the fate of many nutrients. However, they also unveil the complexity of this regulatory framework, as evidenced by the sometimes divergent results obtained from different *Fxr*^{-/-} mouse models studied under specific metabolic conditions.

4.3.1.1. LIPID HOMEOSTASIS. It has been known for a long time that treating gallstone patients with CDCA decreases hepatic very low-density lipoprotein (VLDL) production and serum TGs (214), while treating hypercholesterolemic patients with BA sequestrants increases circulating TGs (215). In mouse models of hypertriglyceridemia, BAs reduce VLDL secretion and serum TGs and counteract hepatic steatosis (216). These effects have been confirmed by subsequent studies in which FXR agonists were found to reduce circulating TGs (128, 184, 217) and steatosis (184). This beneficial remodeling of lipid metabolism is orchestrated by the FXR-SHP axis, which represses sterol regulatory binding protein-1c (SREBP-1c), a master regulator of hepatic de novo lipogenesis (216) and by FXR-dependent interference of ChREBP binding to the liver pyruvate kinase (LPK) promoter (218) (FIGURE 4, top left). In the liver, induction of the FXR-SHP axis also blunts hepatocyte nuclear factor 4 α (HNF4 α), a master regulator of microsomal triglyceride transfer protein MTP and ApoB expression, two proteins important for VLDL secretion (219). Of note, FXR regulates several apolipoproteins known to impact lipoprotein lipase activity (220, 221) and reverse cholesterol transport (125, 222, 223), further contributing to the beneficial remodeling of lipid metabolism (extensively reviewed in Ref. 224). As expected, whole body *Fxr*^{-/-} mice display an increase in circulating TGs (65, 95, 225–227) and cholesterol (65, 95, 225–228) levels, together with an accumulation of hepatic lipid deposits (95, 225, 229, 230), and enhanced levels of lipogenic genes in the liver (225, 226, 229–231).

Despite the striking steatotic phenotype in whole-body *Fxr*^{-/-} mice (95), it is still not fully established how FXR signaling keeps hepatic fat deposits in check. While a comparative study in liver- and intestine-specific *Fxr*^{-/-} mice

demonstrate that the liver is the principal site of BA-mediated protection against lipid accumulation (231), others show that FGF15/19 is sufficient to blunt SREBP-1c and hepatic lipogenesis (230, 232). Another report shows that intestinal FXR activation, in contrast, promotes SREBP-1c levels and lipid accumulation in the liver through ceramide-dependent mechanisms (233). Future studies will have to instruct which tissues play a predominant role in controlling hepatic fat accumulation, with well-deserved attention to potential contributions from immune cells.

4.3.1.2. GLUCOSE HOMEOSTASIS. BAs are postprandial mediators of glucose homeostasis. Hepatic FXR activation reinforces the actions of insulin by inducing SHP, which results in the transcriptional inhibition of the gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK), and glucose 6-phosphatase (G6Pase), in part, through the repression of the nuclear receptors FOXO1 and HNF4 α (229, 234–236) (FIGURE 4, bottom left). Similar effects are observed when diabetic mice are subject to short-term treatment with the FXR agonist GW4064 (234). The intestinal FXR-FGF15/19-FGFR4 pathway also largely contributes to the abrogation of hepatic glucose production through an interorgan signaling cascade that counteracts cAMP response element-binding protein (CREB), a critical regulator of gluconeogenesis (185). The same intestinal axis inhibits GSK3 in the liver to sustain hepatic glycogen synthesis after the decline of insulin signaling (186). In a cell-autonomous fashion, hepatic FXR activation decreases the transcription of LPK, resulting in a shunt of glucose metabolites from glycolysis toward glycogen synthesis underscoring, once again, the complementary actions of hepatic and intestinal FXR activation (225). In line with these discoveries, the majority of studies reported that lean *Fxr*^{-/-} mice suffer from reduced hepatic glycogen storage and reduced insulin sensitivity (225, 237). FXR also modulates glucose homeostasis directly in the pancreas, where its activation induces glucose-stimulated insulin secretion in isolated pancreatic β -cells, an effect that is lost in islets from *Fxr*^{-/-} mice (238–240). Contrary to physiological BA signaling, chronic pharmacological activation of FXR with OCA enhances glucocorticoid-induced gluconeogenesis during fasting (241).

4.3.1.3. AMINO ACID HOMEOSTASIS. Sustained activation of FXR by OCA (TABLE 2) triggers the expression of amino acid catabolism and ammonium detoxification genes (242, 243). Conversely, the expression of the urea cycle rate-limiting enzyme carbamoyl phosphate synthetase I and other amino acid catabolizing

enzymes is reduced in *Fxr*^{-/-} mice (242, 243) (FIGURE 4, bottom right). In addition, FXR activation in the intestine promotes de novo protein synthesis in the liver (186). Similar to its effect on glycogen synthesis, this process is mediated by the gut-liver FXR-FGF15/19-FGFR4 axis that triggers activation of the hepatic RAS/ERK signaling cascade and phosphorylation of the eukaryotic translation initiation factor 4B and 4E (eIF4B and eIF4E) (186). These proteins are components of the eIF4F complex, whose phosphorylation promotes the initiation of translation (244). Binding of FGF15/19 to FGFR4 also promotes phosphorylation of ribosomal protein S6 (rpS6), which improves the efficiency of global protein synthesis by inducing cap-dependent translation (186).

4.3.2. BAs and the metabolic syndrome.

Obesity is tightly associated with the development of insulin resistance and nonalcoholic liver disease (NAFLD). BAs and their receptors play a central role in the etiology of these obesity-related conditions. Despite the existence of discrepancies among studies, the use of diverse modulators of FXR and TGR5 signaling has significantly increased our knowledge of how BA signaling intersects with multiple pathways known to promote metabolic disease. As a result, novel promising therapies are emerging that target FXR or TGR5 signaling. Especially in the context of NASH, an advanced form of NAFLD, significant progress has been made (described in detail in sect. 5.3). We provide below an overview of the most significant preclinical studies in various mouse models of metabolic diseases. The link between BA signaling and cardiovascular disease, another condition of the metabolic syndrome, is described in sect. 4.4.

4.3.2.1. FXR IN OBESITY AND INSULIN RESISTANCE.

While there is a fairly general consensus on the phenotype of chow-fed lean *Fxr*^{-/-} animals, diverging findings are reported on the role of FXR during obesity. As an example, several groups reported that FXR disruption in obese mice attenuates body weight gain (245–247) and improves insulin sensitivity (245, 247, 248); however, the same disruption in lean mice worsens glucose tolerance (229, 234, 236). Gut-restricted inhibition of FXR activity with synthetic Gly-MCA (28), natural tauro-βMCA (TβMCA) (26, 249) (TABLE 2), or alternatively by genetic disruption of intestinal FXR (233) protects from obesity and diet-induced glucose intolerance (26, 28, 249). Mechanistically, the beneficial effects of intestinal FXR antagonism were attributed to reduced ileal ceramide production that attenuates hepatic gluconeogenesis (249). Recent studies concluded that disruption of the FXR/SHP signaling axis in the liver also improves glucose and fatty

acid metabolism when mice are fed an HFD (250, 251). The exacerbation of obesity and insulin resistance in the setting of HFD feeding is consistent with FXR's role as a postprandial anabolic regulator of nutrient metabolism.

The effects of FXR activation by various synthetic agonists (TABLE 2) also led to discordant results in the setting of obesity. Long-term oral supplementation of GW4064 to obese and insulin-resistant mice exacerbated weight gain, dyslipidemia, and glucose intolerance (160), effects that can be attributed to the lower BA pool size following FXR activation. Conversely, FXR activation with the FXR/TGR5 dual-agonist INT-767 induces a TGR5-dependent increase in GLP-1 secretion, leading to improved glucose and lipid homeostasis in DIO mice (184). Of interest, a deuterated analog of the intestine-specific agonist fexaramine (24), FexD, attenuated DIO and insulin resistance by increasing the thermogenic response in brown (BAT) and white (WAT) adipose fat and blunting gluconeogenesis (252). The same agonist also improved alcoholic liver disease through stimulation of the FXR/FGF15/19 axis (253), although others showed the existence of a cross-talk with TGR5 as a consequence of enhanced production of tauro lithocholic acid (183). Of interest, systemic administration of FGF15/19 to obese and diabetic mice induced an anti-diabetic effect (191). This could be, in part, coordinated by the CNS, since activation of central FGF15/19 signaling reduces food intake (188, 190), body weight (187, 188, 190), and improves glucose homeostasis (187–190) in rodent models of obesity. Consistent with these findings, a human clinical trial (TABLE 3) demonstrated that treatment with OCA (25 and 50 mg/day) increased insulin sensitivity by almost 25% in a cohort of patients with NAFLD and T2D (254).

4.3.2.2. TGR5 IN OBESITY AND INSULIN RESISTANCE.

The role of TGR5 in enhancing lipid catabolism has been extensively studied in the setting of DIO. The first indication for such a role came from the observation that chronic supplementation of CA protects mice against DIO and insulin resistance by enhancing local thyroid signaling and mitochondrial activation in BAT and muscle (266) (FIGURE 8). This was further corroborated by the finding that dietary supplementation of HFD with INT-777 improves glycemic control, reduces liver steatosis, protects against weight gain (33), and induces beiging of the subcutaneous WAT (57). The beiging phenotype was associated with enhanced mitochondrial biogenesis and function, along with marked lipolysis and fatty acid oxidation in response to environmental cues, such as cold exposure or high caloric intake (57) (FIGURE 8). Similarly, TGR5 activation with the specific agonist BAR501 (TABLE 2) prevented DIO and increased the expression of thermogenic genes in BAT

Table 3. FXR agonists in clinical trials

Drug	NCT Number	Acronym	Disease	Phase, Status	Outcome	n	Ref.
OCA, placebo	00501592		T2D, NAFLD	II, completed	Improved insulin sensitivity and reduced hepatic inflammation and fibrosis.	64	(254)
OCA, placebo	01265498	FLINT	NAFLD, NASH	II, completed	Improved liver histology and serum biochemistry, weight loss, increased VLDL and LDL, decreased HDL, pruritus.	283	(255–258)
OCA, placebo	01473524	POISE	PBC	III, completed	Decreased serum ALP and bilirubin, improvement or stabilization of disease features, pruritus, fatigue.	217	(259–261)
OCA	01585025	OBADIAH1	primary and secondary BA malabsorption, chronic diarrhea	II, completed	Increase in FGF19 levels, reduced BA synthesis, reduced TGs, clinical improvements, increase in total and LDL cholesterol.	35	(201)
OCA, placebo	01625026	OCABSGS	obesity, gallstones	II, completed	Increased biliary FGF19, decreased biliary BAs, higher cholesterol saturation index, increased risk of gallstone formation.	40	(167)
OCA	01904539		liver cirrhosis	I, completed	Hepatic impairment increases by two-fold the exposure of the liver to the drug.	32	(262)
OCA, placebo	02177136	AESOP	PSC	II, active not recruiting	Sustained reduction of serum ALP, pruritus.	77	(263)
OCA, placebo	02548351	REGENERATE	NASH	III, active, not recruiting	Improvement of liver fibrosis (interim analysis) while the NASH resolution endpoint was not met.	2480	(168, 264)
Cilofexor, placebo	02854605		NASH	II, completed	Reduction of hepatic fat and serum BAs, improvement in hepatic biochemistry, pruritus.	140	(265)

Continued

Table 3.—Continued

Drug	NCT Number	Acronym	Disease	Phase, Status	Outcome	n	Ref.
Cilofexor, placebo	02943460	PBC-Phase 2	PSC	II, active, not recruiting	Significant improvement of plasma and liver biochemistry, as well as in cholestasis markers. Treatment well tolerated.	52	(20)

AESOP, obeticholic acid in primary sclerosing cholangitis; ALP, alkaline phosphatase; BA, bile acid; FGF19, fibroblast growth factor 19; FLINT, the farnesoid X receptor ligand obeticholic acid in NASH treatment trial; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OBADIAH1, obeticholic acid in bile acid diarrhea; OCA, obeticholic acid; OCABSGS, obeticholic acid in bariatric and gallstone disease; PBC, primary biliary cholangitis; POISE, phase 3 study of obeticholic acid in patients with primary biliary cirrhosis; PSC, primary sclerosing cholangitis; REGENERATE, randomized global phase III study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment; TGs, triglycerides; T2D, Type 2 diabetes; VLDL, very low-density lipoprotein.

and WAT (267). In humans, CDCA oral supplementation increased energy expenditure and BAT activity (268). In vitro assays showed that CDCA induces mitochondrial uncoupling through TGR5 in brown adipocytes isolated from healthy women (268), confirming the results obtained in mice. However, genetics plays an important role in regulating the BA-dependent thermogenic effect, as demonstrated by the resistance of 129S6/SvEvTac mice to the beneficial effects of CA on body weight loss (269).

In addition to stimulating energy expenditure, which indirectly restores insulin resistance, TGR5 also directly regulates glucose homeostasis through its impact on enteroendocrine and immune cells of the myeloid lineage (described in sects. 4.2.1 and 4.4.2, respectively). Administration of TGR5 agonists (33) or intestine-selective activators (270, 271) increases circulating GLP-1 levels and improves glucose tolerance in obese and insulin-resistant mice. Conversely, nutrient-dependent GLP-1 secretion and glucose homeostasis are impaired in whole-body *Tgr5*^{-/-} mice (33). BA sequestrants furthermore improve glucose homeostasis through TGR5-dependent GLP-1 release (175, 272). Treatment with the BA sequestrant, colestimide, reduces body weight gain and increases insulin sensitivity in DIO mice, possibly via TGR5 (273). More recently, it was demonstrated that TGR5 contributes to exercise-induced improvement of muscle function (274) and ameliorates glucose homeostasis by increasing insulin responsiveness in skeletal muscle (275).

4.3.2.3. FXR AND TGR5 IN NAFLD. NAFLD is a common disease affecting more than 70% of the obese and diabetic population worldwide. It includes a spectrum of liver conditions ranging from simple steatosis to more advanced NASH, which in the later stages can culminate into end-stage liver fibrosis and cancer. Although its

etiology is complex and not fully elucidated, accumulating evidence indicates that BA levels and signaling are profoundly disrupted in NAFLD (276–279). FXR is a master regulator of hepatic lipid homeostasis (sect. 4.3.1.1), and disruption of whole body FXR signaling is associated with enhanced NAFLD susceptibility. Consistent with these findings, hepatic lipid accumulation is inversely correlated with FXR expression in NAFLD mouse models or patients (280, 281) and *Fxr*^{-/-} mice show marked steatosis (95), hepatic inflammation, and spontaneous progression to NASH and hepatocellular carcinoma (HCC) (282, 283). Conversely, FXR activation by CA (216), OCA (284), GW4064 (236), WAY-362450 (285, 286), or the intestine-restricted FXR agonist fexaramine (252) (TABLE 2), significantly dampens fat accumulation in the liver and protects against the development of NAFLD, and other hepatobiliary diseases as described in sect. 5.3. Of note, blockage of FXR signaling by genetic disruption of the receptor in the intestine (233), or by administration of the FXR antagonist Gly-MCA (28), also protects against steatosis. These paradoxical results may be explained by the fact that some FXR agonists, such as fexaramine, also impact on TGR5 signaling outside of the enterohepatic axis (252). Indeed, some of the effects of fexaramine, especially those related to WAT browning, were blunted in *Tgr5*^{-/-} mice, suggesting an indirect, yet secondary BA-dependent, activation of this receptor by fexaramine (183, 252). These results would be in line with the known role of TGR5 activation in browning (57). Alternatively, the inhibition of intestinal FXR by Gly-MCA could also impact on the gut microbiome composition and, thereof, on global metabolic health. Indeed, FXR antagonism in the intestine results in a stimulation of BA synthesis that protects against obesity and insulin resistance (287). This would be in line with the established association between gut dysbiosis and NAFLD (288, 289).




FIGURE 8. BA-TGR5 signaling in muscle, adipose tissue, and immune cells. Physiological and environmental cues (gray rectangles on top) modulate gut microbiome and BA pool size/composition to control TGR5 signaling in the depicted cell types and regulate the physiological processes indicated in the green rectangles. Green arrows indicate an increase while red ones indicate a reduction of the indicated cellular functions/processes. TGR5, Takeda G-protein-coupled receptor 5; T_{H17}, T helper 17 cell; T_{reg}, regulatory T cell.

Similar to FXR, TGR5 activation by INT-777 or BAR501 blunts hepatic lipid accumulation in mouse models of obesity (33, 290, 291). As expected, combined pharmacological activation of TGR5 and FXR with the dual agonist INT-767 reverses the progression of several hallmarks of NAFLD and NASH (184, 292–295). Of interest, TGR5/FXR dual agonism shows increased efficacy than OCA in reducing hepatic steatosis and liver damage in mouse NASH models (296).

4.4. BAs in Immune Homeostasis

On the basis of their detergent properties and capacity to disrupt cellular membranes, BAs were initially categorized as proinflammatory agents. Furthermore, this was supported by the knowledge that BA accumulation caused by bile duct obstruction or liver disease leads to hepatic inflammation (297, 298) and that systemic accumulation of BAs can damage extrahepatic tissues, particularly, the kidney (299). Conversely, BAs can also elicit potent anti-inflammatory responses, as first

demonstrated in patients with jaundice and elevated levels of circulating BAs, who experienced significant alleviation of rheumatic symptoms (300). Furthermore, recent evidence suggests that activation of BA receptors exerts anti-inflammatory effects in multiple inflammatory diseases, including experimental autoimmune encephalomyelitis (301, 302), atherosclerosis (53, 217, 303–307), and hepatic inflammation (61, 286, 295, 308–311).

4.4.1. Immunoregulatory properties of FXR.

Compared with its abundant expression in enterocytes and hepatocytes, FXR is only discretely expressed in immune cells (312). Nonetheless, anti-inflammatory responses have been reported in peripheral blood mononuclear cells, in mouse and human myeloid cells, in dendritic cells (DCs), and in hepatic natural killer T cells after exposure to FXR agonists (311, 313–315). On the basis of these findings, several studies have been conducted to elucidate its role in modulating diseases that are triggered by a disturbed immune balance. Despite these efforts, it has not yet been established

whether the anti-inflammatory actions of FXR arise from its cell-autonomous actions on immune cell modulation or rather indirectly from its potent BA and lipid-lowering effect, the latter being essential in protecting the tissues from lipid-induced toxicity.

4.4.1.1. LIVER DISEASE AND NASH. The first tangible indications of an anti-inflammatory role of FXR and its signaling in the liver were derived from *in vivo* studies. *Fxr*^{-/-} mice exhibit a higher incidence of hepatic carcinogenesis (283, 316) and suffer from exacerbated hepatic inflammation and necrosis in a model of autoimmune hepatitis (317), or after LPS-induced inflammation (310, 311). To what extent these phenotypes result from an excessive accumulation of BAs or hepatic lipid deposits is not fully established. Mechanistic studies proposed that the hepatic inflammatory phenotype is triggered by a derepression of NF- κ B, a master transcriptional regulator of proinflammatory cytokines (310). FXR is also tightly connected with inflammation and cholestasis. Activation by GW4064 ameliorates cholestatic liver damage in rats (119), as well as ischemia-/reperfusion-induced liver damage by upregulating SHP in Kupffer cells (318). Furthermore, BAs and FXR modulate sepsis via control of the NLRP3 inflammasome, which could be relevant for cholestasis-associated sepsis. Cholestasis is a common complication in patients with sepsis and significantly increases mortality rate (319). In this pathological context, BAs have been proposed to act as a new class of danger-associated molecular pathways (DAMPs), triggering a hyperinflammatory response via activation of both signal-1 and -2 of the NLRP inflammasome (320). Remarkably, FXR would act as a negative regulator of the NLRP3 inflammasome via direct physical interaction with NLRP3 and caspase 1, hence, preventing its assembly in the mitochondria of activated macrophages (320). Additionally, FXR could also inhibit the inflammasome indirectly by reducing endoplasmic reticulum stress in hepatocytes (321). Of note, engineered FGF19 analog treatment also blunts hepatic inflammation, along with a significant amelioration of cholangiopathies and NASH in mouse models (322, 323). The protective role of FXR/FGF19 signaling in different immunity-related liver diseases, including NASH, PBC and PSC, has been confirmed in patients, as described in sect. 5.3.

4.4.1.2. INTESTINAL INFLAMMATION. Several mouse models of colitis, including dextran sulfate sodium (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis demonstrated that functional disruption of FXR increases, whereas small molecule FXR agonist treatment suppresses, mucosal inflammation (324, 325). Similar phenotypes were found in two independent models of intestinal hyperpermeability and inflammation,

i.e., cholestatic liver injury (326), and ischemia-reperfusion injury (327). Mechanistically, colons from mice with DSS-induced colitis treated with OCA displayed reduced proinflammatory cytokine (mainly IL-1 β and IL-6) and chemokine expression (324). OCA also repressed Toll-like receptor 4-induced proinflammatory gene expression in intestinal epithelial cells (IECs) (315) and attenuated inflammatory cytokine and chemokine expression in cultured human CD14⁺ monocytes and DCs (324). Thus, FXR appears to limit mucosal inflammatory responses by acting on both IECs and innate immune cells. Of note, intestinal FXR expression was decreased in patients with colitis, and its activation reduced disease severity (315, 328, 329). More recently, the bacteria-derived secondary BA, 3 β -hydroxydeoxycholic acid (isoDCA), was shown to further refine the immunological balance of the colon by limiting FXR activity in DCs to allow the differentiation of pT_{reg} cells (313). This highlights the complex interplay between BAs, the gut microbiome, and FXR, a topic discussed in detail in sect. 4.6.3.

4.4.1.3. CARDIOVASCULAR DISEASE. The role of FXR in atherosclerosis is still under debate. An increase in the atherosclerotic lesion area and an altered plasma lipid profile was observed in a *Fxr*^{-/-} *ApoE*^{-/-} double knockout (DKO) mouse model fed a HF/HC diet (304). Conversely, two other studies showed reduced atherogenic lesion size after FXR disruption in mice on a *Ldlr*^{-/-} or *ApoE*^{-/-} background, together with unexplained differences in plasma lipids (217, 303). Studies using FXR agonists, however, observe protection against lesion formation in *ApoE*^{-/-} or *Ldlr*^{-/-} atherosclerosis-prone mice (305, 314). FXR signaling is also functional in vascular smooth muscle cells (330), and its stimulation blunts the inflammatory response and reduces cell migration. Mechanistically, FXR induces SHP and inhibits the expression of both cyclooxygenase-2 and inducible nitric oxide synthase (331).

4.4.2. Immunoregulatory properties of TGR5.

TGR5 is highly expressed in cells of the myeloid lineage (31) and is considered a negative modulator of inflammation (reviewed in Ref. 332) and FIGURE 8). In addition to its cross talk with master regulators of inflammation, such as NF- κ B and C/EBP β (discussed below), indications exist that the BA-TGR5 axis shifts macrophages toward a more regulatory and anti-inflammatory phenotype (59, 295, 333–335). The anti-inflammatory role of TGR5 signaling in monocytes and macrophages profoundly modulates the physiology of metabolic tissues, such as liver, adipose tissue, and vasculature, and, consequently, influences the development of NASH, T2D, and atherosclerosis.

4.4.2.1. LIVER DISEASE AND NASH. Stimulation of TGR5 in myeloid cells exerts potent immunosuppressive actions and dampens NF- κ B-mediated cytokine expression in mouse models of LPS-induced hepatic inflammation (61). Furthermore, dual activation of FXR and TGR5 by INT-767 improved NAFLD and increased the number of intrahepatic anti-inflammatory monocytes, suggesting that both receptors act hand in hand to reduce liver inflammation (295). More recently, it was demonstrated that TGR5 agonism by itself can rescue the hepatic and vascular damage caused by exposure to a high-fat, high-fructose diet (290). TGR5-dependent suppression of cytokine production in Kupffer cells is, furthermore, potentiated following bile duct ligation in rats, indicating a protective role of TGR5 in cholestasis-induced liver injury (336).

4.4.2.2. INTESTINAL INFLAMMATION. TGR5 activation by natural BAs or INT-777 suppresses LPS-induced inflammatory cytokine expression, whereas these responses are elevated and unresponsive to BAs in macrophages lacking TGR5 (337, 338). In mouse models of TNBS- or DSS-induced colitis, TGR5 activation attenuates the symptoms of inflammatory bowel disease (IBD), whereas functional disruption of TGR5 impairs intestinal barrier and exacerbates the inflammatory response (337, 339). In addition, activation of TGR5 by BAR501 was shown to switch mucosa-associated macrophage phenotypes from M1 (proinflammatory) to M2 (tissue-protective) during chemically induced colitis (333). In this setting, TGR5 activation reduced the expression of proinflammatory cytokines (TNF- α , IL-1 β , IL-6, and IFN- γ) and increased the expression of anti-inflammatory cytokines (TGF- β and IL-10) (333). Induction of IL-10 in macrophages allowed the recruitment of T_{reg} cells to inflamed colonic tissue (333). These TGR5-mediated anti-inflammatory pathways not only acutely suppress innate immune responses, but also guide the downstream priming of inflammatory T-cell responses. In particular, activation of TGR5 by BAs directs the differentiation of monocytes toward tolerogenic DCs that secrete low levels of TNF- α and IL-12, cytokines required for the priming of proinflammatory Th1 responses (340). In addition, ex vivo treatment of mucosa-associated macrophages isolated from Crohn's disease patient biopsies with a TGR5 agonist reduced inflammatory cytokine expression, including TNF- α (338), suggesting that disturbed BA circulation and/or metabolism during chronic intestinal inflammation may limit endogenous TGR5 activation.

4.4.2.3. CARDIOVASCULAR AND METABOLIC DISEASE. The role of TGR5 as an anti-inflammatory mediator has also been studied in the context of atherosclerosis. In

vivo experiments showed that INT-777 supplementation blunts the development of atherosclerosis in *Ldlr*^{-/-} mice fed a HC diet. This anti-atherogenic effect is driven by cAMP induction, followed by repression of NF- κ B-activation and cytokine production in macrophage-resident plaques (53). Similar results were observed in *ApoE*^{-/-} and *Ldlr*^{-/-} mice treated with the dual FXR/TGR5 agonist INT-767 (307), an effect that was lost in the triple *Ldlr*^{-/-}, *Fxr*^{-/-}, and *Tgr5*^{-/-} mice (306). In other metabolic tissues, additional mechanisms contribute to the TGR5-mediated anti-inflammatory effects. For instance, insulin resistance is exacerbated by increased inflammation, especially in white fat depots. TGR5 activation of adipose tissue macrophages reduces LPS-induced chemokine expression and protects DIO animals from adipose tissue-associated insulin resistance (59) (FIGURE 8). Specifically, INT-777 treatment of macrophages activates mTOR complex 1 (mTORC1), which induces the differential translation of the liver-enriched inhibitory protein (LIP) to reduce cytokine transcription and macrophage migration (59). In line with these observations, a recent study demonstrated that activation of the TGR5-cAMP-PKA pathway in innate macrophages induces phosphorylation and degradation of the NLRP3 inflammasome, resulting in an improvement of insulin sensitivity and glucose tolerance (341).

4.4.2.4. ANTIVIRAL RESPONSE AND SENESCENCE. In addition to its role in macrophages, TGR5 has been suggested to control antiviral innate immunity through the activation of an AKT/IRF3 (342) and the β -arrestin-SRC signaling axis (58). Furthermore, TGR5 modulates cytokine levels in the context of cell proliferation and senescence, as INT-777 prevents IL-1 β induction of cell senescence in human chondrocytes (343), indicating that the anti-inflammatory effect of TGR5 signaling is widespread.

4.5. BAs in Tissue Plasticity and Remodeling

Tissue plasticity and regeneration are dynamic processes that involve multiple signaling pathways. Several lines of evidence suggest that BAs are implicated in liver regeneration through modulation of FXR and TGR5 signaling. In addition, BA signaling contributes to cellular reprogramming, a process with great potential for the treatment of hematopoietic, immune, and metabolic diseases.

4.5.1. BAs in liver regeneration.

The liver is one of the few organs that can robustly regenerate itself in response to partial ablation or injury.

BAs, together with cytokines and growth factors, activate specific signaling pathways and gene expression programs essential for hepatic regeneration. Several studies demonstrated an inhibition of liver regeneration following interruption of the normal enterohepatic biliary circulation (344, 345). BAs were also found to directly stimulate hepatocyte proliferation (346) and a study based on a 70% partial hepatectomy (PHx) mouse model demonstrated that low doses of BAs promote liver regeneration (347) (FIGURE 9). Conversely, reduction of total BA levels with BA sequestrants delayed liver regeneration (347). FXR and TGR5 display distinct roles in this complex adaptive process.

4.5.1.1. HEPATOCYTE FXR AND LIVER REGENERATION.

FXR was initially described as the master regulator of BA-mediated homeostrophic liver growth during hepatic

regeneration (347). Enhanced activity of both intestinal and hepatic FXR contributes to this process (FIGURE 9). The first physiological change during PHx is the redistribution of portal and arterial blood supply to the remnant liver. As a result, hepatocytes become exposed to an approximately threefold greater amount of regenerative factors, including BAs, which are mainly supplied by the portal vein (348). This leads to a robust activation of hepatic FXR that induces the expression of the forkhead box M1b (FOXM1B), a key transcription factor controlling hepatocyte DNA replication during liver regeneration (347, 349). FXR posttranslational modifications can also have an impact on hepatocyte regeneration, as illustrated by SIRT1-mediated deacetylation of FXR, which inhibits its activity and impairs hepatocyte proliferation after PHx (350). In addition to directly stimulating hepatocyte proliferation, FXR activation promotes the active




FIGURE 9. BA signaling in liver regeneration. Molecular mechanisms by which a sudden rise in BA concentration following partial hepatectomy coordinates liver regeneration. FXR and TGR5 play complementary roles in stimulating proliferation in hepatocytes and cholangiocytes, respectively. EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; FGF15/19, fibroblast growth factor 15/19; FGFR4, fibroblast growth factor receptor 4; FOXM1B, forkhead box M1b; FXR, farnesoid X receptor; JAK/STAT, janus kinase/signal transducer and activator of transcription; MAPK, mitogen-activated protein kinase; ROS, reactive oxygen species; SRC, steroid receptor coactivator; TGR5, Takeda G-protein-coupled receptor 5.

efflux of BAs from hepatocytes through the transcriptional upregulation of dedicated transporters (described in sect. 4.1.1) (117). BA efflux from the remnant liver is further reinforced by coordinated activation of TGR5 in cholangiocytes (139) (see section below). This harmonized mechanism helps to protect the remnant liver from apoptosis triggered by the cytotoxic effects of BA overload (139, 351) and leads to an acute increase in BA levels in the intestine and systemic circulation (352). In turn, BAs activate intestinal FXR, which stimulates FGF15 secretion, whose signaling is also implicated in liver regeneration. Mechanistically, the FGF15/FGFR4 axis reinforces the effects of hepatic FXR activation by upregulating FOXM1B and its downstream mitogenic target genes (*Cdc25b*, *Ccnd1*, and *Pcna*) (353). In addition, FGF15 helps to protect hepatocytes against apoptosis triggered by high levels of BAs by suppressing *Cyp7a1* transcription and, thus, de novo BA synthesis (354). Consequently, *Fgf15*^{-/-} mice were found to suffer from severe liver injury and had exacerbated mortality after PHx. This effect is attenuated upon treatment with the BA sequestrant, cholestyramine, or after adenoviral delivery of FGF15 (353). Kong et al. (355) observed similar effects in *Fgf15*^{-/-} mice and identified additional mitogenic pathways controlled by this growth factor. *Fgf15*^{-/-} mice exhibited reduced activation of the JNK and p38 pathways, confirming earlier reports on FGF15-induced MAPK signaling (356). The mutant mice also suffered from reduced activation of the JAK/STAT pathway (356), a pathway known to be activated during liver regeneration (357, 358). Mechanistically, the mitogenic effects of STAT3 appear to be mediated by FOXM1B (359, 360), suggesting that both cell-autonomous (FXR-mediated) and non-cell autonomous (FGF15-mediated) effects of BAs on proliferation converge on this transcription factor. Interestingly, selective activation of intestinal FXR or treatment with FGF19 also reduces inflammation and liver necrosis after obstructive cholestasis induced by bile duct ligation (153).

In addition to their role in pathological settings, BAs have been reported to mediate FXR-dependent hepatocyte proliferation under physiological conditions. For instance, during pregnancy, FXR is important for fetal liver growth, and its loss of function reduces fetal liver enlargement (361).

4.5.1.2. CHOLANGIOCYTE TGR5 AND LIVER REGENERATION. Although the role of FXR in liver regeneration has been extensively studied, less is known about TGR5 in this process. Nonetheless, TGR5 is an important player involved in cholangiocyte proliferation, while simultaneously protecting the liver against BA overload. A study demonstrated that PHx was followed by cholestasis and hepatocyte necrosis and markedly delayed liver

regeneration in *Tgr5*^{-/-} mice (139). At the molecular level, the mechanisms through which TGR5 protects the remnant liver from BA cytotoxicity are different and complementary from those of FXR. The origin of this difference lays in the divergent patterns of expression of these two receptors with FXR being highly expressed in hepatocytes, while TGR5 is especially enriched in the gallbladder and biliary tract (134), where it contributes to adaptation of ion bile composition after PHx. Indeed, in cholangiocytes, TGR5 controls CFTR-dependent Cl⁻ secretion (134), and the observed TGR5-dependent increase in biliary HCO₃⁻ and Cl⁻ output after PHx likely constitutes an adaptive mechanism to enhance bile secretion and fluidity and, consequently, protect the overloaded remnant liver from BA toxicity (139) (also discussed in sect. 4.1.2). In line with the idea that TGR5 contributes toward increase in bile turnover during liver regeneration is the observation that TGR5 facilitates BA elimination in the urine, protecting the entire organism from BA overload (139). Another mechanism through which TGR5 protects the liver from BA toxicity during regeneration is through its control of BA hydrophobicity. Several studies demonstrated that *Tgr5*^{-/-} mice exhibit a more hydrophobic BA composition (137–139), which exacerbates hepatocyte injury immediately after PHx. Accordingly, liver injury in *Tgr5*^{-/-}-hepatectomized mice can be rescued by BA resins (139). Consistently, an enlargement of a hydrophobic BA pool was also associated with an inhibition of liver regeneration in a model of PHx (350).

BA feeding is also known to induce cholangiocyte proliferation (362), an effect later on attributed to its potential to activate TGR5 (56) (FIGURE 9). Mechanistically, conjugated LCA and TGR5-selective agonists were shown to induce cholangiocyte proliferation through elevation of reactive oxygen species and SRC-mediated EGFR transactivation. Subsequent MAPK phosphorylation induced proliferation in *Tgr5*^{+/+}, but not in *Tgr5*^{-/-}-derived cells (56). Similar interactions between BA signaling and transactivation of the EGFR have been reported to control the proliferation of other cell types (363–366), suggesting that it may represent a universal and novel mitogenic branch of BA signaling.

4.5.2. BAs in differentiation and cellular reprogramming.

4.5.2.1. FXR IN STROMAL CELL DIFFERENTIATION. Mesenchymal stromal cells give rise to osteoblasts and adipocytes. FXR activation regulates this process by promoting both osteoblast (367, 368) and adipocyte differentiation (369). The proadipogenic phenotype was attributed to a synergism with the master regulator of adipogenesis PPAR γ and to the suppression of the Wnt/ β -catenin signaling pathway (369). The FXR antagonist,

guggulsterone (29), impairs osteoblast differentiation but induces the expression of adipogenic markers, suggesting a role for FXR in the regulation of the osteoblast/adipocyte balance (368). Altogether, these studies show that FXR disruption significantly impacts diverse aspects of bone homeostasis and adipogenesis. A recent study demonstrates that overexpression of FXR in WAT alters its architecture, under-scoring the need for a tight regulation of FXR expression/activity in white fat (370).

4.5.2.2. TGR5 IN ADIPOCYTE REPROGRAMMING. The white-to-brown conversion of adipose tissue, a phenomenon referred to as beiging, is a dynamic process involving the genetic rewiring toward a mitochondrial phenotype. Beiging is triggered by chronic cold exposure and β -adrenergic stimulation, and multiple cell types, including adipocyte precursors, immune cells, and mature adipocytes, participate in this process (371). TGR5 is required for the emergence of beige adipocytes within WAT upon cold exposure (57) (FIGURE 8). Pharmacological stimulation of TGR5-induced beige remodeling during HFD feeding (57, 267), independently of adrenergic stimulation (57). Mechanistically, TGR5 activation leads to lipolysis, mitochondrial fission, and mitochondrial biogenesis over time (57). These results highlight a critical role of the TGR5 signaling axis in mitochondria dynamics that could underlie a general feature linked to cell differentiation and/or reprogramming.

4.5.3. BAs as components of the intestinal stem cell niche.

Epithelial cells of the intestine undergo rapid renewal to counteract intestinal damage and disruption of the barrier function (372). Renewal and patterning of the intestinal epithelium are carried by intestinal stem cells (ISCs) that reside at the bottom of intestinal crypts (372). These crypts define an ISC niche that regulates the balance between self-renewal and cell fate specification (372). Recent studies demonstrated that BAs constitute an intrinsic regulatory component of the ISC niche capable of regulating both the renewal and the specification of ISCs (172, 373). In particular, BAs were shown to foster epithelial regeneration under both physiological and colitis-induced conditions by activating TGR5 in the ISC compartment through a mechanism involving yes-associated protein 1 (YAP) and its upstream regulator SRC. Importantly, endogenous BA release in the intestinal lumen was found to be sufficient to coordinate ISC renewal and proliferation (373). These findings suggest that the physiological cycles of food intake followed by discharge of BAs in the intestinal lumen represent an intrinsic stimulus that dictates ISC proliferation rhythms to sustain daily regeneration (373). BAs also seem to play a role in

the patterning of the intestinal epithelium, as another study reported that the BA/TGR5 axis regulates L-cell differentiation and abundance in the intestinal epithelium (172). In vivo, TGR5 activation elevated GLP-1 secretory capacity and improved glucose tolerance (172). While BAs appear to be an integral component of the ISC niche, their levels and chemical structure must be kept in check, as both quantitative and qualitative changes in the BA pool can initiate and drive the proliferation of cancer ISCs (25). Indeed, BA species known to antagonize FXR (mainly T β MCA and DCA) were shown to induce proliferation and DNA damage in *Lgr5*⁺ cancer stem cells (25). Therapeutically, FexD, a gut-biased FXR agonist, delayed tumor progression and profoundly increased survival in APC^{min/+} mouse models of adenoma and adenocarcinoma (25), suggesting that restoring a healthy BA balance might represent a therapeutic approach to treat colorectal cancer.

4.6. BAs, Gut Microbiota, and Host Metabolism

The gut is home to one of the most complex ecosystems known, the gut microbiome, which has an impact on nearly every aspect of physiology (reviewed in Ref. 374). How the host and the microbiome communicate with one another is an intense area of research. Because the BA pool is generated by the host and actively modulated by intestinal bacteria, these molecules are key in mediating this symbiotic communication (FIGURE 6). Furthermore, BAs actively shape the microbiome at the highest taxonomic levels. This interlinked dependence turns the BA-microbiome axis into a chief determinant of health and disease.

4.6.1. The gut microbiome shapes the BA Pool.

Microbial conversion of primary into secondary BAs increases BA diversity and promotes hydrophobicity of the BA pool (11). Several studies using germ-free (GF) or antibiotic-treated rodents revealed both a quantitative and a qualitative modification of the BA pool, characterized by an overall enlargement of the BA pool size and an increased ratio of primary conjugated to secondary BAs (375–378). In the host, TGR5 signaling is particularly affected by the microbiome, as the secondary BAs, LCA, and DCA, and their conjugated forms are potent TGR5 activators. In fact, microbial transformation of primary to secondary BAs represents the most direct link between BA 7 α -dehydroxylating gut bacteria and host health. This is exemplified in humans, who unlike rodents, cannot reconvert secondary BAs into primary ones by hepatic 7 α -hydroxylation (379). Therefore, dietary or pharmacological interventions (e.g., antibiotics) that modulate the proportion of intestinal bacteria with 7 α -dehydroxylation activity alter the availability of endogenous TGR5 ligands (380). In fact, dietary modification,

including changes in protein (381) or fat (382, 383) source, can modulate the gut microbiota composition and, consequently, the intestinal BA pool. In turn, major changes in the BA pool, such as those triggered by antibiotics, can influence whole body energy and glucose homeostasis (FIGURE 6) (384). Other environmental cues, including cold exposure (4, 385, 386) induce similar phenotypes (FIGURE 6). In line with these findings, a recent study demonstrated that broad-spectrum antibiotics given to healthy adults prior and subsequent to seasonal influenza vaccination significantly impaired H1N1-specific neutralization (387). This was accompanied by a dramatic reduction in serum secondary BAs, which was highly correlated with AP-1/NR4A signaling and inflammasome activation, suggesting an involvement of TGR5 signaling in systemic immune homeostasis as described in sect. 4.4.2 (387).

The microbiome also directly affects quantitative aspects of the BA pool size, which is nearly doubled in GF mice (376). The mechanisms explaining this effect are only starting to be understood and involve the gut microbiome-mediated shift of BA composition from FXR antagonists to agonists. For instance, the absence of microbiota resulted in the accumulation of BAs with FXR-antagonizing properties, such as T β MCA, which were identified as the main endogenous FXR antagonists that could not be metabolized in the absence of intestinal bacteria (376). Consistent with the obesogenic phenotype of mice after long-term FXR agonist treatment (160), accumulation of T β MCA enhanced BA synthesis and recycling (376), which, in turn, contributed to the resistance against DIO observed in GF *Fxr*^{-/-} mice (287). Similarly, administration of glycine- β -MCA (Gly-MCA), a β MCA analog resistant to bacterial deconjugation, improves metabolic homeostasis by inhibiting FXR specifically in the intestine (28). Of note, novel gut microbiome-produced secondary BAs have recently been discovered that would act as FXR agonists (388). In addition to the well-studied BA deconjugating activity, gut bacteria of the *Clostridium* species were shown to conjugate cholates with phenylalanine, tyrosine, and leucine through a yet unknown enzymatic reaction (388). These novel BA conjugates are absent upon antibiotic treatment and seem to be increased in HFD-fed mice and IBD patients (388), indicating a potential role of these metabolites in metabolic and inflammatory disorders.

Antioxidants and drugs can similarly impact on the BA pool because of their effects on BA metabolizing members of the microbiome. For instance, remodeling of the gut microbiota with the antioxidant tempol increases T β MCA levels, resulting in an inhibition of intestinal FXR signaling and a decrease in obesity (26). Probiotic supplementation can also positively or negatively modulate

BA synthesis in the liver. Treating mice with the VSL#3 probiotic formulation increased BA deconjugation and fecal excretion along with an induction of hepatic BA synthesis (389). Conversely, *Lactobacillus rhamnosus* GG supplementation reduced hepatic BA levels by promoting the synthesis of FXR agonists, which prevented excessive BA-induced liver injury and fibrosis in mice (390). Finally, it should be noted that the glucose-lowering effects of metformin are, in part, mediated by the intestinal reduction of *Bacteroides fragilis*, leading to an increase in the production of the intestinal FXR antagonist glyco-UDCA (GUDCA) (27). Conversely, certain pathological conditions can lead to a microbiota-host cross talk, in which the modified BA profile will propel the disease. For instance, progressive hypercholanemia during pregnancy was recently reported to originate from an altered microbiome associated with a lowering of ileal FXR activity and subsequent enhancement of hepatic BA synthesis leading to an elevation of circulating BAs (391). UDCA can treat this condition but only in women with a microbiome characterized by a high ratio of *Bacteroidetes* to *Firmicutes* (391). In these women, it is suggested that UDCA could be converted to CDCA, leading to an activation of ileal FXR and to an increase of the FGF19-mediated enterohepatic feedback on BA production (392). On the other hand, UDCA has also been described as an FXR antagonist able to increase BA synthesis and reduce FGF19 levels in obese patients (393). Similarly, a *Clostridia*-rich microbiota and their BA metabolites, including UDCA, were shown to suppress intestinal FGF19 expression, contributing to excessive BA excretion in patients with diarrhea-predominant irritable bowel syndrome (394). Remodeling of the gut microbiota and alteration of the BA profile also takes place after chronic alcohol consumption (253). In turn, this altered BA pool was shown to promote alcoholic liver disease that could be ameliorated by treating alcoholic mice with the intestine-restricted FXR agonist fexaramine or by overexpression of a nontumorigenic FGF19 variant (253). Finally, the metabolic benefits of surgical interventions also seem to depend on changes in the gut microbial communities and affect FXR-dependent processes (246). This topic is further developed in sect. 5.2.

4.6.2. The BA pool shapes the gut microbiome.

The effects of the microbiome on the BA pool are bidirectional since BAs also modulate the gut microbiota composition. Similar to HFD feeding which stimulates bile secretion (395), BAs reshape the microbial landscape and shift the ratio of bacterial phyla (396) through both direct antimicrobial effects (397) and indirect effects mediated by FXR-induced antimicrobial program

(398). The antimicrobial properties of BAs are a function of their hydrophobicity. DCA, for instance, is a more potent antimicrobial agent than CA, owing to its high hydrophobicity and detergent properties on bacterial membranes (399). DCA promotes the survival of microbe populations that resist BA-induced membrane damage (400). Complex and significant changes in the gut microbiome are observed when rats are fed BAs. A high-CA (5 mmol/kg) diet profoundly alters the gut microbiome at both the taxon and phylum levels (396), with significant inhibition of the *Bacteroidetes* and *Actinobacteria*, two of the three major phyla reported in human microbiomes (396). Consequently, expansion of the *Firmicutes*, in particular *Clostridium* cluster XVa, increased the number of DCA-producing bacteria, highlighting the bidirectionality of the BA-microbiome axis (396). Although the potential contribution of BA-responsive receptors to this phenotype was not investigated in this study, it is now recognized that the effects of BAs on the microbial landscape can also be mediated through these receptors. It was recently demonstrated that FXR activation by OCA reduces endogenous BA levels and increases the proportion of Gram-positive bacteria (401), demonstrating that the human microbiome can dynamically respond to BA modulation. Modulating the BA pool can also be a therapeutic strategy in the fight against intestinal infections, in particular, nosocomial infections caused by *Clostridium difficile*. This infection often arises following the depletion of intestinal bacterial species after antibiotic treatment (402). In this context, *Clostridium scindens*, a species able to 7 α -dehydroxylate BAs, was identified to confer protection by generating secondary BAs that block the germination of *Clostridium difficile* spores (403). Similarly, LCA was recently demonstrated to lock vancomycin-resistant *Enterococcus* bacteria in diplococcal mode, impairing their biofilm formation and increasing their susceptibility to the antibiotic daptomycin, demonstrating that BAs not only select bacteria but also actively shape their morphotype (404). Thus, BA pool size and composition appear to be some of the most important host factors in regulating gut microbial density, community, and structure in humans.

4.6.3. The BA-microbiome axis modulates intestinal immunity along the gastrointestinal tract.

Immune cells at the mucosal surface of the gut are challenged with the rapid detection and elimination of pathogenic microorganisms, while also maintaining tolerance toward commensal bacteria (405). Genetic or environmental insults can disrupt this balance and precipitate chronic intestinal inflammation characteristic of IBD (406). The BA-microbiome axis finely shapes the

immunoregulatory microenvironment along the gastrointestinal tract. In the ileum, high (millimolar) concentrations of conjugated primary BAs prevent bacterial overgrowth through both direct antimicrobial effects (reviewed in Ref. 397), and indirect, FXR-mediated, induction of an antimicrobial program (398). In the colon, the immunological balance requires further adjustments during microbial colonization when immune cells need to develop tolerance toward commensal bacteria (405). The BA-microbiome axis plays a key role in this process as the bacteria-derived secondary BA isoDCA limits FXR activity in DCs to diminish their immunostimulatory properties (313). The anti-inflammatory phenotype acquired by DCs, in turn, allows the differentiation of pT_{reg} cells that help dampen immune responses during bacterial colonization (313). In the colon, microbiome-derived secondary BAs can also maintain a healthy pool of FOXP3⁺ ROR γ ⁺ T_{reg} cells by selectively activating VDR signaling (72). Colonic, microbiome-derived BAs further modulate TGR5 activity in DCs to instruct tolerance toward commensal microbes. Specifically, activation of TGR5 by secondary BAs channels the differentiation of human monocytes into tolerogenic DCs that secrete low levels of TNF- α and IL-12 cytokines (340). Similarly, two BA microbial metabolites were recently shown to fine-tune intestinal immunity (407). 3-oxo-LCA blocked TH17 differentiation via retinoid-related orphan receptor- γ t (ROR γ t), while isoallo-LCA increased T_{reg} differentiation through a mitochondrial ROS-FOXP3-dependent signaling (407), possibly by activating TGR5 (FIGURE 8). These data suggest that the host-BA-microbiome axis defines a BA-mediated, pan-genomic network of communication. Immunological tolerance toward commensal bacteria is instructed by the microbiome itself through complex modifications of the host's BA profile. Disturbance of this BA-based communication network can propel the development of inflammatory diseases. Indeed, reduced microbial metabolism of primary BA precursors into secondary BA products during states of dysbiosis negatively impacts on TGR5 signaling during intestinal inflammation, as observed in IBD (408, 409). Therapeutically, restoration of secondary BA levels directly through rectal administration (409) or indirectly through administration of a hydrolyzed protein diet (410) can help in the management of these diseases.

4.7. BAs and Aging

Aging is defined as the progressive decline of cellular and, ultimately, organismal function. Although BAs are known to be beneficial in the treatment of chronic metabolic and inflammatory disorders, their effect on lifespan remains elusive in mammals. There are, nonetheless,

indications that steroid acids with BA-like features or bona fide BAs can regulate longevity in *C. elegans* (411–414). The first tangible evidence for a role of BAs in lifespan regulation stems from high-throughput screens in yeast, in which the secondary BA LCA was identified to extend the chronological lifespan in a calorie restriction-independent fashion (415). Another report proposed that intracellular LCA modifies the inner mitochondrial membrane lipidome to enlarge mitochondria and increase the number of disconnected cristae (416). This remodeling would enhance respiration, ATP synthesis, and production of ROS, resulting in a global increase of mitochondrial long-term stress resistance (416, 417).

In mammals, age-related changes in the BA composition of bile (418), liver, and serum (419) have been reported. Although the nature of these modifications differs according to various factors, including gender, aging is mainly associated with a decline in BA levels (420). In further support of this notion, long-lived dwarf mice (*Ghrhr^{lit/lit}*), characterized by a defect in growth hormone/IGF-1 signaling, exhibit an enlarged BA pool size (421). Of interest, xenobiotic detoxification is enhanced in these mice, most likely through a BA-mediated mechanism (421). Moreover, CA administration in wild-type mice mimics the changes in drug-metabolizing enzymes observed in *Ghrhr^{lit/lit}* mice, suggesting that the xenobiotic stress response induced by BAs could contribute to extending lifespan (422). Remarkably, methionine restriction was found to extend healthspan and lifespan of progeroid mice by normalizing a dysfunctional BA pool (423). The same phenotype could be recapitulated by dietary intervention with CA (423). Premature aging was also delayed in progeroid mice by fecal microbiota transplantation of healthy wild-type mice (424), and the reconstitution of the secondary BA pool size was identified as a mechanism that accounts for the prolonged lifespan. Although these observations point to a role for TGR5 in this process, its exact role remains to be identified. It is, however, noteworthy that the expression of FXR and TGR5 declines with age and that dual agonists for TGR5 and FXR delay age-related kidney deterioration (425), as well as osteoporosis, another age-related disease (426). The intricate relationship between BA signaling, healthspan, and longevity, thus, seems to represent an interesting area of future investigations that will undoubtedly shed light on how BAs modulate lifespan.

5. STRATEGIES TO MODULATE BA SIGNALING

5.1. Physiological and Environmental Cues

Food ingestion and circadian rhythmicity are well-established physiological cues that coordinate BA homeosta-

sis. Recent evidence, however, indicates that multiple environmental factors dramatically alter this tightly regulated process (FIGURE 6). Often, these effects imposed by the environment go along with changes in the gut microbiota. In the last decade, the role of HFD feeding on microbiota-host interactions has been the focus of intense research. In addition to its marked impact on the gut microbial community (427), HFD significantly influences the BA pool size and composition (25). The consumption of HFD increases the synthesis of CA and DCA and decreases the levels of CDCA in healthy subjects (428). In rodents, secondary BAs are significantly higher in HFD compared to CD-fed controls (25, 373, 429). Cold exposure also dramatically alters the microbiome and counteracts metabolic disease. This was first illustrated by the observation that bacteria transplanted from cold-exposed mice improve the metabolic outcome of recipient mice (385) and that BAs could play a role in this process (4, 386). Cold exposure increased the ratio of conjugated BAs (4, 386), and enlarged the BA pool through selective induction of the alternative BA synthesis pathway (4). In support of the latter finding, *Cyp7b1^{-/-}* mice were unable to adjust their BA pool and displayed lower body temperature after cold challenge. A similar phenotype on body temperature was observed in adipose-specific *Tgr5^{-/-}* mice, suggesting that an adequate thermogenic response requires TGR5 in adipocytes (57). Furthermore, one of the main BA species to be increased in response to cold is the FXR antagonist T β MCA (386). Altogether, these results suggest that cold, as an environmental cue, impacts the gut microbiota in such a way that it induces TGR5 signaling while concomitantly attenuating FXR activation. Another environmental factor that enhances energy expenditure is exercise. Morville et al. (430), observed that several BAs are significantly altered following endurance and resistance exercise. Among those, the TGR5 endogenous agonists LCA and DCA were consistently induced (430). The hallmarks of exercise-induced phenotypes, such as increased energy expenditure and improved glucose tolerance, may, hence, be coordinated, at least in part, by an activated TGR5 signaling pathway.

5.2. Surgical Interventions

Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG) and bile diversion to the ileum (GB-IL) are surgical procedures that promote weight loss and induce a rapid remission of T2D in patients. Although the mechanistic basis for this phenomenon is not fully established, an elevated concentration of circulating incretin hormones is a hallmark that may contribute to these metabolic improvements (reviewed in Ref. 431). In 2009, Patti et al. (432) demonstrated for the first time

that serum BAs are also significantly elevated in patients following RYGB, and proposed TGR5 as a putative mechanism by which improvements in glucose and body fat management can be achieved, which was later confirmed by other studies (433, 434). A subsequent study confirmed that DCA, a very strong TGR5 agonist, is increased in patients 24 mo after RYGB, while UDCA and its conjugated forms are the most changed BAs 1 mo after surgery (433). Although some studies reported TGR5 as a mediator of the RYGB-mediated metabolic improvements, including GLP-1 secretion (60), others failed to confirm these findings (435). Furthermore, although there is agreement that activation of TGR5 improves glucose response and attenuates fatty liver disease (436, 437), controversy exists relative to its role in energy expenditure in the context of VSG. A study using a DKO model of TGR5 and glucagon receptor suggested that TGR5 is not critical for the secretion of proglucagon-derived peptides (438). Although sustained elevation in circulating BAs is a phenotypic consequence of all bariatric procedures, they are also typified by a relocation of BA delivery to more distal segments of the small intestine and an induction of the ileal signaling factor and FXR target, FGF19 (439). Two independent studies demonstrated that DIO whole-body or intestine-specific *Fxr*^{-/-} mice can no longer recapitulate the metabolic improvements observed after VSG (246) or GB-IL (440). Further studies are required to identify the missing link between gastric bypass surgeries, FXR, and weight loss, but dynamic alterations of the BA pool and the gut microbiome seem to play a key role in this process (441) (FIGURE 6). Consistently, fecal microbiota transplantation from postbariatric donors improved metabolic parameters in patients with metabolic syndrome (442).

5.3. Pharmacological Interventions

In addition to surgery, a series of Food and Drug Administration (FDA)-approved chemicals exist that modulate BA signaling, thereby improving metabolic disorders. The oldest group of BA-modifying drugs are the BA sequestrants, initially designed to interrupt the enterohepatic circulation. BA sequestrants are effective in lowering LDL cholesterol and inducing GLP-1 release, by promoting the hepatic conversion of elevated cholesterol levels into BAs and by coordinately modulating intestinal FXR and TGR5 activities. IBAT/ASBT inhibitors have a similar mechanism of action, preventing BA reuptake across the intestinal epithelium (extensively reviewed in Refs. 7, 116, and 443). Only recently, antibiotics have regained new interest, not so much because of their impact on the size, but rather on the composition of the BA pool (FIGURE 6). The decrease in secondary BAs after short-term use of antibiotics was recently shown to reduce serum glucose

and triglyceride levels (444). However, caution should be taken when developing therapeutic strategies as the same antibiotic-driven reduction in secondary BAs was linked to the development of cholestasis in pediatric patients (445) and to *Clostridium difficile* outgrowth in the large intestine (446).

Therapies using natural BAs, such as UDCA, have proven to be successful in a subset of patients with cholestatic disorders (447). UDCA is the first-line therapy for PBC and is effective in ~60% of patients (448). Although its efficacy is still debated for PSC (449) and NAFLD/NASH (450), the UDCA-homolog 24-norursodeoxycholic acid (*norUDCA*) seems to be effective for PSC (451). Finally, promising therapeutic opportunities with selective FXR and/or TGR5 modulators have made their appearance. Several selective and dual agonists, but also antagonists, have been developed (TABLE 2) and tested in human subjects for their ability to prevent or delay cholestatic liver disorders, obesity, T2D, NASH, atherosclerosis, and IBD, as described above. Although to date only one TGR5 agonist has been studied in T2D patients with unexpected outcomes on glucose management (35), numerous FXR agonists have been tested in clinical trials (TABLE 3). Of these, the most advanced is the CDCA semi-synthetic derivative, OCA (16), which has been FDA-approved as second-line therapy for UDCA-unresponsive or -intolerant PBC patients (261). OCA treatment blunts cholestasis and inflammation in PBC patients (260, 261, 452, 453) and stabilizes or even improves hepatic damage and fibrosis (259). Although the most common adverse effect of OCA is pruritus, severe nonhepatic ascites and varices can occur in a minority of patients, and worsening of liver disease in cirrhotic patients has been reported (454). In noncirrhotic NASH patients, however, OCA treatment is beneficial and diminishes liver steatosis, inflammation, and fibrosis, while enhancing insulin sensitivity (168, 254, 257). FXR activation, however, also increased total and LDL cholesterol and decreased HDL cholesterol levels in NASH patients (257) and healthy volunteers (455), warranting long-term studies to further assess the clinical relevance of this dyslipidemia. Phase III clinical trials (REGENERATE and REVERSE) are currently ongoing to assess clinical outcomes and long-term safety, as well as OCA efficacy in cirrhotic NASH patients (REVERSE trial). Interestingly, similar improvements in fibrosis were reported in patients after a 3-yr follow-up, suggesting long-term clinical benefits (168, 264).

In addition to the steroidal OCA compound, which is the most advanced in the clinic, several nonsteroidal FXR agonists, including Tropifexor (18), Nidufexor (19), EDP305, and Cilofexor (TABLE 2), have reached the phase II clinical test stage and have the potential to become novel therapeutic agents for NASH (265), PSC (20), and PBC (18). Likewise, the FGF19 analog,

NGM282, has also been evaluated in clinical trials and has proven efficacy in PSC (456), PBC (457), and NASH (458–460).

6. UNDESIRE SIDE EFFECTS OF BA SIGNALING

6.1. BAs and Cancer

Exposure to elevated BA levels has been linked with higher cancer incidence in several digestive organs. Already in 1940, BAs were demonstrated to be inducers of cancer in rodents that were subcutaneously injected with DCA (461). Hence, the consensus was that BAs, especially hydrophobic species, were tumor-promoting molecules. Subsequently, several pathways linking BAs to cancer were identified, including oxidative stress with DNA damage and genomic instability, apoptosis, and interactions with gut microbiota (reviewed in Ref. 462). These mechanisms can also be secondary to environmental stimuli (diet, lifestyle, exposure to environmental toxins) and affect predominantly the hepato-gastrointestinal tract [reviewed in (462)], especially the liver (463), biliary tract (464), and colon (25). The main mechanisms involved are the increased intracellular production of reactive oxygen and nitrogen species (465) and the altered expression of tumor suppressor/promoting genes (466). In this process, the degree of hydrophobicity dictates the oncogenic potential of BAs, as illustrated by the fact that in the liver, feeding various concentrations of BAs produced the following hepatotoxicity: UDCA < CA < CDCA < DCA < LCA (467). Consistently, *Fxr*^{-/-} mice develop spontaneous liver cancer because of increased levels of BAs (283) and lowering their BA pool with cholestyramine significantly inhibits tumor lesions (283). Although intestine-restricted FXR agonists are usually seen as having positive therapeutic impacts, it should be noted that chronically elevated levels of circulating FGF19 are linked with liver cancer (323). The protumorigenic effects of FGF19 are due to a non-cell autonomous activation of IL-6/STAT3 signaling (468). Interestingly, an FGF19-engineered analog NGM282, which differs from wild-type FGF19 in the amino terminus, retains the ability to repress *Cyp7a1* expression without triggering the activation of STAT3, eliminating FGF19-associated tumorigenicity (322, 460, 469). Recently, a direct link between BAs and cancer progression was described. TβMCA was shown to not only initiate colorectal cancer through DNA damage but also to actively promote cancer stem cell proliferation via inhibition of FXR activity in *Lgr5*⁺ intestinal stem cells (25). Therapeutically, restoring FXR

activation with FexD, a gut-biased FXR agonist, delayed tumor progression and profoundly increased survival of APC^{min/+} mouse models of adenoma and adenocarcinoma (25). Similarly, the growth of lymph node-metastatic melanoma was shown to depend on BA-mediated activation of YAP (470). Unexpectedly, this study suggests that lymph node-metastatic tumors themselves can upregulate *Cyp7a1* and produce BAs in an autocrine manner to further stimulate their own growth (470). Importantly, evidence also exists in support of an oncoprotective role for BAs. While some studies involve direct effects of BAs on cancerous cells (471–473), a new report demonstrated that the gut microbiome can use BAs to shape immunity against liver cancer (297). In this study, the authors demonstrated that microbiome-mediated primary-to-secondary BA conversion triggers *Cxcl16* expression in liver sinusoidal endothelial cells, enabling the recruitment of natural killer T cells to mediate liver-selective tumor inhibition (297).

6.2. BAs and Adverse Cardiovascular Outcomes

Despite the established benefits of BA signaling in cardiometabolic homeostasis (see sect. 4.4), elevated BAs can be cardiotoxic and lead to progressive cardiomyopathy (reviewed in Ref. 474). Conjugated BAs, in particular TCA, furthermore induces arrhythmic contractions in human atria (475), underscoring once more the potential detrimental action of BAs in disease. While BA-responsive receptors are expressed in the heart, their contribution to human cardiac disease is not completely understood. FXR activation triggers apoptosis in cardiomyocytes, while conversely, inhibition of FXR is protective against ischemia-induced cardiac insults (476). In addition, long-term FXR activation by OCA in humans can elevate LDL cholesterol levels (257). This unfavorable and atherogenic serum lipid profile may originate from the ability of FXR to blunt BA synthesis and LDL clearance via repression of *Cyp7a1* (224) and hepatic proprotein convertase subtilisin/kexin type 9 (*Pcsk9*) expression (477, 478), respectively. However, HDL-cholesterol is also decreased (257). The FXR-dependent repression of ApoA1 (222) and paraoxonase 1, involved in the inactivation of proatherogenic lipids (479, 480), may contribute to this effect and, ultimately, lead to long-term adverse clinical outcomes. Further studies will be needed to fully understand the underlying mechanisms.

Although less studied, cardiovascular concerns have been raised for TGR5 as well. TGR5 has been proposed to mediate cardiac hypertrophy in a mouse model of liver injury by triggering AKT signaling (481), and reflex tachycardia (as a result of reduced

vascular tone and blood pressure) has been observed in dogs treated with a synthetic TGR5 agonist (482). Other studies, however, attribute a cardioprotective role to TGR5 by improving the myocardial response to cardiac stress (483), as well as by reducing atherosclerosis (53). In line with this, LCA negatively correlates with atheroma presence in patients (484). Dedicated studies and clinical trials will be required to identify the exact impact of TGR5, as well as the other noncanonical BA receptors, such as the muscarinic receptors, on cardiovascular risk.

6.3. BAs and Pruritus

Although itching can be seen as a protective reflex to remove pathogens and skin irritants, chronic pruritus is associated with pathological states and significantly impacts the quality of life. TGR5 is expressed in peripheral neurons of the dorsal root ganglia, where its activation stimulates the release of neuropeptide transmitters of itch. The TGR5 dependence of this effect was proven *in vivo* where DCA treatment induced spontaneous scratching in *Tgr5*^{+/+} but not in *Tgr5*^{-/-} mice (485). Later, it was reported that the neuronal hyperexcitability followed by TGR5 stimulation is mediated through activation of the transient receptor potential ankyrin 1 (TRPA1) channel, required for the acute pruritogenic response (486). However, it should be mentioned that TGR5 activation in the dorsal root innervation can also attenuate pain through an opioid-dependent mechanism (485), thus, blunting the perception of what was initially considered as an unfortunate side effect. Of note, BA derivatives predominantly targeting FXR, such as OCA, can also trigger itching (257). Furthermore, no adverse effects of itching were observed in humans with the selective TGR5 agonist, SB-756050 (35). The mechanism underlying pruritus may, therefore, be more complex than originally proposed.

7. FINAL REMARKS AND FUTURE PERSPECTIVES

BA signaling has many beneficial roles, as it enables tissues to adapt to environmental, nutritional, and physiological cues. However, this signaling can also become maladaptive, especially when the tight feedback regulation of BA synthesis is compromised to the point that BAs become cytotoxic. Several diseases and conditions, as diverse as cholestasis, fibrosis, cardiomyopathy, gallbladder stones, cancer, and pruritus, have been associated with an uncontrolled rise in BA concentrations or observed after BA treatment, and are the focus of intense research aimed at better understanding the

molecular basis of BA-induced disease progression. However, the field should remain cautious about the contrasting features of BAs, swiftly fluctuating between good and bad.

The prime effectors of BA signaling are the receptors FXR and TGR5, which have evolved often complementary functions. Their balanced contributions translate the signals conveyed by the many different BAs to shape not only cellular responses but also tissues, and even entire systems, to the quality and quantity of BAs. There are still many challenges ahead to grasp the full complexity of BA signaling, and their roles in many contexts are only starting to be elucidated. For instance, we are only on the verge of understanding how the gut microbiome affects BA composition and levels, which constitutes a prime way for the microbiome to synchronize a wide range of physiological processes. There is still controversy about the metabolic benefits of intestinal FXR agonists versus antagonists, and a more in-depth analysis of its impact on the microbiota will be needed to fully elucidate the intricate interplay of microbial and host factors. Likewise, we know very little about the signaling roles of BAs in the brain, although bile has been postulated to affect our mood since ancient times. Furthermore, we are only starting to understand how convergent signaling by two BA receptors controls cellular processes as fundamental as cell proliferation, differentiation, and death. In this respect, the discovery that BAs influence stem cell homeostasis opens a new field that may fuel novel opportunities in regenerative medicine. Finally, from an evolutionary point of view, we still need to understand the impressive species-specific differences in BA production and signaling pathways.

Although many aspects of BA signaling still need to be deciphered, the first therapeutics targeting FXR are making their way into the clinic. Likewise, it is expected that TGR5-based therapies for targeted diseases will soon arise, although a creative approach will be needed to generate compounds with a more restricted bioavailability and/or activity. Similarly, OCA, the current FDA-approved FXR agonist for the treatment of PBC, is safe and effective, but undesired side effects urge the development of next-generation drugs with fewer side effects. Overall, given the wide distribution and numerous actions of FXR and TGR5, the future of these molecules will lie in the development of selective FXR and TGR5 modulators, whose activities should be tailored to target only a set of functions that are relevant to the type of disease. In summary, drugs targeting BA signaling have a bright future, and the continuing efforts on studying the impact of changing BA signaling pathways in humans will be extremely useful to translate our emerging knowledge on BA physiology in model organisms into clinical benefits.

CORRESPONDENCE

Kristina Schoonjans: kristina.schoonjans@epfl.ch

GRANTS

This study was supported by EPFL funding and grants from the Swiss National Science Foundation (SNSF No. 310030_189178 and CRSII5_180317/1). A.P. and L.V.V. were supported by a postdoctoral fellowship from the AXA Research Fund. H.D. is recipient of a Marie Skłodowska-Curie fellowship (EU H2020).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

A.P. prepared figures; K.S., A.P., H.D., and L.A.V.-V. drafted manuscript; K.S., A.P., H.D., and L.A.V.-V. edited and revised manuscript; K.S., A.P., H.D., and L.A.V.-V. approved final version of manuscript.

REFERENCES

- Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. *Cell Mol Life Sci* 65: 2461–2483, 2008. doi:10.1007/s00018-008-7568-6.
- Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem* 72: 137–174, 2003. doi:10.1146/annurev.biochem.72.121801.161712.
- Hofmann AF, Hagey LR, Krasowski MD. Bile salts of vertebrates: structural variation and possible evolutionary significance. *J Lipid Res* 51: 226–246, 2010. doi:10.1194/jlr.R000042.
- Worthmann A, John C, Rühlemann MC, Baguhl M, Heinsen FA, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C, Fischer M, Dandri M, Kremoser C, Scheja L, Franke A, Shaul PW, Heeren J. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. *Nat Med* 23: 839–849, 2017. doi:10.1038/nm.4357.
- Yetti H, Naito H, Yuan Y, Jia X, Hayashi Y, Tamada H, Kitamori K, Ikeda K, Yamori Y, Nakajima T. Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet. *PLoS One* 13: e0192863, 2018. doi:10.1371/journal.pone.0192863.
- Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. *Toxicol Appl Pharmacol* 268: 132–140, 2013. doi:10.1016/j.taap.2013.01.022.
- Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap—bile acids in metabolic control. *Nat Rev Endocrinol* 10: 488–498, 2014. doi:10.1038/nrendo.2014.60.
- Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. *EMBO J* 25: 1419–1425, 2006. doi:10.1038/sj.emboj.7601049.
- Dawson PA, Lan T, Rao A. Bile acid transporters. *J Lipid Res* 50: 2340–2357, 2009. doi:10.1194/jlr.R900012-JLR200.
- Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. *J Hepatol* 58: 155–168, 2013. doi:10.1016/j.jhep.2012.08.002.
- Wählstrom A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. *Cell Metab* 24: 41–50, 2016. doi:10.1016/j.cmet.2016.05.005.
- Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* 81: 687–693, 1995. doi:10.1016/0092-8674(95)90530-8.
- Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. *Science* 284: 1362–1365, 1999. doi:10.1126/science.284.5418.1362.
- Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. *Science* 284: 1365–1368, 1999. doi:10.1126/science.284.5418.1365.
- Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 3: 543–553, 1999. doi:10.1016/S1097-2765(00)80348-2.
- Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM. 6 α -ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. *J Med Chem* 45: 3569–3572, 2002. doi:10.1021/jm025529g.
- Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, Jones SA, Willson TM. Identification of a chemical tool for the orphan nuclear receptor FXR. *J Med Chem* 43: 2971–2974, 2000. doi:10.1021/jm0002127.
- Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, Alper PB, Mutnick D, Bursulaya B, Schmeits J, Wu X, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Seidel HM, Molteni V, Liu B, Phimister A, Joseph SB, Laffitte B. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). *J Med Chem* 60: 9960–9973, 2017. doi:10.1021/acs.jmedchem.7b00907.
- Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, Bursulaya B, Hernandez ED, Wu J, Prashad M, Schlama T, Liu Y, Chu A, Schmeits J, Huang DJ, Hill R, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Liu B, Richmond W, Sancho-Martinez I, Phimister A, Seidel HM, Badman MK, Joseph SB, Laffitte B, Molteni V. Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis. *J Med Chem* 63: 3868–3880, 2020. doi:10.1021/acs.jmedchem.9b01621.
- Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. The nonsteroidal farnesoid X receptor

- agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. **Hepatology** 70: 788–801, 2019. doi:10.1002/hep.30509.
21. Erstad DJ, Farrar CT, Ghoshal S, Masia R, Ferreira DS, Chen YI, Choi JK, Wei L, Waghorn PA, Rotile NJ, Tu C, Graham-O'Regan KA, Sojoodi M, Li S, Li Y, Wang G, Corey KE, Or YS, Jiang L, Tanabe KK, Caravan P, Fuchs BC. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. **Hepato Comm** 2: 821–835, 2018. doi:10.1002/hep4.1193.
 22. Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perović-Ottstadt S, Schlüter T, Kinzel O, Krol HD, Deuschle U, Burnet M, Levi M, Schmitz G, Miyazaki M, Kremoser C. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (–/–) mice. **J Pharmacol Exp Ther** 343: 556–567, 2012. doi:10.1124/jpet.112.196519.
 23. Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C, Mohan R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). **J Med Chem** 52: 904–907, 2009. doi:10.1021/jm8014124.
 24. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. **Mol Cell** 11: 1079–1092, 2003. doi:10.1016/S1097-2765(03)00104-7.
 25. Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins AR, Yu RT, Knight R, Liddle C, Downes M, Evans RM. FXR regulates intestinal cancer stem cell proliferation. **Cell** 176: 1098–1112, 2019. doi:10.1016/j.cell.2019.01.036.
 26. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. **Nat Commun** 4: 2384, 2013. doi:10.1038/ncomms3384.
 27. Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. **Nat Med** 24: 1919–1929, 2018. doi:10.1038/s41591-018-0222-4.
 28. Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH, Liu Y, Gavrilova O, Patterson AD, Gonzalez FJ. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. **Nat Commun** 6: 10166, 2015. doi:10.1038/ncomms10166.
 29. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. **Science** 296: 1703–1706, 2002. doi:10.1126/science.1072891.
 30. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. **Mol Endocrinol** 16: 1590–1597, 2002. doi:10.1210/mend.16.7.0894.
 31. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. **J Biol Chem** 278: 9435–9440, 2003. doi:10.1074/jbc.M209706200.
 32. Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B, Sardella R, Pruzanski M, Roda A, Pastorini E, Schoonjans K, Auwerx J. Discovery of 6 α -ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabetes. **J Med Chem** 52: 7958–7961, 2009. doi:10.1021/jm901390p.
 33. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Matakaki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. **Cell Metab** 10: 167–177, 2009. doi:10.1016/j.cmet.2009.08.001.
 34. Renga B, Cipriani S, Carino A, Simonetti M, Zampella A, Fiorucci S. Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT/FOXO1 dependent regulation of H2S generation and endothelin-1. **PLoS One** 10: e0141082, 2015. doi:10.1371/journal.pone.0141082.
 35. Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ; SB-756050 Project Team. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in Type 2 diabetes. **Clin Pharmacol Drug Dev** 2: 213–222, 2013. doi:10.1002/cpdd.34.
 36. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, Mioskowski C, Auwerx J, Saladin R. Anti-hyperglycemic activity of a TGR5 agonist isolated from *Olea europaea*. **Biochem Biophys Res Commun** 362: 793–798, 2007. doi:10.1016/j.bbrc.2007.06.130.
 37. Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX, Jiang T, Levi M, Pruzanski M, Adorini L. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. **Mol Pharmacol** 78: 617–630, 2010. doi:10.1124/mol.110.064501.
 38. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor- γ coactivator 1 α (PGC-1 α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. **Genes Dev** 18: 157–169, 2004. doi:10.1101/gad.1138104.
 39. Ananthanarayanan M, Li S, Balasubramanian N, Suchy FJ, Walsh MJ. Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. **J Biol Chem** 279: 54348–54357, 2004. doi:10.1074/jbc.M410021200.
 40. Bauer UM, Daujat S, Nielsen SJ, Nightingale K, Kouzarides T. Methylation at arginine 17 of histone H3 is linked to gene activation. **EMBO Rep** 3: 39–44, 2002. doi:10.1093/embo-reports/kv013.
 41. Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. **Mol Pharmacol** 68: 551–558, 2005. doi:10.1124/mol.105.012104.
 42. Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J, Ploton M, Mazuy C, Caron S, Tailleux A, Eeckhoutte J, Lefebvre T, Staels B, Lefebvre P. Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). **Hepatology** 59: 2022–2033, 2014. doi:10.1002/hep.26710.
 43. Balasubramanian N, Ananthanarayanan M, Suchy FJ. Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes. **Am J Physiol Gastrointest Liver Physiol** 302: G937–G947, 2012. doi:10.1152/ajpgi.00441.2011.
 44. Balasubramanian N, Luo Y, Sun AQ, Suchy FJ. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target

- genes. **J Biol Chem** 288: 13850–13862, 2013. doi:[10.1074/jbc.M112.443937](https://doi.org/10.1074/jbc.M112.443937).
45. Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, Tsang S, Wu SY, Chiang CM, Veenstra TD. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. **Cell Metab** 10: 392–404, 2009. doi:[10.1016/j.cmet.2009.09.009](https://doi.org/10.1016/j.cmet.2009.09.009).
 46. Lien F, Berthier A, Bouchaert E, Gheeraert C, Alexandre J, Porez G, Prawitt J, Dehondt H, Ploton M, Colin S, Lucas A, Patrice A, Pattou F, Diemer H, Van Dorsselaer A, Rachez C, Kamilic J, Groen AK, Staels B, Lefebvre P. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. **J Clin Invest** 124: 1037–1051, 2014. doi:[10.1172/JCI68815](https://doi.org/10.1172/JCI68815).
 47. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. **Nat Rev Drug Discov** 7: 678–693, 2008. doi:[10.1038/nrd2619](https://doi.org/10.1038/nrd2619).
 48. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). **Biochem Biophys Res Commun** 298: 714–719, 2002. doi:[10.1016/S0006-291X\(02\)02550-0](https://doi.org/10.1016/S0006-291X(02)02550-0).
 49. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D, Murgolo NJ, Keane K, Davis HR Jr, Hedrick J, Gustafson EL. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. **Biochem J** 398: 423–430, 2006. doi:[10.1042/BJ20060537](https://doi.org/10.1042/BJ20060537).
 50. Keitel V, Görg B, Bidmon HJ, Zemtsova I, Spomer L, Zilles K, Häussinger D. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. **Glia** 58: 1794–1805, 2010. doi:[10.1002/glia.21049](https://doi.org/10.1002/glia.21049).
 51. Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R, Auwerx J. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. **J Med Chem** 51: 1831–1841, 2008. doi:[10.1021/jm7015864](https://doi.org/10.1021/jm7015864).
 52. Kumar DP, Asgharpour A, Mirshahi F, Park SH, Liu S, Imai Y, Nadler JL, Grider JR, Murthy KS, Sanyal AJ. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet α cells to promote glucose homeostasis. **J Biol Chem** 291: 6626–6640, 2016. doi:[10.1074/jbc.M115.699504](https://doi.org/10.1074/jbc.M115.699504).
 53. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, Auwerx J, Schoonjans K. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. **Cell Metab** 14: 747–757, 2011. doi:[10.1016/j.cmet.2011.11.006](https://doi.org/10.1016/j.cmet.2011.11.006).
 54. Rajagopal S, Kumar DP, Mahavadi S, Bhattacharya S, Zhou R, Corvera CU, Bunnett NW, Grider JR, Murthy KS. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway. **Am J Physiol Gastrointest Liver Physiol** 304: G527–G535, 2013. doi:[10.1152/ajpgi.00388.2012](https://doi.org/10.1152/ajpgi.00388.2012).
 55. Jensen DD, Godfrey CB, Niklas C, Canals M, Kocan M, Poole DP, Murphy JE, Alemi F, Cottrell GS, Korbmacher C, Lambert NA, Bunnett NW, Corvera CU. The bile acid receptor TGR5 does not interact with β -arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. **J Biol Chem** 288: 22942–22960, 2013. doi:[10.1074/jbc.M113.455774](https://doi.org/10.1074/jbc.M113.455774).
 56. Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, Ullmer C, Knoefel WT, Herebian D, Mayatepek E, Häussinger D, Keitel V. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. **Gut** 65: 487–501, 2016. doi:[10.1136/gutjnl-2015-309458](https://doi.org/10.1136/gutjnl-2015-309458).
 57. Velazquez-Villegas LA, Perino A, Lemos V, Zietak M, Nomura M, Pols TWH, Schoonjans K. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. **Nat Commun** 9: 245, 2018. doi:[10.1038/s41467-017-02068-0](https://doi.org/10.1038/s41467-017-02068-0).
 58. Hu MM, He WR, Gao P, Yang Q, He K, Cao LB, Li S, Feng YQ, Shu HB. Virus-induced accumulation of intracellular bile acids activates the TGR5- β -arrestin-SRC axis to enable innate antiviral immunity. **Cell Res** 29: 193–205, 2019. doi:[10.1038/s41422-018-0136-1](https://doi.org/10.1038/s41422-018-0136-1).
 59. Perino A, Pols TW, Nomura M, Stein S, Pellicciari R, Schoonjans K. TGR5 reduces macrophage migration through mTOR-induced C/EBP β differential translation. **J Clin Invest** 124: 5424–5436, 2014. doi:[10.1172/JCI76289](https://doi.org/10.1172/JCI76289).
 60. Zhai H, Li Z, Peng M, Huang Z, Qin T, Chen L, Li H, Zhang H, Zhang W, Xu G, Takeda G protein-coupled receptor 5-mechanistic target of rapamycin complex 1 signaling contributes to the increment of glucagon-like peptide-1 production after Roux-en-Y gastric bypass. **EBioMed** 32: 201–214, 2018. doi:[10.1016/j.ebiom.2018.05.026](https://doi.org/10.1016/j.ebiom.2018.05.026).
 61. Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF- κ B) in mice. **Hepatology** 54: 1421–1432, 2011. doi:[10.1002/hep.24525](https://doi.org/10.1002/hep.24525).
 62. Shin DJ, Wang L. Bile acid-activated receptors: a review on FXR and other nuclear receptors. **Handb Exp Pharmacol** 256: 51–72, 2019. doi:[10.1007/164_2019_236](https://doi.org/10.1007/164_2019_236).
 63. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. **Proc Natl Acad Sci U S A** 98: 3369–3374, 2001. doi:[10.1073/pnas.051551698](https://doi.org/10.1073/pnas.051551698).
 64. Xie W, Radomska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. **Proc Natl Acad Sci U S A** 98: 3375–3380, 2001. doi:[10.1073/pnas.051014398](https://doi.org/10.1073/pnas.051014398).
 65. Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. **J Biol Chem** 278: 45062–45071, 2003. doi:[10.1074/jbc.M307145200](https://doi.org/10.1074/jbc.M307145200).
 66. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, Moore DD. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). **Proc Natl Acad Sci U S A** 100: 4156–4161, 2003. doi:[10.1073/pnas.0630614100](https://doi.org/10.1073/pnas.0630614100).
 67. Saini SP, Mu Y, Gong H, Toma D, Uppal H, Ren S, Li S, Poloyac SM, Xie W. Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. **Hepatology** 41: 497–505, 2005. doi:[10.1002/hep.20570](https://doi.org/10.1002/hep.20570).
 68. Sberna AL, Assem M, Gautier T, Grober J, Guiu B, Jeannin A, Pais de Barros JP, Athias A, Lagrost L, Masson D. Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice. **J Hepatol** 55: 154–161, 2011. doi:[10.1016/j.jhep.2010.10.029](https://doi.org/10.1016/j.jhep.2010.10.029).
 69. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination

- pathways in mice. **Hepatology** 42: 420–430, 2005. doi:[10.1002/hep.20784](https://doi.org/10.1002/hep.20784).
70. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. **Science** 296: 1313–1316, 2002. doi:[10.1126/science.1070477](https://doi.org/10.1126/science.1070477).
 71. Pols TWH, Puchner T, Korkmaz HI, Vos M, Soeters MR, de Vries CJM. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. **PLoS One** 12: e0176715, 2017. doi:[10.1371/journal.pone.0176715](https://doi.org/10.1371/journal.pone.0176715).
 72. Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C, Kasper DL. Microbial bile acid metabolites modulate gut ROR γ^+ regulatory T cell homeostasis. **Nature** 577: 410–415, 2020. doi:[10.1038/s41586-019-1865-0](https://doi.org/10.1038/s41586-019-1865-0).
 73. Sun J, Mustafi R, Cerda S, Chumsangsri A, Xia YR, Li YC, Bissonnette M. Lithocholic acid down-regulation of NF- κ B activity through vitamin D receptor in colonic cancer cells. **J Steroid Biochem Mol Biol** 111: 37–40, 2008. doi:[10.1016/j.jsbmb.2008.01.003](https://doi.org/10.1016/j.jsbmb.2008.01.003).
 74. Wang J, Thingholm LB, Skiecevičienė² J, Rausch P, Kummen M, Hov JR, Degenhardt F, Heinsen F-A, Rühlemann MC, Szymczak S, Holm K, Esko T, Sun J, Pricop-Jeckstadt M, Al-Dury S, Bohov P, Bethune J, Sommer F, Ellinghaus D, Berge RK, Hübenthal M, Koch M, Schwarz K, Rimbach G, Hübbe P, Pan W-H, Sheibani-Tezerji R, Häsler R, Rosenstiel P, D'Amato M, Cloppenburg-Schmidt K, Künzel S, Laudes M, Marschall H-U, Lieb W, Nöthlings U, Karlsen TH, Baines JF, Franke A. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. **Nat Genet** 48: 1396–1406, 2016. doi:[10.1038/ng.3695](https://doi.org/10.1038/ng.3695).
 75. Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, Pandak WM, Dent P, Spiegel S, Shi R, Xu W, Liu X, Bohdan P, Zhang L, Zhou H, Hylemon PB. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. **Hepatology** 55: 267–276, 2012. doi:[10.1002/hep.24681](https://doi.org/10.1002/hep.24681).
 76. Kageyama Y, Ikeda H, Watanabe N, Nagamine M, Kusumoto Y, Yashiro M, Satoh Y, Shimosawa T, Shinozaki K, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Yokota H, Koyama T, Ishimaru K, Okamoto Y, Takawa Y, Koike K, Yatomi Y. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents. **Hepatology** 56: 1427–1438, 2012. doi:[10.1002/hep.25780](https://doi.org/10.1002/hep.25780).
 77. Wang Y, Aoki H, Yang J, Peng K, Liu R, Li X, Qiang X, Sun L, Gurley EC, Lai G, Zhang L, Liang G, Nagahashi M, Takabe K, Pandak WM, Hylemon PB, Zhou H. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. **Hepatology** 65: 2005–2018, 2017. doi:[10.1002/hep.29076](https://doi.org/10.1002/hep.29076).
 78. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. **Trends Immunol** 23: 541–548, 2002. doi:[10.1016/S1471-4906\(02\)02316-5](https://doi.org/10.1016/S1471-4906(02)02316-5).
 79. Chen X, Yang D, Shen W, Dong HF, Wang JM, Oppenheim JJ, Howard MZ. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. **Inflamm Res** 49: 744–755, 2000. doi:[10.1007/s000110050656](https://doi.org/10.1007/s000110050656).
 80. Chen X, Mellon RD, Yang L, Dong H, Oppenheim JJ, Howard OM. Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niu Huang, on human leukocyte response to chemoattractants. **Biochem Pharmacol** 63: 533–541, 2002. doi:[10.1016/S0006-2952\(01\)00917-0](https://doi.org/10.1016/S0006-2952(01)00917-0).
 81. Amonyngcharoen S, Suriyo T, Thiantanawat A, Watcharasit P, Satayavivad J. Tauroolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. **Int J Oncol** 46: 2317–2326, 2015. doi:[10.3892/ijo.2015.2939](https://doi.org/10.3892/ijo.2015.2939).
 82. Cheng K, Chen Y, Zimniak P, Raufman JP, Xiao Y, Frucht H. Functional interaction of lithocholic acid conjugates with M3 muscarinic receptors on a human colon cancer cell line. **Biochim Biophys Acta** 1588: 48–55, 2002. doi:[10.1016/S0925-4439\(02\)00115-1](https://doi.org/10.1016/S0925-4439(02)00115-1).
 83. Khurana S, Yamada M, Wess J, Kennedy RH, Raufman JP. Deoxycholytaurine-induced vasodilation of rodent aorta is nitric oxide- and muscarinic M₃ receptor-dependent. **Eur J Pharmacol** 517: 103–110, 2005. doi:[10.1016/j.ejphar.2005.05.037](https://doi.org/10.1016/j.ejphar.2005.05.037).
 84. Ibrahim E, Diakonov I, Arunthavarajah D, Swift T, Goodwin M, McLivride S, Nikolova V, Williamson C, Gorelik J. Bile acids and their respective conjugates elicit different responses in neonatal cardiomyocytes: role of Gi protein, muscarinic receptors and TGR5. **Sci Rep** 8: 7110, 2018. doi:[10.1038/s41598-018-25569-4](https://doi.org/10.1038/s41598-018-25569-4).
 85. Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S, Moshkov AV, Xie Q, Keitel V, Nikolaev VO, Williamson C, Gorelik J. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. **PLoS One** 5: e9689, 2010. doi:[10.1371/journal.pone.0009689](https://doi.org/10.1371/journal.pone.0009689).
 86. Gohlke H, Schmitz B, Sommerfeld A, Reinehr R, Häussinger D. α 5 β 1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. **Hepatology** 57: 1117–1129, 2013. doi:[10.1002/hep.25992](https://doi.org/10.1002/hep.25992).
 87. Sommerfeld A, Reinehr R, Häussinger D. Tauroursodeoxycholate protects rat hepatocytes from bile acid-induced apoptosis via β 1-integrin- and protein kinase A-dependent mechanisms. **Cell Physiol Biochem** 36: 866–883, 2015. doi:[10.1159/000430262](https://doi.org/10.1159/000430262).
 88. Cha BH, Jung MJ, Moon BK, Kim JS, Ma Y, Arai Y, Noh M, Shin JY, Kim BS, Lee SH. Administration of tauroursodeoxycholic acid enhances osteogenic differentiation of bone marrow-derived mesenchymal stem cells and bone regeneration. **Bone** 83: 73–81, 2016. doi:[10.1016/j.bone.2015.10.011](https://doi.org/10.1016/j.bone.2015.10.011).
 89. Boyer JL. Bile formation and secretion. **Compr Physiol** 3: 1035–1078, 2013. doi:[10.1002/cphy.c120027](https://doi.org/10.1002/cphy.c120027).
 90. Lo Sasso G, Petruzzelli M, Moschetta AA. translational view on the biliary lipid secretory network. **Biochim Biophys Acta** 1781: 79–96, 2008. doi:[10.1016/j.bbali.2007.12.002](https://doi.org/10.1016/j.bbali.2007.12.002).
 91. Keitel V, Häussinger D. Role of TGR5 (GPBAR1) in liver disease. **Semin Liver Dis**, 38: 333–339, 2018. doi:[10.1055/s-0038-1669940](https://doi.org/10.1055/s-0038-1669940).
 92. Bergström S, Danielsson H. On the regulation of bile acid formation in the rat liver. **Acta Physiol Scand** 43: 1–7, 1958. doi:[10.1111/j.1748-1716.1958.tb01572.x](https://doi.org/10.1111/j.1748-1716.1958.tb01572.x).
 93. Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. **Nat Med** 14: 828–836, 2008. doi:[10.1038/nm.1853](https://doi.org/10.1038/nm.1853).
 94. Rose AJ, Berriel Díaz M, Reimann A, Klement J, Walcher T, Kronen-Herzig A, Strobel O, Werner J, Peters A, Kleyman A, Tuckermann JP, Vegiopoulos A, Herzig S. Molecular control of systemic bile acid homeostasis by the liver glucocorticoid receptor. **Cell Metab** 14: 123–130, 2011. doi:[10.1016/j.cmet.2011.04.010](https://doi.org/10.1016/j.cmet.2011.04.010).
 95. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. **Cell** 102: 731–744, 2000. doi:[10.1016/S0092-8674\(00\)00062-3](https://doi.org/10.1016/S0092-8674(00)00062-3).

96. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LXR-1 represses bile acid biosynthesis. **Mol Cell** 6: 517–526, 2000. doi:10.1016/S1097-2765(00)00051-4.
97. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. **Mol Cell** 6: 507–515, 2000. doi:10.1016/S1097-2765(00)00050-2.
98. Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. Nuclear receptors HNF4 α and LXR-1 cooperate in regulating Cyp7a1 in vivo. **J Biol Chem** 287: 41334–41341, 2012. doi:10.1074/jbc.M112.421834.
99. Brendel C, Schoonjans K, Botrugno OA, Treuter E, Auwerx J. The small heterodimer partner interacts with the liver X receptor α and represses its transcriptional activity. **Mol Endocrinol** 16: 2065–2076, 2002. doi:10.1210/me.2001-0194.
100. Kerr TA, Saeki S, Schneider M, Schaefer K, Berdy S, Redder T, Shan B, Russell DW, Schwarz M. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. **Dev Cell** 2: 713–720, 2002. doi:10.1016/S1534-5807(02)00154-5.
101. Wang L, Han Y, Kim CS, Lee YK, Moore DD. Resistance of SHP-null mice to bile acid-induced liver damage. **J Biol Chem** 278: 44475–44481, 2003. doi:10.1074/jbc.M305258200.
102. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. **Cell Metab** 2: 217–225, 2005. doi:10.1016/j.cmet.2005.09.001.
103. Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C, Walters JR. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. **Am J Physiol Gastrointest Liver Physiol** 304: G940–G948, 2013. doi:10.1152/ajpgi.00398.2012.
104. Somme E, Jornayvaz FR. Fibroblast growth factor 15/19: from basic functions to therapeutic perspectives. **Endocr Rev** 39: 960–989, 2018. doi:10.1210/er.2018-00134.
105. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. **J Lipid Res** 48: 2664–2672, 2007. doi:10.1194/jlr.M700330-JLR200.
106. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. **Genes Dev** 17: 1581–1591, 2003. doi:10.1101/gad.1083503.
107. Li S, Hsu DD, Li B, Luo X, Alderson N, Qiao L, Ma L, Zhu HH, He Z, Suino-Powell K, Ji K, Li J, Shao J, Xu HE, Li T, Feng GS. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. **Cell Metab** 20: 320–332, 2014. doi:10.1016/j.cmet.2014.05.020.
108. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7 α -hydroxylase gene expression. **Hepatology** 49: 297–305, 2009. doi:10.1002/hep.22627.
109. Yu C, Wang F, Jin C, Huang X, McKeehan WL. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. **J Biol Chem** 280: 17707–17714, 2005. doi:10.1074/jbc.M411771200.
110. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M. Tissue-specific expression of β Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. **J Biol Chem** 282: 26687–26695, 2007. doi:10.1074/jbc.M704165200.
111. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. **J Biol Chem** 282: 27277–27284, 2007. doi:10.1074/jbc.M704244200.
112. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking β Klotho. **J Clin Invest** 115: 2202–2208, 2005. doi:10.1172/JCI23076.
113. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. **J Biol Chem** 275: 15482–15489, 2000. doi:10.1074/jbc.275.20.15482.
114. Miao J, Xiao Z, Kanamaluru D, Min G, Yau PM, Veenstra TD, Ellis E, Strom S, Suino-Powell K, Xu HE, Kemper JK. Bile acid signaling pathways increase stability of small heterodimer partner (SHP) by inhibiting ubiquitin-proteasomal degradation. **Genes Dev** 23: 986–996, 2009. doi:10.1101/gad.1773909.
115. Tarling EJ, Clifford BL, Cheng J, Morand P, Cheng A, Lester E, Sallam T, Turner M, de Aguiar Vallim TQ. RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism. **J Clin Invest** 127: 3741–3754, 2017. doi:10.1172/JCI94029.
116. Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. **Hepatology** 65: 1393–1404, 2017. doi:10.1002/hep.28991.
117. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. **J Biol Chem** 276: 28857–28865, 2001. doi:10.1074/jbc.M011610200.
118. Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, Müller M. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. **Hepatology** 35: 589–596, 2002. doi:10.1053/jhep.2002.31724.
119. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. **J Clin Invest** 112: 1678–1687, 2003. doi:10.1172/JCI18945.
120. Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. **Nat Med** 10: 1352–1358, 2004. doi:10.1038/nm1138.
121. Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter- α and - β genes. **Am J Physiol Gastrointest Liver Physiol** 290: G476–G485, 2006. doi:10.1152/ajpgi.00430.2005.
122. Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter- α/β in the adaptive response to bile acids. **Am J Physiol Gastrointest Liver Physiol** 290: G923–G932, 2006. doi:10.1152/ajpgi.00490.2005.
123. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear

- receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. **J Biol Chem** 277: 2908–2915, 2002. doi:10.1074/jbc.M109326200.
124. Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, Hobbs HH, Cohen JC. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. **J Biol Chem** 280: 8742–8747, 2005. doi:10.1074/jbc.M411080200.
 125. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, Edwards PA. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. **J Biol Chem** 285: 3035–3043, 2010. doi:10.1074/jbc.M109.083899.
 126. Xu Y, Li F, Zalzal M, Xu J, Gonzalez FJ, Adorini L, Lee YK, Yin L, Zhang Y. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. **Hepatology** 64: 1072–1085, 2016. doi:10.1002/hep.28712.
 127. Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. **J Hepatol** 64: 1158–1166, 2016. doi:10.1016/j.jhep.2016.01.016.
 128. de Boer JF, Schonewille M, Boesjes M, Wolters H, Bloks VW, Bos T, van Dijk TH, Jurdzinski A, Boverhof R, Wolters JC, Kuivenhoven JA, van Deursen JM, Oude Elferink RPJ, Moschetta A, Kremoser C, Verkade HJ, Kuipers F, Groen AK. Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice. **Gastroenterology** 152: 1126–1138, 2017. doi:10.1053/j.gastro.2016.12.037.
 129. Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. **J Lipid Res** 56: 1085–1099, 2015. doi:10.1194/jlr.R054114.
 130. Li H, Chen F, Shang Q, Pan L, Shneider BL, Chiang JY, Forman BM, Ananthanarayanan M, Tint GS, Salen G, Xu G. FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. **Am J Physiol Gastrointest Liver Physiol** 288: G60–G66, 2005. doi:10.1152/ajpgi.00170.2004.
 131. Frankenberg T, Rao A, Chen F, Haywood J, Shneider BL, Dawson PA. Regulation of the mouse organic solute transporter α - β , Ost α -Ost β , by bile acids. **Am J Physiol Gastrointest Liver Physiol** 290: G912–G922, 2006. doi:10.1152/ajpgi.00479.2005.
 132. Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA. FXR regulates organic solute transporters α and β in the adrenal gland, kidney, and intestine. **J Lipid Res** 47: 201–214, 2006. doi:10.1194/jlr.M500417-JLR200.
 133. Jakulj L, van Dijk TH, de Boer JF, Kootte RS, Schonewille M, Paalvast Y, Boer T, Bloks VW, Boverhof R, Nieuwdorp M, Beuers UH, Stroes ES, Groen AK. Transintestinal cholesterol transport is active in mice and humans and controls ezetimibe-induced fecal neutral sterol excretion. **Cell Metab** 24: 783–794, 2016. doi:10.1016/j.cmet.2016.10.001.
 134. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. **Hepatology** 50: 861–870, 2009. doi:10.1002/hep.23032.
 135. Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. **J Cyst Fibros** 12: 116–124, 2013. doi:10.1016/j.jcf.2012.11.010.
 136. Keitel V, Ullmer C, Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. **Biol Chem** 391: 785–789, 2010. doi:10.1515/BC.2010.077.
 137. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, Mangelsdorf DJ. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. **Mol Endocrinol** 25: 1066–1071, 2011. doi:10.1210/me.2010-0460.
 138. Donepudi AC, Boehme S, Li F, Chiang JY. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. **Hepatology** 65: 813–827, 2017. doi:10.1002/hep.28707.
 139. Péan N, Doignon I, Garcin I, Besnard A, Julien B, Branchereau S, Spraul A, Guettier C, Humbert L, Schoonjans K, Rainteau D, Tordjmann T. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. **Hepatology** 58: 1451–1460, 2013. doi:10.1002/hep.26463.
 140. Merlen GM, Bedoya JEU, Kahale N, Simerabet H, Bidault-Jourdaine V, Doignon I, Tanfin Z, Garcin I, Pean N, Gautherot J, Humbert L, Rainteau D, Ebnet K, Ullmer C, Cassio D, Tordjmann T. TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function. **Hepatology** 68: 182a–183a, 2018. doi:10.1136/gutjnl-2018-316975.
 141. Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, Corvera CU, Nelson MT, Mawe GM. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of K_{ATP} channels. **J Physiol** 588: 3295–3305, 2010. doi:10.1113/jphysiol.2010.192146.
 142. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, Suino-Powell K, Xu HE, Richardson JA, Gerard RD, Mangelsdorf DJ, Kliewer SA. Identification of a hormonal basis for gallbladder filling. **Nat Med** 12: 1253–1255, 2006. doi:10.1038/nm1501.
 143. Poupon R, Chazouillères O, Poupon RE. Chronic cholestatic diseases. **J Hepatol** 32: 129–140, 2000. doi:10.1016/S0168-8278(00)80421-3.
 144. Rodriguez-Garay EA. Cholestasis: human disease and experimental animal models. **Ann Hepatol** 2: 150–158, 2003. doi:10.1016/S1665-2681(19)32126-X.
 145. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. **J Clin Gastroenterol** 39: S90–S102, 2005. doi:10.1097/O1.mcg.0000155549.29643.ad.
 146. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL. The genetics of complex cholestatic disorders. **Gastroenterology** 144: 1357–1374, 2013. doi:10.1053/j.gastro.2013.03.053.
 147. Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, ElSharawy A, Melum E, Boberg KM, Manke T, Balschun T, Schramm C, Bergquist A, Weismüller T, Gotthardt D, Rust C, Henckaerts L, Onnie CM, Weersma RK, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen CY, Wijmenga C, Vatn MH, Stokkers PCF, Vermeire S, Mathew CG, Lie BA, Beuers U, Manns MP. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. **PLoS One** 5: e12403, 2010. doi:10.1371/journal.pone.0012403.
 148. Van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. **Gastroenterology** 133: 507–516, 2007. doi:10.1053/j.gastro.2007.05.015.
 149. Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, Shneider BL, Picarsic JL, Jacobson TA, Zhang J, He W, Liu P, Knisely AS, Finegold MJ, Muzny DM, Boerwinkle E, Lupski JR, Plon SE, Gibbs RA, Eng CM, Yang Y, Washington GC, Porteus MH, Berquist

- WE, Kambham N, Singh RJ, Xia F, Enns GM, Moore DD. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. **Nat Commun** 7: 10713, 2016. doi:10.1038/ncomms10713.
150. Keitel V, Dröge C, Häussinger D. Targeting FXR in cholestasis. **Handb Exp Pharmacol** 256: 299–324, 2019. doi:10.1007/164_2019_231.
151. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. **Nucl Recept Signal** 8: e005, 2010. doi:10.1621/nrs.08005.
152. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. **J Pharmacol Exp Ther** 313: 604–612, 2005. doi:10.1124/jpet.104.079665.
153. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. **Gastroenterology** 142: 355–365, 2012. doi:10.1053/j.gastro.2011.10.028.
154. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. **Sci Transl Med** 6: 247ra100, 2014. doi:10.1126/scitranslmed.3009098.
155. Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bässmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Roskopf D, Timm B, Höll C, Seeger M, ElSharawy A, Lu T, Egberts J, Fändrich F, Fölsch UR, Krawczak M, Schreiber S, Nürnberg P, Tepel J, Hampe J. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. **Nat Genet** 39: 995–999, 2007. doi:10.1038/ng2101.
156. Grünhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, Mosteanu O, Sauerbruch T, Lammert F. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. **Hepatology** 46: 793–801, 2007. doi:10.1002/hep.21847.
157. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. **Hepatology** 53: 640–648, 2011. doi:10.1002/hep.24046.
158. Wittenburg H, Lyons MA, Li R, Churchill GA, Carey MC, Paigen B. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. **Gastroenterology** 125: 868–881, 2003. doi:10.1016/S0016-5085(03)01053-9.
159. Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. **Nat Clin Pract Gastroenterol Hepatol** 2: 423–433, 2005. doi:10.1038/ncpgasthep0257.
160. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Matakaki C, Sato H, Tanigawara Y, Schoonjans K, Itoh H, Auwerx J. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. **J Biol Chem** 286: 26913–26920, 2011. doi:10.1074/jbc.M111.248203.
161. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. **N Engl J Med** 286: 1–8, 1972. doi:10.1056/NEJM197201062860101.
162. Duncan Bell G, Whitney B, Hermon Dowling R. Gallstone dissolution in man using chenodeoxycholic acid. **Lancet** 300: 1213–1216, 1972. doi:10.1016/S0140-6736(72)92266-0.
163. Fromm H, Roat JW, Gonzalez V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. **Gastroenterology** 85: 1257–1264, 1983. doi:10.1016/S0016-5085(83)80004-3.
164. Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. **Gut** 56: 815–820, 2007. doi:10.1136/gut.2006.109934.
165. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsichler A, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. **Gastroenterology** 129: 476–485, 2005. doi:10.1053/j.gastro.2005.05.009.
166. Miettinen TE, Kiviluoto T, Taavitsainen M, Vuoristo M, Miettinen TA. Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments. **Hepatology** 27: 649–655, 1998. doi:10.1002/hep.510270302.
167. Al-Dury S, Wahlstrom A, Panzitt K, Thorell A, Stöhlman M, Trauner M, Fickert P, Bäckhed F, Fändriks L, Wagner M, Marschall HU. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. **J Hepatol** 71: 986–991, 2019. doi:10.1016/j.jhep.2019.06.011.
168. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knappe W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Oliveira A, Cortez-Pinto H, Graupera I, Orr D, Lotte Gluud L, Dufour J-F, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. **Lancet** 394: 2184–2196, 2019. doi:10.1016/S0140-6736(19)33041-7.
169. Briere DA, Ruan X, Cheng CC, Siesky AM, Fitch TE, Dominguez C, Sanfeliciano SG, Montero C, Suen CS, Xu Y, Coskun T, Michael MD. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. **PLoS One** 10: e0136873, 2015. doi:10.1371/journal.pone.0136873.
170. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). **Mol Metab** 30: 72–130, 2019. doi:10.1016/j.molmet.2019.09.010.
171. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. **Biochem Biophys Res Commun** 329: 386–390, 2005. doi:10.1016/j.bbrc.2005.01.139.
172. Lund ML, Sorrentino G, Egerod KL, Kroone C, Mortensen B, Knop FK, Reimann F, Gribble FM, Drucker DJ, de Koning EJP, Schoonjans K, Bäckhed F, Schwartz TW, Petersen N. L-cell differentiation is induced by bile acids through GPBAR1 and paracrine GLP-1 and serotonin signaling. **Diabetes** 69: 614–623, 2020. doi:10.2337/db19-0764.

173. Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM, Reimann F. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. **Endocrinology** 156: 3961–3970, 2015. doi:[10.1210/en.2015-1321](https://doi.org/10.1210/en.2015-1321).
174. Parker HE, Wallis K, Le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. **Br J Pharmacol** 165: 414–423, 2012. doi:[10.1111/j.1476-5381.2011.01561.x](https://doi.org/10.1111/j.1476-5381.2011.01561.x).
175. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, Schoonjans K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. **Sci Rep** 2: 430, 2012. doi:[10.1038/srep00430](https://doi.org/10.1038/srep00430).
176. Calderon G, McRae A, Rievaj J, Davis J, Zandvakili I, Linker-Nord S, Burton D, Roberts G, Reimann F, Gedulin B, Vella A, LaRusso NF, Camilleri M, Gribble FM, Acosta A. Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. **EBioMedicine** 55: 102759, 2020. doi:[10.1016/j.ebiom.2020.102759](https://doi.org/10.1016/j.ebiom.2020.102759).
177. Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-Möller E, Andersen DB, Deacon CF, Schoonjans K, Reimann F, Gribble FM, Albrechtsen R, Hartmann B, Rosenkilde MM, Holst JJ. Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. **Mol Metab** 11: 84–95, 2018. doi:[10.1016/j.molmet.2018.03.007](https://doi.org/10.1016/j.molmet.2018.03.007).
178. Goldspink DA, Lu VB, Billing LJ, Larraufie P, Tolhurst G, Gribble FM, Reimann F. Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells. **Mol Metab** 7: 90–101, 2018. doi:[10.1016/j.molmet.2017.11.005](https://doi.org/10.1016/j.molmet.2017.11.005).
179. Hauge M, Ekberg JP, Engelstoft MS, Timshel P, Madsen AN, Schwartz TW. Gq and Gs signaling acting in synergy to control GLP-1 secretion. **Mol Cell Endocrinol** 449: 64–73, 2017. doi:[10.1016/j.mce.2016.11.024](https://doi.org/10.1016/j.mce.2016.11.024).
180. Briere DA, Bueno AB, Gunn EJ, Michael MD, Sloop KW. Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. **Diabetes** 67: 309–320, 2018. doi:[10.2337/db17-0607](https://doi.org/10.2337/db17-0607).
181. Trabelsi M-S, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchie E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Bäckhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. **Nat Commun** 6: 7629, 2015. doi:[10.1038/ncomms8629](https://doi.org/10.1038/ncomms8629).
182. Ducastel S, Touche V, Trabelsi MS, Boulinguez A, Butruille L, Nawrot M, Peschard S, Chávez-Talavera O, Dorchie E, Vallez E, Annicotte JS, Lancel S, Briand O, Bantubungi K, Caron S, Bindels LB, Delzenne NM, Tailleux A, Staels B, Lestavel S. The nuclear receptor FXR inhibits glucagon-like peptide-1 secretion in response to microbiota-derived short-chain fatty acids. **Sci Rep** 10: 174, 2020. doi:[10.1038/s41598-019-56743-x](https://doi.org/10.1038/s41598-019-56743-x).
183. Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. **Hepatology** 68: 1574–1588, 2018. doi:[10.1002/hep.29857](https://doi.org/10.1002/hep.29857).
184. Pathak P, Liu H, Boehme S, Xie C, Krausz KW, Gonzalez F, Chiang JYL. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. **J Biol Chem** 292: 11055–11069, 2017. doi:[10.1074/jbc.M117.784322](https://doi.org/10.1074/jbc.M117.784322).
185. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN, Burgess SC, Mangelsdorf DJ, Kliewer SA. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1 α pathway. **Cell Metab** 13: 729–738, 2011. doi:[10.1016/j.cmet.2011.03.019](https://doi.org/10.1016/j.cmet.2011.03.019).
186. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. **Science** 331: 1621–1624, 2011. doi:[10.1126/science.1198363](https://doi.org/10.1126/science.1198363).
187. Lan T, Morgan DA, Rahmouni K, Sonoda J, Fu X, Burgess SC, Holland WL, Kliewer SA, Mangelsdorf DJ. FGF19, FGF21, and an FGFR1/ β -klotho-activating antibody act on the nervous system to regulate body weight and glycemia. **Cell Metab** 26: 709–718, 2017. doi:[10.1016/j.cmet.2017.09.005](https://doi.org/10.1016/j.cmet.2017.09.005).
188. Marcelin G, Jo YH, Li X, Schwartz GJ, Zhang Y, Dun NJ, Lyu RM, Blouet C, Chang JK, Chua S. Jr. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. **Mol Metab** 3: 19–28, 2014. doi:[10.1016/j.molmet.2013.10.002](https://doi.org/10.1016/j.molmet.2013.10.002).
189. Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, Bergman RN, Wasserman DH, Schwartz MW. FGF19 action in the brain induces insulin-independent glucose lowering. **J Clin Invest** 123: 4799–4808, 2013. doi:[10.1172/JCI70710](https://doi.org/10.1172/JCI70710).
190. Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. **Endocrinology** 154: 9–15, 2013. doi:[10.1210/en.2012-1891](https://doi.org/10.1210/en.2012-1891).
191. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. **Endocrinology** 145: 2594–2603, 2004. doi:[10.1210/en.2003-1671](https://doi.org/10.1210/en.2003-1671).
192. Somm E, Henry H, Bruce SJ, Aeby S, Rosikiewicz M, Sykiotis GP, Asrih M, Jornayvaz FR, Denechaud PD, Albrecht U, Mohammadi M, Dwyer A, Acierno JS Jr, Schoonjans K, Fajas L, Greub G, Pitteloud N. β -Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. **JCI Insight** 2, 2017. doi:[10.1172/jci.insight.91809](https://doi.org/10.1172/jci.insight.91809).
193. Hegyi P, Maléth J, Walters JR, Hofmann AF, Keely SJ. Guts and gall: bile acids in regulation of intestinal epithelial function in health and disease. **Physiol Rev** 98: 1983–2023, 2018. doi:[10.1152/physrev.00054.2017](https://doi.org/10.1152/physrev.00054.2017).
194. Keating N, Mroz MS, Scharl MM, Marsh C, Ferguson G, Hofmann AF, Keely SJ. Physiological concentrations of bile acids down-regulate agonist induced secretion in colonic epithelial cells. **J Cell Mol Med** 13: 2293–2303, 2009. doi:[10.1111/j.1582-4934.2009.00838.x](https://doi.org/10.1111/j.1582-4934.2009.00838.x).
195. Mroz MS, Keating N, Ward JB, Sarker R, Amu S, Aviello G, Donowitz M, Fallon PG, Keely SJ. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. **Gut** 63: 808–817, 2014. doi:[10.1136/gutjnl-2013-305088](https://doi.org/10.1136/gutjnl-2013-305088).
196. Devor DC, Sekar MC, Frizzell RA, Duffey ME. Taurodeoxycholate activates potassium and chloride conductances via an IP3-mediated release of calcium from intracellular stores in a colonic cell line (T84). **J Clin Invest** 92: 2173–2181, 1993. doi:[10.1172/JCI116819](https://doi.org/10.1172/JCI116819).
197. Dharmasathaphorn K, Huott PA, Vongkovit P, Beuerlein G, Pandol SJ, Ammon HV. Cl⁻ secretion induced by bile salts. A study of the

- mechanism of action based on a cultured colonic epithelial cell line. **J Clin Invest** 84: 945–953, 1989. doi:[10.1172/JCI114257](https://doi.org/10.1172/JCI114257).
198. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. **J Clin Invest** 50: 1569–1577, 1971. doi:[10.1172/JCI106644](https://doi.org/10.1172/JCI106644).
 199. Keely SJ, Walters JR. The farnesoid X receptor: good for BAD. **Cell Mol Gastroenterol Hepatol** 2: 725–732, 2016. doi:[10.1016/j.jcmgh.2016.08.004](https://doi.org/10.1016/j.jcmgh.2016.08.004).
 200. Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, Le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. **Clin Gastroenterol HJepatol** 7: 1189–1194, 2009. doi:[10.1016/j.cgh.2009.04.024](https://doi.org/10.1016/j.cgh.2009.04.024).
 201. Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. **Aliment Pharmacol Ther** 41: 54–64, 2015. doi:[10.1111/apt.12999](https://doi.org/10.1111/apt.12999).
 202. Ward JB, Mroz MS, Keely SJ. The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. **Neurogastroenterol Motil** 25: 708–711, 2013. doi:[10.1111/nmo.12148](https://doi.org/10.1111/nmo.12148).
 203. Gustafsson JK, Ermund A, Ambort D, Johansson ME, Nilsson HE, Thorell K, Hebert H, Sjövall H, Hansson GC. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. **J Exp Med** 209: 1263–1272, 2012. doi:[10.1084/jem.20120562](https://doi.org/10.1084/jem.20120562).
 204. Flynn M, Hammond P, Darby C, Taylor I. Effects of bile acids on human colonic motor function in vitro. **Digestion** 23: 211–216, 1982. doi:[10.1159/000198729](https://doi.org/10.1159/000198729).
 205. Penagini R, Misiewicz JJ, Frost PG. Effect of jejunal infusion of bile acids on small bowel transit and fasting jejunal motility in man. **Gut** 29: 789–794, 1988. doi:[10.1136/gut.29.6.789](https://doi.org/10.1136/gut.29.6.789).
 206. Snape WJ Jr, Shiff S, Cohen S. Effect of deoxycholic acid on colonic motility in the rabbit. **Am J Physiol Gastrointest Liver Physiol** 238: G321–G325, 1980. doi:[10.1152/ajpgi.1980.238.4.G321](https://doi.org/10.1152/ajpgi.1980.238.4.G321).
 207. Armstrong DN, Krenz HK, Modlin IM, Ballantyne GH. Bile salt inhibition of motility in the isolated perfused rabbit terminal ileum. **Gut** 34: 483–488, 1993. doi:[10.1136/gut.34.4.483](https://doi.org/10.1136/gut.34.4.483).
 208. Shiff SJ, Soloway RD, Snape WJ. Jr. Mechanism of deoxycholic acid stimulation of the rabbit colon. **J Clin Invest** 69: 985–992, 1982. doi:[10.1172/JCI110538](https://doi.org/10.1172/JCI110538).
 209. Umaphathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, Rayner CK, Chapman MJ, Nauck MA, Horowitz M, Deane AM. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. **Diabetes** 63: 785–790, 2014. doi:[10.2337/db13-0893](https://doi.org/10.2337/db13-0893).
 210. Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW, Corvera CU. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. **Gastroenterology** 144: 145–154, 2013. doi:[10.1053/j.gastro.2012.09.055](https://doi.org/10.1053/j.gastro.2012.09.055).
 211. Keely SJ. Missing link identified: GpBAR1 is a neuronal bile acid receptor. **Neurogastroenterol Motil** 22: 711–717, 2010. doi:[10.1111/j.1365-2982.2010.01528.x](https://doi.org/10.1111/j.1365-2982.2010.01528.x).
 212. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, Bunnett NW, Corvera CU. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. **Neurogastroenterol Motil** 22: 814–825, 2010. doi:[10.1111/j.1365-2982.2010.01487.x](https://doi.org/10.1111/j.1365-2982.2010.01487.x).
 213. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. **Scand J Gastroenterol** 45: 645–664, 2010. doi:[10.3109/00365521003702734](https://doi.org/10.3109/00365521003702734).
 214. Schoenfield LJ, Lachin JM. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. **Ann Intern Med** 95: 257–282, 1981. doi:[10.7326/0003-4819-95-3-257](https://doi.org/10.7326/0003-4819-95-3-257).
 215. Angelin B, Einarsson K, Hellstrom K, Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. **J Lipid Res** 19: 1017–1024, 1978.
 216. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. **J Clin Invest** 113: 1408–1418, 2004. doi:[10.1172/JCI21025](https://doi.org/10.1172/JCI21025).
 217. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA. FXR deficiency causes reduced atherosclerosis in Ldlr^{-/-} mice. **ATVB** 26: 2316–2321, 2006. doi:[10.1161/01.ATV.0000235697.35431.05](https://doi.org/10.1161/01.ATV.0000235697.35431.05).
 218. Caron S, Huaman Samanez C, Dehondt H, Ploton M, Briand O, Lien F, Dorchie E, Dumont J, Postic C, Cariou B, Lefebvre P, Staels B. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. **Mol Cell Biol** 33: 2202–2211, 2013. doi:[10.1128/MCB.01004-12](https://doi.org/10.1128/MCB.01004-12).
 219. Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. **J Biol Chem** 279: 45685–45692, 2004. doi:[10.1074/jbc.M404255200](https://doi.org/10.1074/jbc.M404255200).
 220. Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. **Gastroenterology** 125: 544–555, 2003. doi:[10.1016/S0016-5085\(03\)00896-5](https://doi.org/10.1016/S0016-5085(03)00896-5).
 221. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. **Mol Endocrinol** 15: 1720–1728, 2001. doi:[10.1210/mend.15.10.0712](https://doi.org/10.1210/mend.15.10.0712).
 222. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. **J Clin Invest** 109: 961–971, 2002. doi:[10.1172/JCI0214505](https://doi.org/10.1172/JCI0214505).
 223. Gautier T, de Haan W, Grober J, Ye D, Bahr MJ, Claudel T, Nijstad N, Van Berkel TJ, Havekes LM, Manns MP, Willems SM, Hogendoorn PC, Lagrost L, Kuipers F, Van Eck M, Rensen PC, Tietge UJ. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. **J Lipid Res** 54: 2195–2205, 2013. doi:[10.1194/jlr.M038141](https://doi.org/10.1194/jlr.M038141).
 224. Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, Type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. **Gastroenterology** 152: 1679–1694, 2017. doi:[10.1053/j.gastro.2017.01.055](https://doi.org/10.1053/j.gastro.2017.01.055).
 225. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. **J Biol Chem** 280: 29971–29979, 2005. doi:[10.1074/jbc.M501931200](https://doi.org/10.1074/jbc.M501931200).

226. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. **J Pharmacol Exp Ther** 328: 116–122, 2009. doi:10.1124/jpet.108.144600.
227. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. **J Biol Chem** 278: 2563–2570, 2003. doi:10.1074/jbc.M209525200.
228. Li G, Thomas AM, Williams JA, Kong B, Liu J, Inaba Y, Xie W, Guo GL. Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. **PLoS One** 7: e35895, 2012. doi:10.1371/journal.pone.0035895.
229. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. **J Clin Invest** 116: 1102–1109, 2006. doi:10.1172/JCI25604.
230. Miyata M, Sakaida Y, Matsuzawa H, Yoshinari K, Yamazoe Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. **Biol Pharm Bull** 34: 1885–1889, 2011. doi:10.1248/bpb.34.1885.
231. Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M, Weber A, Müllhaupt B, Guo GL, Geier A. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. **Liver Int** 35: 1133–1144, 2015. doi:10.1111/liv.12456.
232. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. **J Biol Chem** 284: 10023–10033, 2009. doi:10.1074/jbc.M808818200.
233. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. **J Clin Invest** 125: 386–402, 2015. doi:10.1172/JCI76738.
234. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. **J Biol Chem** 281: 11039–11049, 2006. doi:10.1074/jbc.M510258200.
235. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. **J Biol Chem** 279: 23158–23165, 2004. doi:10.1074/jbc.M314322200.
236. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. **Proc Natl Acad Sci U S A** 103: 1006–1011, 2006. doi:10.1073/pnas.0506982103.
237. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, Bouchaert E, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B. Transient impairment of the adaptive response to fasting in FXR-deficient mice. **FEBS Lett** 579: 4076–4080, 2005. doi:10.1016/j.febslet.2005.06.033.
238. Dufer M, Horth K, Wagner R, Schittenhelm B, Prowald S, Wagner TF, Oberwinkler J, Lukowski R, Gonzalez FJ, Krippeit-Drews P, Drews G. Bile acids acutely stimulate insulin secretion of mouse β -cells via farnesoid X receptor activation and K_{ATP} channel inhibition. **Diabetes** 61: 1479–1489, 2012. doi:10.2337/db11-0815.
239. Popescu IR, Helleboid-Chapman A, Lucas A, Vandewalle B, Dumont J, Bouchaert E, Derudas B, Kerr-Conte J, Caron S, Pattou F, Staels B. The nuclear receptor FXR is expressed in pancreatic β -cells and protects human islets from lipotoxicity. **FEBS Lett** 584: 2845–2851, 2010. doi:10.1016/j.febslet.2010.04.068.
240. Seyer P, Vallois D, Poitry-Yamate C, Schütz F, Metref S, Tarussio D, Maechler P, Staels B, Lanz B, Grueter R, Decaris J, Turner S, da Costa A, Preitner F, Minehira K, Foretz M, Thorens B. Hepatic glucose sensing is required to preserve beta cell glucose competence. **J Clin Invest** 123: 1662–1676, 2013. doi:10.1172/JCI65538.
241. Renga B, Mencarelli A, D'Amore C, Cipriani S, Baldelli F, Zampella A, Distrutti E, Fiorucci S. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. **FASEB J** 26: 3021–3031, 2012. doi:10.1096/fj.11-195701.
242. Massafra V, Milona A, Vos HR, Ramos RJJ, Gerrits J, Willemsen ECL, Ramos Pittol JM, Ijssennagger N, Houweling M, Prinsen H, Verhoeven-Duif NM, Burgering BMT, van Mil SWC. Farnesoid X receptor activation promotes hepatic amino acid catabolism and ammonium clearance in mice. **Gastroenterology** 152: 1462–1476, 2017. doi:10.1053/j.gastro.2017.01.014.
243. Renga B, Mencarelli A, Cipriani S, D'Amore C, Zampella A, Monti MC, Distrutti E, Fiorucci S. The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate. **Biochim Biophys Acta** 1812: 1522–1531, 2011. doi:10.1016/j.bbadis.2011.06.009.
244. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. **Annu Rev Biochem** 68: 913–963, 1999. doi:10.1146/annurev.biochem.68.1.913.
245. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. **Diabetes** 60: 1861–1871, 2011. doi:10.2337/db11-0030.
246. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Perez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ. FXR is a molecular target for the effects of vertical sleeve gastrectomy. **Nature** 509: 183–188, 2014. doi:10.1038/nature13135.
247. Zhang Y, Ge X, Heemstra LA, Chen WD, Xu J, Smith JL, Ma H, Kasim N, Edwards PA, Novak CM. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. **Mol Endocrinol** 26: 272–280, 2012. doi:10.1210/me.2011-1157.
248. Schittenhelm B, Wagner R, Kahny V, Peter A, Krippeit-Drews P, Dufer M, Drews G. Role of FXR in β -cells of lean and obese mice. **Endocrinology** 156: 1263–1271, 2015. doi:10.1210/en.2014-1751.
249. Xie C, Jiang C, Shi J, Gao X, Sun D, Sun L, Wang T, Takahashi S, Anitha M, Krausz KW, Patterson AD, Gonzalez FJ. An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice. **Diabetes** 66: 613–626, 2017. doi:10.2337/db16-0663.
250. Akinrotimi O, Riessen R, VanDuyn P, Park JE, Lee YK, Wong LJ, Zavacki AM, Schoonjans K, Anakk S. Small heterodimer partner deletion prevents hepatic steatosis and when combined with farnesoid X receptor loss protects against type 2 diabetes in mice. **Hepatology** 66: 1854–1865, 2017. doi:10.1002/hep.29305.
251. Kim KH, Choi S, Zhou Y, Kim EY, Lee JM, Saha PK, Anakk S, Moore DD. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice. **Hepatology** 66: 498–509, 2017. doi:10.1002/hep.29199.

252. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukashova Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. **Nat Med** 21: 159–165, 2015. doi:10.1038/nm.3760.
253. Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. **Hepatology** 67: 2150–2166, 2018. doi:10.1002/hep.29676.
254. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. **Gastroenterology** 145: 574–582, 2013. doi:10.1053/j.gastro.2013.05.042.
255. Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. **Liver Int** 39: 924–932, 2019. doi:10.1111/liv.13974.
256. Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML; for the NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. **Aliment Pharmacol Ther** 47: 645–656, 2018. doi:10.1111/apt.14492.
257. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, Network NCR. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. **Lancet** 385: 956–965, 2015. doi:10.1016/S0140-6736(14)61933-4.
258. Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J, Chalasani N, Sanyal AJ; Nash CRN. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. **J Hepatol** 72: 25–33, 2020. doi:10.1016/j.jhep.2019.10.006.
259. Bowlus CL, Pockros PJ, Kremer AE, Pares A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, Pencek R, Iloeje U, MacConell L, Bedossa P. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis. **Clin Gastroenterol Hepatol** 18: 1170–1178, 2020. doi:10.1016/j.cgh.2019.09.050.
260. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JPH, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall H-U, Kowdley K-V, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. **N Engl J Med** 375: 631–643, 2016. doi:10.1056/NEJMoa1509840.
261. Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. **Lancet Gastroenterol Hepatol** 4: 445–453, 2019. doi:10.1016/S2468-1253(19)30094-9.
262. Edwards JE, LaCerte C, Peyret T, Gosselin NH, Marier JF, Hofmann AF, Shapiro D. Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage. **Clin Transl Sci** 9: 328–336, 2016. doi:10.1111/cts.12421.
263. Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, Hirschfield GM, Schiano T, Jin Y, Pencek R, MacConell L, Shapiro D, Bowlus CL; AESOP Study Investigators. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. **J Hepatol** 73: 94–101, 2020. doi:10.1016/j.jhep.2020.02.033.
264. Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. **Contemp Clin Trials** 84: 105803, 2019. doi:10.1016/j.cct.2019.06.017.
265. Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW-S, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjoo CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial. **Hepatology** 72: 58–71, 2020. doi:10.1002/hep.31205.
266. Watanabe M, Houten SM, Matakai C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. **Nature** 439: 484–489, 2006. doi:10.1038/nature04330.
267. Carino A, Cipriani S, Marchianò S, Biagioli M, Scarpelli P, Zampella A, Monti MC, Fiorucci S. Gpbar1 agonism promotes a Pgc-1 α -dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. **Sci Rep** 7: 13689, 2017. doi:10.1038/s41598-017-13102-y.
268. Broeders EP, Nascimento EB, Havekes B, Brans B, Roumans KH, Tailleux A, Schaart G, Kouach M, Charton J, Deprez B, Bouvy ND, Mottaghy F, Staels B, van Marken Lichtenbelt WD, Schrauwen P. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. **Cell Metab** 22: 418–426, 2015. doi:10.1016/j.cmet.2015.07.002.
269. Fromme T, Hüttinger K, Maurer S, Li Y, Gantert T, Fiamoncini J, Daniel H, Westphal S, Klingenspor M. Bile acid supplementation decreases body mass gain in C57BL/6J but not 129S6/SvEvTac mice without increasing energy expenditure. **Sci Rep** 9: 131, 2019. doi:10.1038/s41598-018-37464-z.
270. Finn PD, Rodriguez D, Kohler J, Jiang Z, Wan S, Blanco E, King AJ, Chen T, Bell N, Dragoli D, Jacobs JW, Jain R, Leadbetter M, Siegel M, Carreras CW, Koo-McCoy S, Shaw K, Le C, Vanegas S, Hsu IH, Kozuka K, Okamoto K, Caldwell JS, Lewis JG. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. **Am J Physiol Gastrointest Liver Physiol** 316: G412–G424, 2019. doi:10.1152/ajpgi.00300.2018.
271. Lasalle M, Hoguet V, Hennuyer N, Leroux F, Piveteau C, Belloy L, Lestavel S, Vallez E, Dorchie E, Duplan I, Sevin E, Culot M, Gosselet F, Boulahjar R, Herledan A, Staels B, Deprez B, Tailleux A, Charton J. Topical intestinal aminoimidazole agonists of G-protein-coupled bile acid receptor 1 promote glucagon-like peptide-1 secretion and

- improve glucose tolerance. **J Med Chem** 60: 4185–4211, 2017. doi:[10.1021/acs.jmedchem.6b01873](https://doi.org/10.1021/acs.jmedchem.6b01873).
272. Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, Kliewer SA, Burgess SC. Colesevelam suppresses hepatic glycolysis by TGR5-mediated induction of GLP-1 action in DIO mice. **Am J Physiol Gastrointest Liver Physiol** 304: G371–G380, 2013. doi:[10.1152/ajpgi.00400.2012](https://doi.org/10.1152/ajpgi.00400.2012).
273. Watanabe M, Morimoto K, Houten SM, Kaneko-Iwasaki N, Sugizaki T, Horai Y, Matakai C, Sato H, Murahashi K, Arita E, Schoonjans K, Suzuki T, Itoh H, Auwerx J. Bile acid binding resin improves metabolic control through the induction of energy expenditure. **PLoS One** 7: e38286, 2012. doi:[10.1371/journal.pone.0038286](https://doi.org/10.1371/journal.pone.0038286).
274. Sasaki T, Kuboyama A, Mita M, Murata S, Shimizu M, Inoue J, Mori K, Sato R. The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice. **J Biol Chem** 293: 10322–10332, 2018. doi:[10.1074/jbc.RA118.002733](https://doi.org/10.1074/jbc.RA118.002733).
275. Huang S, Ma S, Ning M, Yang W, Ye Y, Zhang L, Shen J, Leng Y. TGR5 agonist ameliorates insulin resistance in skeletal muscles and improves glucose homeostasis in diabetic mice. **Metabolism** 99: 45–56, 2019. doi:[10.1016/j.metabol.2019.07.003](https://doi.org/10.1016/j.metabol.2019.07.003).
276. Appleby RN, Moghul I, Khan S, Yee M, Manousou P, Neal TD, Walters JRF. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. **PLoS One** 14: e0211348, 2019. doi:[10.1371/journal.pone.0211348](https://doi.org/10.1371/journal.pone.0211348).
277. Chevre R, Trigueros-Motos L, Castaño D, Chua T, Corliano M, Patankar JV, Sng L, Sim L, Juin TL, Carissimo G, Ng LFP, Yi CNJ, Eliathamby CC, Groen AK, Hayden MR, Singaraja RR. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. **FASEB J** 32: 3792–3802, 2018. doi:[10.1096/fj.201701084RR](https://doi.org/10.1096/fj.201701084RR).
278. Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. **Gut** 67: 1881–1891, 2018. doi:[10.1136/gutjnl-2017-314307](https://doi.org/10.1136/gutjnl-2017-314307).
279. Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. **Hepatology** 67: 534–548, 2018. doi:[10.1002/hep.29359](https://doi.org/10.1002/hep.29359).
280. Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. **Gut** 63: 170–178, 2014. doi:[10.1136/gutjnl-2012-303150](https://doi.org/10.1136/gutjnl-2012-303150).
281. Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. **Hepatol Int** 4: 741–748, 2010. doi:[10.1007/s12072-010-9202-6](https://doi.org/10.1007/s12072-010-9202-6).
282. Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P, Moschetta A. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. **Hepatology** 61: 161–170, 2015. doi:[10.1002/hep.27274](https://doi.org/10.1002/hep.27274).
283. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. **Cancer Res** 67: 863–867, 2007. doi:[10.1158/0008-5472.CAN-06-1078](https://doi.org/10.1158/0008-5472.CAN-06-1078).
284. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (*fa/fa*) obese rats. **J Lipid Res** 51: 771–784, 2010. doi:[10.1194/jlr.M001602](https://doi.org/10.1194/jlr.M001602).
285. Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, Zhou M, Chen S. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. **Biochem Biophys Res Commun** 450: 117–123, 2014. doi:[10.1016/j.bbrc.2014.05.072](https://doi.org/10.1016/j.bbrc.2014.05.072).
286. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. **J Hepatol** 51: 380–388, 2009. doi:[10.1016/j.jhep.2009.03.025](https://doi.org/10.1016/j.jhep.2009.03.025).
287. Parséus A, Sommer N, Sommer F, Caesar R, Molinaro A, Ståhlman M, Greiner TU, Perkins R, Bäckhed F. Microbiota-induced obesity requires farnesoid X receptor. **Gut** 66: 429–437, 2017. doi:[10.1136/gutjnl-2015-310283](https://doi.org/10.1136/gutjnl-2015-310283).
288. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. **Hepatology** 63: 764–775, 2016. doi:[10.1002/hep.28356](https://doi.org/10.1002/hep.28356).
289. Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. **Gastroenterology** 151: 845–859, 2016. doi:[10.1053/j.gastro.2016.08.057](https://doi.org/10.1053/j.gastro.2016.08.057).
290. Carino A, Marchianò S, Biagioli M, Bucci M, Vellecco V, Brancaleone V, Fiorucci C, Zampella A, Monti MC, Distrutti E, Fiorucci S. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. **FASEB J** 33: 2809–2822, 2019. doi:[10.1096/fj.201801373RR](https://doi.org/10.1096/fj.201801373RR).
291. de Oliveira MC, Gilgioni EH, de Boer BA, Runge JH, de Waart DR, Salgueiro CL, Ishii-Iwamoto EL, Oude Elferink RP, Gaemers IC. Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. **Biochim Biophys Acta** 1862: 2054–2062, 2016. doi:[10.1016/j.bbadis.2016.07.012](https://doi.org/10.1016/j.bbadis.2016.07.012).
292. Comeglio P, Cellai I, Mello T, Filippi S, Maneschi E, Corcetto F, Corno C, Sarchielli E, Morelli A, Rapizzi E, Bani D, Guasti D, Vannelli GB, Galli A, Adorini L, Maggi M, Vignozzi L. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. **J Endocrinol** 238: 107–127, 2018. doi:[10.1530/JOE-17-0557](https://doi.org/10.1530/JOE-17-0557).
293. Hu YB, Liu XY, Zhan W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. **DDDT** 12: 2213–2221, 2018. doi:[10.2147/DDDT.S170518](https://doi.org/10.2147/DDDT.S170518).
294. Jadhav K, Xu Y, Xu Y, Li Y, Xu J, Zhu Y, Adorini L, Lee YK, Kasumov T, Yin L, Zhang Y. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. **Mol Metab** 9: 131–140, 2018. doi:[10.1016/j.molmet.2018.01.005](https://doi.org/10.1016/j.molmet.2018.01.005).
295. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. **J Biol Chem** 288: 11761–11770, 2013. doi:[10.1074/jbc.M112.446575](https://doi.org/10.1074/jbc.M112.446575).
296. Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. **WJG** 24: 195–210, 2018. doi:[10.3748/wjg.v24.i2.195](https://doi.org/10.3748/wjg.v24.i2.195).

297. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. **Science** 360: eaan5931, 2018. doi:10.1126/science.aan5931.
298. Thompson MD, Moghe A, Cornuet P, Marino R, Tian J, Wang P, Ma X, Abrams M, Locker J, Monga SP, Nejak-Bowen K. β -Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis. **Hepatology** 67: 955–971, 2018. doi:10.1002/hep.29371.
299. Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, Halilbasic E, Yang M, Jaeschke H, Stokman G, Wells RG, Eller K, Rosenkranz AR, Eggertsen G, Wagner CA, Langner C, Denk H, Trauner M. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. **Hepatology** 58: 2056–2069, 2013. doi:10.1002/hep.26599.
300. Hench PS. Effect of jaundice on rheumatoid arthritis. **Br Med J** 2: 394–398, 1938.
301. Ho PP, Steinman L. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. **Proc Natl Acad Sci USA** 113: 1600–1605, 2016. doi:10.1073/pnas.1524890113.
302. Lewis ND, Patnaude LA, Pelletier J, Souza DJ, Lukas SM, King FJ, Hill JD, Stefanopoulos DE, Ryan K, Desai S, Skow D, Kauschke SG, Broermann A, Kuzmich D, Harcken C, Hickey ER, Modis LK. A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo. **PLoS One** 9: e100883, 2014. doi:10.1371/journal.pone.0100883.
303. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ. Effects of FXR in foam-cell formation and atherosclerosis development. **Biochim Biophys Acta** 1761: 1401–1409, 2006. doi:10.1016/j.bbailip.2006.09.018.
304. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. **J Lipid Res** 46: 2595–2604, 2005. doi:10.1194/jlr.M500390-JLR200.
305. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR^{-/-} and apoE^{-/-} mice. **J Lipid Res** 50: 1090–1100, 2009. doi:10.1194/jlr.M800619-JLR200.
306. Miyazaki-Anzai S, Masuda M, Kohno S, Levi M, Shiozaki Y, Keenan AL, Miyazaki M. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. **J Lipid Res** 59: 1709–1713, 2018. doi:10.1194/jlr.M087239.
307. Miyazaki-Anzai S, Masuda M, Levi M, Keenan AL, Miyazaki M. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. **PLoS One** 9: e108270, 2014. doi:10.1371/journal.pone.0108270.
308. Ferrell JM, Pathak P, Boehme S, Gilliland T, Chiang JYL. Deficiency of both farnesoid X receptor and Takeda G protein-coupled receptor 5 exacerbated liver fibrosis in mice. **Hepatology** 70: 955–970, 2019. doi:10.1002/hep.30513.
309. Kim DH, Xiao Z, Kwon S, Sun X, Ryerson D, Tkac D, Ma P, Wu SY, Chiang CM, Zhou E, Xu HE, Palvimo JJ, Chen LF, Kemper B, Kemper JK. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. **EMBO J** 34: 184–199, 2015. doi:10.15252/emboj.201489527.
310. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor κ B in hepatic inflammatory response. **Hepatology** 48: 1632–1643, 2008. doi:10.1002/hep.22519.
311. Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. **WJG** 20: 14430–14441, 2014. doi:10.3748/wjg.v20.i39.14430.
312. Schote AB, Turner JD, Schiltz J, Muller CP. Nuclear receptors in human immune cells: expression and correlations. **Mol Immunol** 44: 1436–1445, 2007. doi:10.1016/j.molimm.2006.04.021.
313. Campbell C, McKenney PT, Konstantinovskiy D, Isaeva OI, Schizas M, Verter J, Mai C, Jin WB, Guo CJ, Violante S, Ramos RJ, Cross JR, Kadaveru K, Hambor J, Rudensky AY. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. **Nature** 581: 475–479, 2020. doi:10.1038/s41586-020-2193-0.
314. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. **Am J Physiol Heart Circ Physiol** 296: H272–H281, 2009. doi:10.1152/ajpheart.01075.2008.
315. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. **J Immunol** 183: 6251–6261, 2009. doi:10.4049/jimmunol.0803978.
316. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. **Carcinogenesis** 28: 940–946, 2007. doi:10.1093/carcin/bgl249.
317. Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, Santucci L, Fiorucci S. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. **J Immunol** 183: 6657–6666, 2009. doi:10.4049/jimmunol.0901347.
318. Jin D, Lu T, Ni M, Wang H, Zhang J, Zhong C, Shen C, Hao J, Busuttill RW, Kupiec-Weglinski JW, Zhang J, Xu N, Zhai Y. Farnesoid X receptor activation protects liver from ischemia/reperfusion injury by up-regulating small heterodimer partner in Kupffer cells. **Hepatol Commun** 4: 540–554, 2020. doi:10.1002/hep4.1478.
319. Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. **Nat Rev Gastroenterol Hepatol** 14: 55–66, 2017. doi:10.1038/nrgastro.2016.168.
320. Hao H, Cao L, Jiang C, Che Y, Zhang S, Takahashi S, Wang G, Gonzalez FJ. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. **Cell Metab** 25: 856–867, 2017. doi:10.1016/j.cmet.2017.03.007.
321. Han CY, Rho HS, Kim A, Kim TH, Jang K, Jun DW, Kim JW, Kim B, Kim SG. FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury. **Cell Rep** 24: 2985–2999, 2018. doi:10.1016/j.celrep.2018.07.068.
322. Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. **Hepatol Commun** 1: 1024–1042, 2017. doi:10.1002/hep4.1108.
323. Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. **Hepatology** 63: 914–929, 2016. doi:10.1002/hep.28257.
324. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the

- intestinal barrier in inflammatory bowel disease. **Gut** 60: 463–472, 2011. doi:10.1136/gut.2010.212159.
325. Massafra V, Ijssennagger N, Plantinga M, Milona A, Ramos Pittol JM, Boes M, van Mil SW. Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. **Biochim Biophys Acta** 1862: 166–173, 2016. doi:10.1016/j.bbadis.2015.11.001.
326. Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. **Am J Pathol** 185: 409–419, 2015. doi:10.1016/j.ajpath.2014.10.009.
327. Ceulemans LJ, Verbeke L, Decuypere JP, Farré R, De Hertogh G, Lenaerts K, Jochmans I, Monbaliu D, Nevens F, Tack J, Laleman W, Pirenne J. Farnesoid X receptor activation attenuates intestinal ischemia reperfusion injury in rats. **PLoS One** 12: e0169331, 2017. doi:10.1371/journal.pone.0169331.
328. Na Torres J, Bao X, Iuga A, Chen A, Harpaz N, Ullman T, Cohen B, Pineton de Chambrun G, Ascutti S, A Odin J, Sachar D, Gaskins R, Setchell K, Colombel J-F, H Itzkowitz S. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. **Inflamm Bowel Dis** 19: 275–282, 2013. doi:10.1097/MIB.0b013e318286ff2e.
329. Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, Weersma RK, van der Woude CJ, Stapelbroek JM, Schipper ME, Wijmenga C, van Erpecum KJ, Oldenburg B, on behalf of the Dutch Initiative on Crohn, Colitis (ICC). Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. **PLoS One** 6: e23745, 2011. doi:10.1371/journal.pone.0023745.
330. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. **Proc Natl Acad Sci U S A** 101: 3668–3673, 2004. doi:10.1073/pnas.0400046101.
331. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. **ATVB** 27: 2606–2611, 2007. doi:10.1161/ATVBAHA.107.152694.
332. Perino A, Schoonjans K. TGR5 and Immunometabolism: insights from physiology and pharmacology. **Trends Pharmacol Sci** 36: 847–857, 2015. doi:10.1016/j.tips.2015.08.002.
333. Biagioli M, Carino A, Cipriani S, Francisci D, Marchianò S, Scarpelli P, Sorcini D, Zampella A, Fiorucci S. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. **Ji** 199: 718–733, 2017. doi:10.4049/jimmunol.1700183.
334. Högenauer K, Arista L, Schmiedeberg N, Werner G, Jaksche H, Bouhelal R, Nguyen DG, Bhat BG, Raad L, Rauld C, Carballido JM. G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype. **J Med Chem** 57: 10343–10354, 2014. doi:10.1021/jm501052c.
335. Wammers M, Schupp AK, Bode JG, Ehling C, Wolf S, Deenen R, Köhrer K, Haussinger D, Graf D. Reprogramming of pro-inflammatory human macrophages to an anti-inflammatory phenotype by bile acids. **Sci Rep** 8: 255, 2018. doi:10.1038/s41598-017-18305-x.
336. Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. **Biochem Biophys Res Commun** 372: 78–84, 2008. doi:10.1016/j.bbrc.2008.04.171.
337. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S. The bile acid receptor GPBAR1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. **PLoS One** 6: e25637, 2011. doi:10.1371/journal.pone.0025637.
338. Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, Matsuoka K, Sato T, Koganei K, Sugita A, Kanai T, Hibi T. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. **Immunology** 139: 19–29, 2013. doi:10.1111/imm.12045.
339. Garibay D, Zaborska KE, Shanahan M, Zheng Q, Kelly KM, Montrose DC, Dannenberg AJ, Miller AD, Sethupathy P, Cummings BP. TGR5 protects against colitis in mice, but vertical sleeve gastrectomy increases colitis severity. **Obes Surg** 29: 1593–1601, 2019. doi:10.1007/s11695-019-03707-9.
340. Ichikawa R, Takayama T, Yoneno K, Kamada N, Kitazume MT, Higuchi H, Matsuoka K, Watanabe M, Itoh H, Kanai T, Hisamatsu T, Hibi T. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. **Immunology** 136: 153–162, 2012. doi:10.1111/j.1365-2567.2012.03554.x.
341. Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, Zheng M, Zhang X, Xia D, Ke Y, Lu L, Wang D. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. **Immunity** 45: 802–816, 2016. doi:10.1016/j.immuni.2016.09.008.
342. Xiong Q, Huang H, Wang N, Chen R, Chen N, Han H, Wang Q, Siwko S, Liu M, Qian M, Du B. Metabolite-sensing G protein coupled receptor TGR5 protects host from viral infection through amplifying Type I interferon responses. **Front Immunol** 9: 2289, 2018. doi:10.3389/fimmu.2018.02289.
343. Huang H, Lei H, Yang F, Fan X, Dang Q, Li Y. Activation of the bile acid receptor GPBAR1 (TGR5) ameliorates interleukin-1 β (IL-1 β)-induced chondrocytes senescence. **Biomed Pharmacother** 106: 1713–1719, 2018. doi:10.1016/j.biopha.2018.06.154.
344. Otao R, Beppu T, Isiko T, Mima K, Okabe H, Hayashi H, Masuda T, Chikamoto A, Takamori H, Baba H. External biliary drainage and liver regeneration after major hepatectomy. **Br J Surg** 99: 1569–1574, 2012. doi:10.1002/bjs.8906.
345. Ueda J, Chijiwa K, Nakano K, Zhao G, Tanaka M. Lack of intestinal bile results in delayed liver regeneration of normal rat liver after hepatectomy accompanied by impaired cyclin E-associated kinase activity. **Surgery** 131: 564–573, 2002. doi:10.1067/msy.2002.123008.
346. Barone M, Francavilla A, Polimeno L, Ierardi E, Romanelli D, Berloco P, Di Leo A, Panella C. Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies. **Hepatology** 23: 1159–1166, 1996. doi:10.1053/jhep.1996.v23.pm0008621149.
347. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, Dong B, Huang X, Moore DD. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. **Science** 312: 233–236, 2006. doi:10.1126/science.1121435.
348. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. **Am J Pathol** 176: 2–13, 2010. doi:10.2353/ajpath.2010.090675.
349. Chen WD, Wang YD, Zhang L, Shiah S, Wang M, Yang F, Yu D, Forman BM, Huang W. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating

- forkhead box m1b transcription. **Hepatology** 51: 953–962, 2010. doi:[10.1002/hep.23390](https://doi.org/10.1002/hep.23390).
350. Garcia-Rodríguez JL, Barbier-Torres L, Fernández-Álvarez S, Gutiérrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Álvarez L, Aspichueta P, Marín JJ, Trauner M, Mato JM, Serrano M, Beraza N, Martínez-Chantar ML. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. **Hepatology** 59: 1972–1983, 2014. doi:[10.1002/hep.26971](https://doi.org/10.1002/hep.26971).
 351. Wang YD, Yang F, Chen WD, Huang X, Lai L, Forman BM, Huang W. Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. **Mol Endocrinol** 22: 1622–1632, 2008. doi:[10.1210/me.2007-0527](https://doi.org/10.1210/me.2007-0527).
 352. Naugler WE. Bile acid flux is necessary for normal liver regeneration. **PLoS One** 9: e97426, 2014. doi:[10.1371/journal.pone.0097426](https://doi.org/10.1371/journal.pone.0097426).
 353. Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion AR, Medina JF, Marín JJ, Berasain C, Prieto J, Avila MA. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. **Gut** 62: 899–910, 2013. doi:[10.1136/gutjnl-2012-302945](https://doi.org/10.1136/gutjnl-2012-302945).
 354. Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, Lin M, Forman BM, Huang W. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. **Hepatology** 56: 2336–2343, 2012. doi:[10.1002/hep.25905](https://doi.org/10.1002/hep.25905).
 355. Kong B, Huang J, Zhu Y, Li G, Williams J, Shen S, Aleksunes LM, Richardson JR, Apte U, Rudnick DA, Guo GL. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. **Am J Physiol Gastrointest Liver Physiol** 306: G893–G902, 2014. doi:[10.1152/ajpgi.00337.2013](https://doi.org/10.1152/ajpgi.00337.2013).
 356. Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. **Hepatology** 56: 1034–1043, 2012. doi:[10.1002/hep.25740](https://doi.org/10.1002/hep.25740).
 357. Cressman DE, Diamond RH, Taub R. Rapid activation of the Stat3 transcription complex in liver regeneration. **Hepatology** 21: 1443–1449, 1995. doi:[10.1002/hep.1840210531](https://doi.org/10.1002/hep.1840210531).
 358. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. **J Biol Chem** 277: 28411–28417, 2002. doi:[10.1074/jbc.M202807200](https://doi.org/10.1074/jbc.M202807200).
 359. Mencalha AL, Binato R, Ferreira GM, Du Rocher B, Abdelhay E. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. **PLoS One** 7: e48160, 2012. doi:[10.1371/journal.pone.0048160](https://doi.org/10.1371/journal.pone.0048160).
 360. Padrisa-Altés S, Bachofner M, Bogorad RL, Pohlmeier L, Rossolini T, Böhm F, Liebisch G, Hellerbrand C, Koteliensky V, Speicher T, Werner S. Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. **Gut** 64: 1444–1453, 2015. doi:[10.1136/gutjnl-2014-307874](https://doi.org/10.1136/gutjnl-2014-307874).
 361. Milona A, Owen BM, van Mil S, Dormann D, Matakı C, Boudjelal M, Cairns W, Schoonjans K, Milligan S, Parker M, White R, Williamson C. The normal mechanisms of pregnancy-induced liver growth are not maintained in mice lacking the bile acid sensor Fxr. **Am J Physiol Gastrointest Liver Physiol** 298: G151–G158, 2010. doi:[10.1152/ajpgi.00336.2009](https://doi.org/10.1152/ajpgi.00336.2009).
 362. Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, Holcomb LA, Caligiuri A, LeSage GD. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. **Gastroenterology** 116: 179–186, 1999. doi:[10.1016/S0016-5085\(99\)70242-8](https://doi.org/10.1016/S0016-5085(99)70242-8).
 363. Liang H, Estes MK, Zhang H, Du G, Zhou Y. Bile acids target proteolipid nano-assemblies of EGFR and phosphatidic acid in the plasma membrane for stimulation of MAPK signaling. **PLoS One** 13: e0198983, 2018. doi:[10.1371/journal.pone.0198983](https://doi.org/10.1371/journal.pone.0198983).
 364. Nagathihalli NS, Beesetty Y, Lee W, Washington MK, Chen X, Lockhart AC, Merchant NB. Novel mechanistic insights into ectodomain shedding of EGFR ligands amphiregulin and TGF- α : impact on gastrointestinal cancers driven by secondary bile acids. **Cancer Res** 74: 2062–2072, 2014. doi:[10.1158/0008-5472.CAN-13-2329](https://doi.org/10.1158/0008-5472.CAN-13-2329).
 365. Sommerfeld A, Reinehr R, Häussinger D. Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis. **J Biol Chem** 284: 22173–22183, 2009. doi:[10.1074/jbc.M109.005355](https://doi.org/10.1074/jbc.M109.005355).
 366. Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate EGF receptor via a TGF- α -dependent mechanism in human cholangiocyte cell lines. **Am J Physiol Gastrointest Liver Physiol** 285: G31–G36, 2003. doi:[10.1152/ajpgi.00536.2002](https://doi.org/10.1152/ajpgi.00536.2002).
 367. Cho SW, An JH, Park H, Yang JY, Choi HJ, Kim SW, Park YJ, Kim SY, Yim M, Baek WY, Kim JE, Shin CS. Positive regulation of osteogenesis by bile acid through FXR. **J Bone Miner Res** 28: 2109–2121, 2013. doi:[10.1002/jbmr.1961](https://doi.org/10.1002/jbmr.1961).
 368. Id Boufker H, Lagneaux L, Fayyad-Kazan H, Badran B, Najar M, Wiedig M, Ghanem G, Laurent G, Body JJ, Journé F. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. **Bone** 49: 1219–1231, 2011. doi:[10.1016/j.bone.2011.08.013](https://doi.org/10.1016/j.bone.2011.08.013).
 369. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, Bouchaert E, Briand O, Brozek J, Kuipers F, Fievet C, Cariou B, Staels B. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor- γ and interfering with the Wnt/ β -catenin pathways. **J Biol Chem** 285: 36759–36767, 2010. doi:[10.1074/jbc.M110.166231](https://doi.org/10.1074/jbc.M110.166231).
 370. van Zutphen T, Stroeve JHM, Yang J, Bloks VW, Jurdzinski A, Roelofsens H, Huijckman NCA, van Dijk TH, Vonk RJ, van Deursen J, Staels B, Groen AK, Kuipers F. FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. **J Lipid Res** 60: 1547–1561, 2019. doi:[10.1194/jlr.M094508](https://doi.org/10.1194/jlr.M094508).
 371. Chouchani ET, Kajimura S. Metabolic adaptation and maladaptation in adipose tissue. **Nat Metab** 1: 189–200, 2019. doi:[10.1038/s42255-018-0021-8](https://doi.org/10.1038/s42255-018-0021-8).
 372. Gehart H, Clevers H. Tales from the crypt: new insights into intestinal stem cells. **Nat Rev Gastroenterol Hepatol** 16: 19–34, 2019. doi:[10.1038/s41575-018-0081-y](https://doi.org/10.1038/s41575-018-0081-y).
 373. Sorrentino G, Perino A, Yildiz E, El Alam G, Sleiman MB, Gioiello A, Pellicciari R, Schoonjans K. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration. **Gastroenterology** 159: 956–968.e8, 2020. doi:[10.1053/j.gastro.2020.05.067](https://doi.org/10.1053/j.gastro.2020.05.067).
 374. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. **Physiol Rev** 90: 859–904, 2010. doi:[10.1152/physrev.00045.2009](https://doi.org/10.1152/physrev.00045.2009).
 375. Kellogg TF, Wostmann BS. Fecal neutral steroids and bile acids from germfree rats. **J Lipid Res** 10: 495–503, 1969.
 376. Sayin SI, Wählstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešić M, Bäckhed F. Gut microbiota

- regulates bile acid metabolism by reducing the levels of tauro- β -muricholic acid, a naturally occurring FXR antagonist. **Cell Metab** 17: 225–235, 2013. doi:10.1016/j.cmet.2013.01.003.
377. Selwyn FP, Csanaky IL, Zhang Y, Klaassen CD. Importance of large intestine in regulating bile acids and glucagon-like peptide-1 in germ-free mice. **Drug Metab Dispos** 43: 1544–1556, 2015. doi:10.1124/dmd.115.065276.
378. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. **Proc Natl Acad Sci U S A** 108: 4523–4530, 2011. doi:10.1073/pnas.1006734107.
379. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. **J Lipid Res** 47: 241–259, 2006. doi:10.1194/jlr.R500013-JLR200.
380. Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, Soto M, Konishi M, Softic S, Altindis E, Li N, Gerber G, Bry L, Kahn CR. Antibiotic effects on gut microbiota and metabolism are host dependent. **J Clin Invest** 126: 4430–4443, 2016. doi:10.1172/JCI86674.
381. Watanabe K, Igarashi M, Li X, Nakatani A, Miyamoto J, Inaba Y, Sutou A, Saito T, Sato T, Tachibana N, Inoue H, Kimura I. Dietary soybean protein ameliorates high-fat diet-induced obesity by modifying the gut microbiota-dependent biotransformation of bile acids. **PLoS One** 13: e0202083, 2018. doi:10.1371/journal.pone.0202083.
382. Devkota S, Chang EB. Interactions between diet, bile acid metabolism, gut microbiota, and inflammatory bowel diseases. **Dig Dis** 33: 351–356, 2015. doi:10.1159/000371687.
383. Just S, Mondot S, Ecker J, Wegner K, Rath E, Gau L, Streidl T, Hery-Arnaud G, Schmidt S, Lesker TR, Bieth V, Dunkel A, Strowig T, Hofmann T, Haller D, Liebisch G, Gérard P, Rohn S, Lepage P, Clavel TT. Gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. **Microbiome** 6: 134, 2018. doi:10.1186/s40168-018-0510-8.
384. Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, Knight R, Panda S. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. **Nat Commun** 9: 2872, 2018. doi:10.1038/s41467-018-05336-9.
385. Chevalier C, Stojanović O, Colin DJ, Suarez-Zamorano N, Tarallo V, Veyrat-Durebex C, Rigo D, Fabbiano S, Stevanović A, Hagemann S, Montet X, Seimille Y, Zamboni N, Hafelmeier S, Trajkovski M. Gut microbiota orchestrates energy homeostasis during cold. **Cell** 163: 1360–1374, 2015. doi:10.1016/j.cell.2015.11.004.
386. Ziętak M, Kovatcheva-Datchary P, Markiewicz LH, Ståhlman M, Kozak LP, Bäckhed F. Altered microbiota contributes to reduced diet-induced obesity upon cold exposure. **Cell Metab** 23: 1216–1223, 2016. doi:10.1016/j.cmet.2016.05.001.
387. Hagan T, Cortese M, Roupheal N, Boudreau C, Linde C, Maddur MS, Das J, Wang H, Guthmiller J, Zheng NY, Huang M, Uphadhyay AA, Gardinassi L, Petitdemange C, McCullough MP, Johnson SJ, Gill K, Cervasi B, Zou J, Bretin A, Hahn M, Gewirtz AT, Bosinger SE, Wilson PC, Li S, Alter G, Khurana S, Golding H, Pulendran B. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. **Cell** 178: 1313–1328, 2019. doi:10.1016/j.cell.2019.08.010.
388. Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, et al. Global chemical effects of the microbiome include new bile-acid conjugations. **Nature** 579: 123–129, 2020. doi:10.1038/s41586-020-2047-9.
389. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. **Cell Rep** 7: 12–18, 2014. doi:10.1016/j.celrep.2014.02.032.
390. Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, Shao T, Song Q, Zhu F, Zhang L, Jiang M, Zhou Y, Barve S, Zhang X, McClain CJ, Feng W. Probiotic *Lactobacillus rhamnosus* GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. **Hepatology** 71: 2050–2066, 2020. doi:10.1002/hep.30975.
391. Ovardia C, Perdones-Montero A, Spagou K, Smith A, Sarafian MH, Gomez-Romero M, Bellafante E, Clarke LCD, Sadiq F, Nikolova V, Mitchell A, Dixon PH, Santa-Pinter N, Wåhlström A, Abu-Hayyeh S, Walters JRF, Marschall HU, Holmes E, Marchesi JR, Williamson C. Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis. **Hepatology** 70: 276–293, 2019. doi:10.1002/hep.30661.
392. Ovardia C, Perdones-Montero A, Fan HM, Mullish BH, McDonald JAK, Papacleovoulou G, Wåhlström A, Ståhlman M, Tsakmaki A, Clarke LCD, Sklavounos A, Dixon PH, Bewick GA, Walters JRF, Marschall HU, Marchesi JR, Williamson C. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. **Sci Rep** 10: 3895, 2020. doi:10.1038/s41598-020-60821-w.
393. Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. **J Hepatol** 62: 1398–1404, 2015. doi:10.1016/j.jhep.2014.12.034.
394. Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, Huang T, Ning Z, Zhai L, Zhong LL, Lam W, Yang Z, Zhang X, Cheng C, Han L, Qiu Q, Shang X, Huang R, Xiao H, Ren Z, Chen D, Sun S, El-Nezami H, Cai Z, Lu A, Fang X, Jia W, Bian Z. A *Clostridia*-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. **J Clin Invest** 130: 438–450, 2019. doi:10.1172/JCI130976.
395. Reddy BS, Mangat S, Sheinfil A, Weisburger JH, Wynder EL. Effect of type and amount of dietary fat and 1,2-dimethylhydrazine on biliary bile acids, fecal bile acids, and neutral sterols in rats. **Cancer Res** 37: 2132–2137, 1977.
396. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. **Gastroenterology** 141: 1773–1781, 2011. doi:10.1053/j.gastro.2011.07.046.
397. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. **FEMS Microbiol Rev** 29: 625–651, 2005. doi:10.1016/j.femsre.2004.09.003.
398. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. **Proc Natl Acad Sci U S A** 103: 3920–3925, 2006. doi:10.1073/pnas.0509592103.
399. Sung JY, Shaffer EA, Costerton JW. Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. **Digest Dis Sci** 38: 2104–2112, 1993. doi:10.1007/BF01297092.
400. Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. **JB** 188: 1979–1986, 2006. doi:10.1128/JB.188.5.1979-1986.2006.
401. Friedman ES, Li Y, Shen TD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, Carr RM, Bittinger K, Li H, Wu GD.

- FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid. **Gastroenterology** 155: 1741–1752, 2018. doi:10.1053/j.gastro.2018.08.022.
402. Theriot CM, Koenigsnecht MJ, Carlson PE Jr, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li JZ, Young VB. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to *Clostridium difficile* infection. **Nat Commun** 5: 3114, 2014. doi:10.1038/ncomms4114.
403. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile acid mediated resistance to *Clostridium difficile*. **Nature** 517: 205–208, 2015. doi:10.1038/nature13828.
404. McKenney PT, Yan J, Vaubourgeix J, Becattini S, Lampen N, Motzer A, Larson PJ, Dannaoui D, Fujisawa S, Xavier JB, Pamer EG. Intestinal bile acids induce a morphotype switch in vancomycin-resistant enterococcus that facilitates intestinal colonization. **Cell Host Microbe** 25: 695–705, 2019. doi:10.1016/j.chom.2019.03.008.
405. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. **Cell** 157: 121–141, 2014. doi:10.1016/j.cell.2014.03.011.
406. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. **Nature** 474: 298–306, 2011. doi:10.1038/nature10208.
407. Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, Zheng Y, Longman RS, Rastinejad F, Devlin AS, Krout MR, Fischbach MA, Littman DR, Huh JR. Bile acid metabolites control TH17 and Treg cell differentiation. **Nature** 576: 143–148, 2019. doi:10.1038/s41586-019-1785-z.
408. Das P, Marcišauskas S, Ji B, Nielsen J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. **BMC Genomics** 20: 517, 2019. doi:10.1186/s12864-019-5899-3.
409. Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G, Namkoong H, Bittinger K, Fischbach MA, Sonnenburg JL, Habtezion A. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. **Cell Host Microbe** 27: 659–670, 2020. e655. doi:10.1016/j.chom.2020.01.021.
410. Wang S, Martins R, Sullivan MC, Friedman ES, Misis AM, El-Fahmawi A, De Martinis ECP, O'Brien K, Chen Y, Bradley C, Zhang G, Berry ASF, Hunter CA, Baldassano RN, Rondeau MP, Beiting DP. Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids. **Microbiome** 7: 126, 2019. doi:10.1186/s40168-019-0740-4.
411. Gerisch B, Rottiers V, Li D, Motola DL, Cummins CL, Lehrach H, Mangelsdorf DJ, Antebi A. A bile acid-like steroid modulates *Caenorhabditis elegans* lifespan through nuclear receptor signaling. **Proc Natl Acad Sci U S A** 104: 5014–5019, 2007. doi:10.1073/pnas.0700847104.
412. Mahanti P, Bose N, Bethke A, Judkins JC, Wollam J, Dumas KJ, Zimmerman AM, Campbell SL, Hu PJ, Antebi A, Schroeder FC. Comparative metabolomics reveals endogenous ligands of DAF-12, a nuclear hormone receptor, regulating *C. elegans* development and lifespan. **Cell Metab** 19: 73–83, 2014. doi:10.1016/j.cmet.2013.11.024.
413. Motola DL, Cummins CL, Rottiers V, Sharma KK, Li T, Li Y, Suino-Powell K, Xu HE, Auchus RJ, Antebi A, Mangelsdorf DJ. Identification of ligands for DAF-12 that govern dauer formation and reproduction in *C. elegans*. **Cell** 124: 1209–1223, 2006. doi:10.1016/j.cell.2006.01.037.
414. Shen Y, Wollam J, Magner D, Karalay O, Antebi A. A steroid receptor-microRNA switch regulates life span in response to signals from the gonad. **Science** 338: 1472–1476, 2012. doi:10.1126/science.1228967.
415. Goldberg AA, Richard VR, Kyryakov P, Bourque SD, Beach A, Burstein MT, Glebov A, Koupaki O, Boukh-Viner T, Gregg C, Juneau M, English AM, Thomas DY, Titorenko VI. Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes. **Aging** 2: 393–414, 2010. doi:10.18632/aging.100168.
416. Beach A, Richard VR, Leonov A, Burstein MT, Bourque SD, Koupaki O, Juneau M, Feldman R, Iouk T, Titorenko VI. Mitochondrial membrane lipidome defines yeast longevity. **Aging** 5: 551–574, 2013. doi:10.18632/aging.100578.
417. Burstein MT, Titorenko VI. A mitochondrially targeted compound delays aging in yeast through a mechanism linking mitochondrial membrane lipid metabolism to mitochondrial redox biology. **Redox Biol** 2: 305–307, 2014. doi:10.1016/j.redox.2014.01.011.
418. Lee G, Lee H, Hong J, Lee SH, Jung BH. Quantitative profiling of bile acids in rat bile using ultrahigh-performance liquid chromatography-orbitrap mass spectrometry: Alteration of the bile acid composition with aging. **J Chromatogr B Analyt Technol Biomed Life Sci** 1031: 37–49, 2016. doi:10.1016/j.jchromb.2016.07.017.
419. Fu ZD, Csanaky IL, Klaassen CD. Gender-divergent profile of bile acid homeostasis during aging of mice. **PLoS One** 7: e32551, 2012. doi:10.1371/journal.pone.0032551.
420. Frommherz L, Bub A, Hummel E, Rist MJ, Roth A, Watzl B, Kulling SE. Age-related changes of plasma bile acid concentrations in healthy adults—results from the cross-sectional KarMeN Study. **PLoS One** 11: e0153959, 2016. doi:10.1371/journal.pone.0153959.
421. Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D, Darlington G. Alterations in xenobiotic metabolism in the long-lived Little mice. **Aging Cell** 6: 453–470, 2007. doi:10.1111/j.1474-9726.2007.00300.x.
422. Amador-Noguez D, Yagi K, Venable S, Darlington G. Gene expression profile of long-lived Ames dwarf mice and Little mice. **Aging Cell** 3: 423–441, 2004. doi:10.1111/j.1474-9726.2004.00125.x.
423. Bárcena C, Quirós PM, Durand S, Mayoral P, Rodríguez F, Caravia XM, Mariño G, Garabaya C, Fernández-García MT, Kroemer G, Freije JMP, López-Otín C. Methionine restriction extends lifespan in progeroid mice and alters lipid and bile acid metabolism. **Cell Rep** 24: 2392–2403, 2018. doi:10.1016/j.celrep.2018.07.089.
424. Barcena C, Valdés-Mas R, Mayoral P, Garabaya C, Durand S, Rodríguez F, Fernández-García MT, Salazar N, Nogacka AM, Garatachea N, Bossut N, Aprahamian F, Lucia A, Kroemer G, Freije JMP, Quirós PM, López-Otín C. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. **Nat Med** 25: 1234–1242, 2019. doi:10.1038/s41591-019-0504-5.
425. Wang XX, Luo Y, Wang D, Adorini L, Pruzanski M, Dobrinskikh E, Levi M. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. **J Biol Chem** 292: 12018–12024, 2017. doi:10.1074/jbc.C117.794982.
426. Li Z, Huang J, Wang F, Li W, Wu X, Zhao C, Zhao J, Wei H, Wu Z, Qian M, Sun P, He L, Jin Y, Tang J, Qiu W, Siwko S, Liu M, Luo J, Xiao J. Dual targeting of bile acid receptor-1 (TGR5) and farnesoid X receptor (FXR) prevents estrogen-dependent bone loss in mice. **J Bone Miner Res** 34: 765–776, 2018. doi:10.1002/jbmr.3652.

427. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. **Science** 307: 1915–1920, 2005. doi:[10.1126/science.1104816](https://doi.org/10.1126/science.1104816).
428. Bisschop PH, Bandsma RH, Stellaard F, ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. **Am J Clin Nutr** 79: 570–576, 2004. doi:[10.1093/ajcn/79.4.570](https://doi.org/10.1093/ajcn/79.4.570).
429. Eggink HM, Oosterman JE, de Goede P, de Vries EM, Foppen E, Koehorst M, Groen AK, Boelen A, Romijn JA, la Fleur SE, Soeters MR, Kalsbeek A. Complex interaction between circadian rhythm and diet on bile acid homeostasis in male rats. **Chronobiol Int** 34: 1339–1353, 2017. doi:[10.1080/07420528.2017.1363226](https://doi.org/10.1080/07420528.2017.1363226).
430. Morville T, Sahl RE, Trammell SA, Svenningsen JS, Gillum MP, Helge JW, Clemmensen C. Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans. **JCI Insight** 3, 2018. doi:[10.1172/jci.insight.122737](https://doi.org/10.1172/jci.insight.122737).
431. Gribble FM, Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. **Nat Rev Endocrinol** 15: 226–237, 2019. doi:[10.1038/s41574-019-0168-8](https://doi.org/10.1038/s41574-019-0168-8).
432. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamäki J, Auwerx J, Goldfine AB. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. **Obesity** 17: 1671–1677, 2009. doi:[10.1038/oby.2009.102](https://doi.org/10.1038/oby.2009.102).
433. Albaugh VL, Flynn CR, Cai S, Xiao Y, Tamboli RA, Abumrad NN. Early increases in bile acids post Roux-en-Y gastric bypass are driven by insulin-sensitizing, secondary bile acids. **J Clin Endocrinol Metab** 100: E1225–E1233, 2015. doi:[10.1210/jc.2015-2467](https://doi.org/10.1210/jc.2015-2467).
434. Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Kakela P, Pääkkönen M, Hallikainen M, Kolehmainen M, Uusitupa M, Moilanen L, Laakso M, Gylling H, Patti ME, Auwerx J, Pihlajamäki J. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. **Obes Surg** 22: 1473–1480, 2012. doi:[10.1007/s11695-012-0673-5](https://doi.org/10.1007/s11695-012-0673-5).
435. Hao Z, Leigh Townsend R, Mumphy MB, Gettys TW, Yu S, Münzberg H, Morrison CD, Berthoud HR. Roux-en-Y gastric bypass surgery-induced weight loss and metabolic improvements are similar in TGR5-deficient and wildtype mice. **Obes Surg** 28: 3227–3236, 2018. doi:[10.1007/s11695-018-3297-6](https://doi.org/10.1007/s11695-018-3297-6).
436. Ding L, Sousa KM, Jin L, Dong B, Kim BW, Ramirez R, Xiao Z, Gu Y, Yang Q, Wang J, Yu D, Pigazzi A, Schones D, Yang L, Moore D, Wang Z, Huang W. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. **Hepatology** 64: 760–773, 2016. doi:[10.1002/hep.28689](https://doi.org/10.1002/hep.28689).
437. McGavigan AK, Garibay D, Henseler ZM, Chen J, Bettaieb A, Haj FG, Ley RE, Chouinard ML, Cummings BP. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. **Gut** 66: 226–234, 2017. doi:[10.1136/gutjnl-2015-309871](https://doi.org/10.1136/gutjnl-2015-309871).
438. Patel A, Yusta B, Matthews D, Charron MJ, Seeley RJ, Drucker DJ. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr(-/-) mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy. **Mol Metab** 16: 45–54, 2018. doi:[10.1016/j.molmet.2018.06.006](https://doi.org/10.1016/j.molmet.2018.06.006).
439. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JH, Ghatei MA, Bloom SR, Walters JR, Welbourn R, Le Roux CW. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. **Endocrinology** 153: 3613–3619, 2012. doi:[10.1210/en.2011-2145](https://doi.org/10.1210/en.2011-2145).
440. Albaugh VL, Banan B, Antoun J, Xiong Y, Guo Y, Ping J, Alikhan M, Clements BA, Abumrad NN, Flynn CR. Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery. **Gastroenterology** 156: 1041–1051, 2019. doi:[10.1053/j.gastro.2018.11.017](https://doi.org/10.1053/j.gastro.2018.11.017).
441. Kaska L, Sledzinski T, Chomiczewska A, Dettlaff-Pokora A, Swierczynski J. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. **WJG** 22: 8698–8719, 2016. doi:[10.3748/wjg.v22.i39.8698](https://doi.org/10.3748/wjg.v22.i39.8698).
442. de Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, Herrema H, Ackermans M, Serlie MJM, de Brauw M, Levels JHM, Sales A, Gerdes VE, Ståhlman M, Schimmel AWM, Dallinga-Thie G, Bergman JJ, Holleman F, Hoekstra JBL, Groen A, Bäckhed F, Nieuwdorp M. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. **Gut** 69: 502–512, 2020. doi:[10.1136/gutjnl-2019-318320](https://doi.org/10.1136/gutjnl-2019-318320).
443. Spinelli V, Chávez-Talavera O, Tailleux A, Staels B. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors. **Curr Opin Endocrinol Diabetes Obes** 23: 138–144, 2016. doi:[10.1097/MED.000000000000235](https://doi.org/10.1097/MED.000000000000235).
444. Kuno T, Hirayama-Kurogi M, Ito S, Ohtsuki S. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. **Sci Rep** 8: 1253, 2018. doi:[10.1038/s41598-018-19545-1](https://doi.org/10.1038/s41598-018-19545-1).
445. Xiao Y, Zhou K, Lu Y, Yan W, Cai W, Wang Y. Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling. **Exp Mol Med** 50: 1–14, 2018. doi:[10.1038/s12276-018-0181-3](https://doi.org/10.1038/s12276-018-0181-3).
446. Theriot CM, Bowman AA, Young VB. Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. **mSphere** 1, 2016. doi:[10.1128/mSphere.00045-15](https://doi.org/10.1128/mSphere.00045-15).
447. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. **J Hepatol** 62: S25–S37, 2015. doi:[10.1016/j.jhep.2015.02.023](https://doi.org/10.1016/j.jhep.2015.02.023).
448. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. **Gastroenterology** 130: 715–720, 2006. doi:[10.1053/j.gastro.2005.12.029](https://doi.org/10.1053/j.gastro.2005.12.029).
449. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. **Hepatology** 44: 746–764, 2006. doi:[10.1002/hep.21337](https://doi.org/10.1002/hep.21337).
450. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. **Hepatology** 65: 350–362, 2017. doi:[10.1002/hep.28709](https://doi.org/10.1002/hep.28709).
451. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumph E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. Ursodeoxycholic acid improves cholestasis in primary

- sclerosing cholangitis. *J Hepatol* 67: 549–558, 2017. doi:[10.1016/j.jhep.2017.05.009](https://doi.org/10.1016/j.jhep.2017.05.009).
452. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelleo E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. *Gastroenterology* 148: 751–761, 2015. doi:[10.1053/j.gastro.2014.12.005](https://doi.org/10.1053/j.gastro.2014.12.005).
 453. Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D, for the Obeticholic Acid PBC Monotherapy Study Group. Obeticholic acid PBCMSG. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. *Hepatology* 67: 1890–1902, 2018. doi:[10.1002/hep.29569](https://doi.org/10.1002/hep.29569).
 454. Eaton JE, Vuppalanchi R, Reddy R, Satapathy SK, Ali B, Kamath PS. Liver injury in patients with cholestatic liver disease treated with obeticholic acid. *Hepatology* 71: 1511–1514, 2020. doi:[10.1002/hep.31017](https://doi.org/10.1002/hep.31017).
 455. Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. *Diabetes Obes Metab* 18: 936–940, 2016. doi:[10.1111/dom.12681](https://doi.org/10.1111/dom.12681).
 456. Hirschfield GM, Chazouilleres O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. *J Hepatol* 70: 483–493, 2019. doi:[10.1016/j.jhep.2018.10.035](https://doi.org/10.1016/j.jhep.2018.10.035).
 457. Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. *Hepatology Commun* 2: 1037–1050, 2018. doi:[10.1002/hep4.1209](https://doi.org/10.1002/hep4.1209).
 458. DePaoli AM, Zhou M, Kaplan DD, Hunt SC, Adams TD, Learned RM, Tian H, Ling L. FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis. *Diabetes* 68: 1315–1328, 2019. doi:[10.2337/db18-1305](https://doi.org/10.2337/db18-1305).
 459. Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 391: 1174–1185, 2018. doi:[10.1016/S0140-6736\(18\)30474-4](https://doi.org/10.1016/S0140-6736(18)30474-4).
 460. Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. *Hepatology* 71: 1198–1212, 2020. doi:[10.1002/hep.30590](https://doi.org/10.1002/hep.30590).
 461. Cook JW, Kennaway EL, Kennaway NM. Production of tumours in mice by deoxycholic acid. *Nature* 145: 627–627, 1940. doi:[10.1038/145627b0](https://doi.org/10.1038/145627b0), doi:[10.1038/145627a0](https://doi.org/10.1038/145627a0).
 462. Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. *Nat Rev Gastroenterol Hepatol* 15: 111–128, 2018. doi:[10.1038/nrgastro.2017.119](https://doi.org/10.1038/nrgastro.2017.119).
 463. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature* 499: 97–101, 2013. doi:[10.1038/nature12347](https://doi.org/10.1038/nature12347).
 464. Kitamura T, Srivastava J, DiGiovanni J, Kiguchi K. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer. *Mol Carcinog* 54: 459–472, 2015. doi:[10.1002/mc.22118](https://doi.org/10.1002/mc.22118).
 465. Bernstein C, Holubec H, Bhattacharyya AK, Nguyen H, Payne CM, Zaitlin B, Bernstein H. Carcinogenicity of deoxycholate, a secondary bile acid. *Arch Toxicol* 85: 863–871, 2011. doi:[10.1007/s00204-011-0648-7](https://doi.org/10.1007/s00204-011-0648-7).
 466. Wang X, Sun L, Wang X, Kang H, Ma X, Wang M, Lin S, Liu M, Dai C, Dai Z. Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in mice dependent on c-Myc expression. *Cancer Med* 6: 788–797, 2017. doi:[10.1002/cam4.999](https://doi.org/10.1002/cam4.999).
 467. Song P, Zhang Y, Klaassen CD. Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicity in mice. *Toxicol Sci* 123: 359–367, 2011. doi:[10.1093/toxsci/kfr177](https://doi.org/10.1093/toxsci/kfr177).
 468. Zhou M, Yang H, Learned RM, Tian H, Ling L. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. *Nat Commun* 8: 15433, 2017. doi:[10.1038/ncomms15433](https://doi.org/10.1038/ncomms15433).
 469. Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T, Learned RM, DePaoli AM, Tian H, Ling L. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. *Cancer Res* 74: 3306–3316, 2014. doi:[10.1158/0008-5472.CAN-14-0208](https://doi.org/10.1158/0008-5472.CAN-14-0208).
 470. Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, Kim SK, Koh GY. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. *Science* 363: 644–649, 2019. doi:[10.1126/science.aav0173](https://doi.org/10.1126/science.aav0173).
 471. Lee WS, Jung JH, Panchanathan R, Yun JW, Kim DH, Kim HJ, Kim GS, Ryu CH, Shin SC, Hong SC, Choi YH, Jung JM. Ursodeoxycholic acid induces death receptor-mediated apoptosis in prostate cancer cells. *J Cancer Prev* 22: 16–21, 2017. doi:[10.15430/JCP.2017.22.116](https://doi.org/10.15430/JCP.2017.22.116).
 472. Peng S, Huo X, Rezaei D, Zhang Q, Zhang X, Yu C, Asanuma K, Cheng E, Pham TH, Wang DH, Chen M, Souza RF, Spechler SJ. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. *Am J Physiol Gastrointest Liver Physiol* 307: G129–G139, 2014. doi:[10.1152/ajpgi.00085.2014](https://doi.org/10.1152/ajpgi.00085.2014).
 473. Phelan JP, Reen FJ, Dunphy N, O'Connor R, O'Gara F. Bile acids destabilise HIF-1 α and promote anti-tumour phenotypes in cancer cell models. *BMC Cancer* 16: 476, 2016. doi:[10.1186/s12885-016-2528-2](https://doi.org/10.1186/s12885-016-2528-2).
 474. Vasavan T, Ferraro E, Ibrahim E, Dixon P, Gorelik J, Williamson C. Heart and bile acids. Clinical consequences of altered bile acid metabolism. *Biochim Biophys Acta* 1864: 1345–1355, 2018. doi:[10.1016/j.bbadis.2017.12.039](https://doi.org/10.1016/j.bbadis.2017.12.039).
 475. Rainer PP, Primessnig U, Harenkamp S, Doleschal B, Wallner M, Fauler G, Stojakovic T, Wachter R, Yates A, Groschner K, Trauner M, Pieske BM, von Lewinski D. Bile acids induce arrhythmias in human atrial myocardium—implications for altered serum bile acid composition in patients with atrial fibrillation. *Heart* 99: 1685–1692, 2013. doi:[10.1136/heartjnl-2013-304163](https://doi.org/10.1136/heartjnl-2013-304163).
 476. Pu J, Yuan A, Shan P, Gao E, Wang X, Wang Y, Lau WB, Koch W, Ma XL, He B. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. *Eur Heart J* 34: 1834–1845, 2013. doi:[10.1093/eurheartj/ehs011](https://doi.org/10.1093/eurheartj/ehs011).

477. Ghosh Laskar M, Eriksson M, Rudling M, Angelin B. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. **J Intern Med** 281: 575–585, 2017. doi:[10.1111/joim.12594](https://doi.org/10.1111/joim.12594).
478. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. **FEBS Lett** 582: 949–955, 2008. doi:[10.1016/j.febslet.2008.02.038](https://doi.org/10.1016/j.febslet.2008.02.038).
479. Gutierrez A, Ratliff EP, Andres AM, Huang X, McKeehan WL, Davis RA. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. **ATVB** 26: 301–306, 2006. doi:[10.1161/01.ATV.0000195793.73118.b4](https://doi.org/10.1161/01.ATV.0000195793.73118.b4).
480. Shih DM, Kast-Woelbern HR, Wong J, Xia YR, Edwards PA, Lusic AJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. **J Lipid Res** 47: 384–392, 2006. doi:[10.1194/jlr.M500378-JLR200](https://doi.org/10.1194/jlr.M500378-JLR200).
481. Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kusters A, Karpen SJ. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. **Hepatology** 51: 2097–2107, 2010. doi:[10.1002/hep.23585](https://doi.org/10.1002/hep.23585).
482. Fryer RM, Ng KJ, Nodop Mazurek SG, Patnaude L, Skow DJ, Muthukumarana A, Gilpin KE, Dinallo RM, Kuzmich D, Lord J, Sanyal S, Yu H, Harcken C, Cerny MA, Hickey ER, Modis LK. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a $K_{Ca}1.1$ (BK_{Ca} -dependent mechanism. **J Pharmacol Exp Ther** 348: 421–431, 2014. doi:[10.1124/jpet.113.210005](https://doi.org/10.1124/jpet.113.210005).
483. Eblimit Z, Thevananther S, Karpen SJ, Taegtmeier H, Moore DD, Adorini L, Penny DJ, Desai MS. TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice. **Cardiovasc Ther** 36: e12462, 2018. doi:[10.1111/1755-5922.12462](https://doi.org/10.1111/1755-5922.12462).
484. Duboc H, Aelion H, Rainteau D, Rajca S, Sokol H, Humbert L, Farabos D, Coffin B, Weber S, Porcher R, Varenne O, Duboc D. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor? **Hepatology** 56: 2426, 2012. doi:[10.1002/hep.25839](https://doi.org/10.1002/hep.25839).
485. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, Cevikbas F, Steinhoff M, Nassini R, Materazzi S, Guerrero-Alba R, Valdez-Morales E, Cottrell GS, Schoonjans K, Geppetti P, Vanner SJ, Bunnett NW, Corvera CU. The TGR5 receptor mediates bile acid-induced itch and analgesia. **J Clin Invest** 123: 1513–1530, 2013. doi:[10.1172/JCI64551](https://doi.org/10.1172/JCI64551).
486. Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, McIntyre P, Bron R, Wilson YM, Krappitz M, Haerteis S, Korbmacher C, Steinhoff MS, Nassini R, Materazzi S, Geppetti P, Corvera CU, Bunnett NW. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. **Gastroenterology** 147: 1417–1428, 2014. doi:[10.1053/j.gastro.2014.08.042](https://doi.org/10.1053/j.gastro.2014.08.042).

MOLECULAR PHYSIOLOGY OF BILE ACID SIGNALING IN HEALTH, DISEASE, AND AGING

AUTHORS


Alessia Perino, Hadrien Demagny,
Laura Velazquez-Villegas, Kristina Schoonjans

CORRESPONDENCE

kristina.schoonjans@epfl.ch

KEY WORDS

FXR; metabolic syndrome; microbiome; NAFLD;
TGR5



CLINICAL HIGHLIGHTS

Several diseases and conditions have been associated with an uncontrolled rise in bile acid (BA) concentrations. This is often the case when the tight feedback regulation of BA synthesis is compromised to the point that BAs become detrimental. BAs and their cognate receptors, farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5), however, exert many beneficial roles as they enable tissues to adapt to environmental, nutritional, and physiological cues. Over the last two decades, BA mimetics targeting FXR, TGR5, or both, have been proven to be efficacious in alleviating chronic metabolic and inflammatory disorders, such as obesity, Type 2 Diabetes (T2D), atherosclerosis and non-alcoholic steatohepatitis (NASH). While several aspects of BA signaling are still poorly understood, the first therapeutics targeting FXR are making their way into the clinic to treat liver diseases, such as primary biliary cholangitis (PBC) and NASH. Drugs targeting BA signaling may, hence, have a bright future and the continuing efforts on studying the impact of changing BA signaling pathways in humans will be beneficial to translate our emerging knowledge on BA physiology in model organisms into clinical benefits.